<body style="font: 10pt Times New Roman, Times, Serif"> <document>  <type>   10-K   <sequence>    1    <filename>     form10-k.htm     <text>      <title>      </title>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">      </p>      <!-- Field: Rule-Page -->      <div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%">       <div style="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">       </div>      </div>      <!-- Field: /Rule-Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 18pt">        <b>         UNITEDSTATES        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 18pt">        <b>         SECURITIESAND EXCHANGE COMMISSION        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 12pt">        <b>         Washington,D.C. 20549        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 18pt">        <b>         FORM10-K        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         [X]ANNUAL REPORT UNDER SECTION 13 OR 15(d)        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         OFTHE SECURITIES EXCHANGE ACT OF 1934        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         FORTHE FISCAL YEAR ENDED - OCTOBER 31, 2020        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         OR        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        [  ]        <b>         TRANSITION REPORT UNDER SECTION 13 OR 15        </b>        (        <b>         d)        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         OFTHE SECURITIES EXCHANGE ACT OF 1934        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         FORTHE TRANSITION PERIOD FROM ______ TO ______        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         COMMISSIONFILE NUMBER 001-36138        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 18pt">        <b>         ADVAXIS,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        (Exactname of registrant as specified in its charter)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Delaware           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            02-0563870           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (State    or other jurisdiction of          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (IRS    Employer          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           incorporation    or organization)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Identification    No.)          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           305    College Road East, Princeton, NJ          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           08540          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (Address    of principal executive offices)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (Zip    Code)          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        (609)452-9813       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        (Registrant’stelephone number)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Securitiesregistered pursuant to Section 12(b) of the Act:       </font>      </p>      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Title    of each class          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Trading    Symbol(s)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 41%; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Name    of each exchange on which registered          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Common    Stock, par value $0.001 per share          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ADXS          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Nasdaq    Capital Market          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Preferred    Stock Purchase Rights          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Nasdaq    Capital Market          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indicateby check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Yes[  ] No [X]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indicateby check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Yes[  ] No [X]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indicateby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Yes[X] No [  ]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indicateby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuantto Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Yes[X] No [  ]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indicateby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,”“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Large    Accelerated Filer          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           [  ]          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Accelerated    Filer          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           [  ]          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Non-accelerated    Filer          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           [X]          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Smaller    Reporting Company          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           [X]          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Emerging    growth company          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           [  ]          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indicateby check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectivenessof its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registeredpublic accounting firm that prepare or issued its audit report. [  ]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indicateby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Yes[  ] No [X]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof April 30, 2020, the aggregate market value of the voting common equity held by non-affiliates was approximately $39,995,271based on the closing bid price of the registrant’s common stock on the Nasdaq Global Select Market. (For purposes ofdetermining this amount, only directors, executive officers, and 10% or greater shareholders and their respective affiliates havebeen deemed affiliates). [X]       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theregistrant had 111,971,688 shares of common stock, par value $0.001 per share, outstanding as of January 15, 2021.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         DOCUMENTSINCORPORATED BY REFERENCE        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Portionsof the Proxy Statement for the registrant’s 2021 Annual Meeting of Stockholders (the “Proxy Statement”) to befiled within 120 days of the end of the fiscal year ended October 31, 2020 are incorporated by reference into Part III hereof.Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemedto be filed as a part hereof.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">      </p>      <!-- Field: Rule-Page -->      <div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%">       <div style="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">       </div>      </div>      <!-- Field: /Rule-Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 1 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Tableof Contents        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Form10-K Index        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            <a href="#pri_017">             PART 1            </a>           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    1:          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_032">            Business           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    1A:          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_018">            Risk Factors           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           20          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    1B:          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_019">            Unresolved Staff Comments           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           46          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    2:          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_020">            Properties           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           46          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    3:          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_021">            Legal Proceedings           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           46          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    4:          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_022">            Mine Safety Disclosures           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           46          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            <a href="#pri_023">             PART II            </a>           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    5:          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_024">            Market for Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           47          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    6:          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_025">            Selected Financial Data           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           47          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    7:          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_026">            Management’s Discussion and Analysis of Financial Condition and Results of Operations           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           47          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    7A:          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_027">            Quantitative and Qualitative Disclosures About Market Risk           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           55          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    8:          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_028">            Financial Statements and Supplementary Data           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           55          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    9:          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_029">            Changes in and Disagreements with Accountants on Accounting and Financial Disclosures           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           55          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    9A:          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_030">            Controls and Procedures           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           56          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    9B:          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_031">            Other Information           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           56          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            <a href="#pri_007">             PART III            </a>           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    10:          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_008">            Directors, Executive Officers, and Corporate Governance           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           57          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    11:          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_009">            Executive Compensation           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           57          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    12:          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_010">            Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           57          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    13:          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_011">            Certain Relationships and Related Transactions, and Director Independence           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           57          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    14:          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_012">            Principal Accounting Fees and Services           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           57          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            <a href="#pri_013">             Part IV            </a>           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    15:          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_014">            Exhibits, Financial Statements Schedules           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           57          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Item    16:          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_015">            Form 10-K Summary           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           60          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">         <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_016">            Signatures           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           61          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           2           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_017">         </a>         PART1        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         FORWARDLOOKING STATEMENTS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Thisannual report on Form 10-K (“Form 10-K”) includes statements that are, or may be deemed to be, “forward-lookingstatements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology,including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,”“intends,” “may,” “could,” “might,” “will,” “should,”“approximately” or, in each case, their negative or other variations thereon or comparable terminology, although notall forward-looking statements contain these words. They appear in a number of places throughout this Form 10-K and include statementsregarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, ourongoing and planned discovery and development of drug candidates, the strength and breadth of our intellectual property, our ongoingand planned clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvalsfor our product candidates, the degree of clinical utility of our product candidates, particularly in specific patient populations,expectations regarding clinical trial data, our results of operations, financial condition, liquidity, prospects, growth and strategies,the length of time that we will be able to continue to fund our operating expenses and capital expenditures, our expected financingneeds and sources of financing, the industry in which we operate and the trends that may affect the industry or us.        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Bytheir nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics,and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in thefuture or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for eachforward-looking statement contained in this Form 10-K, we caution you that forward-looking statements are not guarantees of futureperformance and that our actual results of operations, financial condition and liquidity, and the development of the industryin which we operate may differ materially from the forward-looking statements contained in this Form 10-K. In addition, even ifour results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistentwith the forward-looking statements contained in this Form 10-K, they may not be predictive of results or developments in futureperiods.        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Someof the factors that we believe could cause actual results to differ from those anticipated or predicted include:        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            the    success and timing of our clinical trials, including patient accrual;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            our    ability to obtain and maintain regulatory approval and/or reimbursement of our product candidates for marketing;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            our    ability to obtain the appropriate labeling of our products under any regulatory approval;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            our    plans to develop and commercialize our products;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            the    successful development and implementation of future sales and marketing campaigns;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            the    change of key scientific or management personnel;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            the    size and growth of the potential markets for our product candidates and our ability to serve those markets;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            our    ability to successfully compete in the potential markets for our product candidates, if commercialized;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            regulatory    developments in the United States and foreign countries;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            the    rate and degree of market acceptance of any of our product candidates;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            new    products, product candidates or new uses for existing products or technologies introduced or announced by our competitors    and the timing of these introductions or announcements;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            market    conditions in the pharmaceutical and biotechnology sectors;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            our    available cash;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            the    accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            our    ability to obtain additional funding;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            our    ability to obtain and maintain intellectual property protection for our product candidates;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            the    ability of our product candidates to successfully perform in clinical trials and to resolve any clinical holds that may occur;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            our    ability to obtain and maintain approval of our product candidates for trial initiation;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            our    ability to manufacture and the performance of third-party manufacturers;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            our    ability to identify license and collaboration partners and to maintain existing relationships;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            the    performance of our clinical research organizations, clinical trial sponsors and clinical trial investigators, and collaboration    partners for any clinical trials we conduct;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            any    outcomes from our review of strategic transactions;           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            our    ability to successfully implement our strategy; and           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            our    ability to maintain the listing of our common stock on the Nasdaq Capital Market.           </i>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 3; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           3           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Anyforward-looking statements that we make in this Form 10-K speak only as of the date of such statement, and we undertake no obligationto update such statements to reflect events or circumstances after the date of this Form 10-K. You should also read carefullythe factors described in the “Risk Factors” section of this Form 10-K to better understand the risks and uncertaintiesinherent in our business and underlying any forward-looking statements. As a result of these factors, we cannot assure you thatthe forward-looking statements in this Form 10-K will prove to be accurate.        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         ThisForm 10-K includes statistical and other industry and market data that we obtained from industry publications and research, surveysand studies conducted by third-parties. Industry publications and third-party research, surveys and studies generally indicatethat their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy orcompleteness of such information. While we believe these industry publications and third-party research, surveys and studies arereliable, we have not independently verified such data.        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Wequalify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-lookingstatements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities LitigationReform Act of 1995.        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inthis Form 10-K, unless otherwise stated or the context otherwise indicates, references to “Advaxis,” “the Company,”“we,” “us,” “our” and similar references refer to Advaxis, Inc., a Delaware corporation.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_032">         </a>         Item1. Business.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         General        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Advaxisis a clinical-stage biotechnology company focused on the development and commercialization of proprietary        <i>         Listeria monocytogenes        </i>        ,or        <i>         Lm        </i>        , Technology antigen delivery products based on a platform technology that utilizes live attenuated        <i>         Lm        </i>        bioengineeredto secrete antigen/adjuvant fusion proteins. These        <i>         Lm        </i>        -based strains are believed to be a significant advancement in immunotherapyas they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cellsto stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneouslyreduce tumor protection in the Tumor Microenvironment, or TME, to enable T cells to eliminate tumors. The Company believes that        <i>         Lm        </i>        Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape.Specifically, the Company’s product candidates have the potential to optimize the clinical impact of checkpoint inhibitorswhile having a generally well-tolerated safety profile. The Company’s passion for the clinical potential of        <i>         Lm        </i>        Technologyis balanced by focus and fiscal discipline which is directed towards improving treatment options for cancer patients and increasingshareholder value.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Advaxisis focused on single antigen and multiple antigen delivery products and is in various stages of clinical development. All of theCompany’s products are anchored in the Company’s        <i>         Lm        </i>        Technology        <sup>         TM        </sup>        , a unique platform designed forits ability to target various cancers in multiple ways. As an intracellular bacterium,        <i>         Lm        </i>        is an effective vector for thepresentation of antigens through both the Major Histocompatibility Complex, or MHC, I and II pathways, due to its active phagocytosisby Antigen Presenting Cells, or APCs. Within the APCs,        <i>         Lm        </i>        produces virulence factors which allow survival in the host cytosoland potently stimulate the immune system.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Througha license from the University of Pennsylvania and through its own development efforts, Advaxis has exclusive access to a proprietaryformulation of attenuated        <i>         Lm        </i>        that we call        <i>         Lm        </i>        Technology.        <i>         Lm        </i>        Technology is designed to optimize this naturalsystem, and one of the keys to the enhanced immunogenicity of        <i>         Lm        </i>        Technology is the        <i>         tLLO        </i>        -fusion protein, which ismade up of tumor associated antigen, or TAA, fused to a highly immunogenic bacterial protein that triggers potent cellular immunity.The        <i>         tLLO        </i>        -fusion protein is also designed to help reduce immune tolerance in the TME and to promote antigen spreading, therebyimproving activity in the TME. Multiple copies of the        <i>         tLLO        </i>        -fusion protein within each construct may increase antigen presentationand TME impact.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asthe field of immunotherapy continues to evolve, the flexibility of the        <i>         Lm        </i>        Technology platform has allowed Advaxis to develophighly innovative products. To date,        <i>         Lm        </i>        Technology has demonstrated preclinical synergy with multiple checkpoint inhibitors,co-stimulatory agents and radiation therapy. The safety profile of all        <i>         Lm        </i>        Technology constructs seen to date across over470 patients has been generally predictable and manageable, consisting mostly of mild to moderate flu-like symptoms that havebeen transient and associated with infusion.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 4; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           4           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         TheAdvaxis Corporate Strategy        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourstrategy is to advance the Lm Technology platform and leverage its unique capabilities to design and develop an array of cancertreatments. We are currently conducting or planning clinical studies of Lm Technology immunotherapies in non-small cell lung cancerand other solid tumor types, prostate cancer and HPV-associated cancers. We are working with, or are in the process of identifying,collaborators and potential licensees for these programs.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Advaxisis currently mainly concentrating on its disease-focused, hotspot/“off-the-shelf” neoantigen-directed therapies calledADXS-HOT. ADXS-HOT is a program that leverages the Company’s proprietary Lm technology to target hotspot mutations thatcommonly occur in specific cancer types. ADXS-HOT drug candidates are designed to target acquired shared or “public”mutations in tumor driver genes along with other cancer-associated antigens that also commonly occur in specific cancer types.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weexpect that we will continue to invest in our core clinical program areas and will also remain opportunistic in evaluating InvestigatorSponsored Trials, or ISTs, as well as licensing opportunities as we are actively looking for partners and/or licensees for theseprograms. The        <i>         Lm        </i>        Technology platform is protected by a range of patents, covering both product and process, some of whichwe believe can be maintained into 2039.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Lm         </i>         Technology and the Immunotherapy Landscape        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.4pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thechallenge of cancer immunotherapy has been to find the best overall balance between efficacy and side effects when mobilizingthe body’s immune system to fight against cancer. The development of immune checkpoint inhibitors was a significant stepforward, particularly with anti-PD-1 therapies, and brought with it impressive clinical activity in many different types of cancers,including melanoma, lung, head and neck and urothelial cancers. However, a literature review published in        <i>         Science        </i>        in 2018noted that anti-PD-1 monotherapy response rates are only in the 15-25% range, and rise to ≥50% only in selected groups of patientswith desmoplastic melanoma, Merkel carcinoma or tumors with mismatch-repair deficiency. Development of secondary resistance withdisease progression is yet another common limitation of these therapies. Therefore, for most cancer patients, there is room forimprovement. Checkpoint inhibitors can expand existing cancer fighting cells that may already be present in low numbers and supporttheir activity against cancer cells, but if the right cancer-fighting cells are not present, checkpoint inhibitors may not provideclinical benefit. Similarly, there are many mechanisms of immune tolerance that are distinct from the checkpoints which may alsobe blocking the immune system from fighting cancer. Based on both pre-clinical and early clinical data, Advaxis believes thatcheckpoint inhibitors, when combined with treatments such as        <i>         Lm        </i>        Technology, can have an amplified anti-tumor effect.        <i>         Lm        </i>        Technology incorporates several complementary elements that include innate immune stimulation, potent generation of cancer-targetedT cells, ability to boost immunity through multiple treatments, enhancing lymphocyte infiltration into tumors, reduction of non-checkpointmediated immune tolerance within the tumor microenvironment, and promotion of antigen spreading which may amplify the effectsof treatment. These results provide rationale for further testing of        <i>         Lm        </i>        Technology agents alone and in combination withcheckpoint inhibitors.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.4pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.4pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Traditionalcancer vaccines were another development within immunotherapy and have a history beginning over 30 years ago. Unfortunately, thesevaccines have largely been unsuccessful for a variety of potential reasons. These include poor selection of targets, imbalancedantigen presentation by inclusion of certain immune enhancing agents (adjuvants), failure to consider the blocking actions ofimmune tolerance, and choice of vaccine vectors. In some cases, patients may develop neutralizing antibodies, preventing furthertreatments. In contrast to traditional cancer vaccines,        <i>         Lm        </i>        Technology takes advantage of a natural pathway in the immunesystem that evolved to protect us against        <i>         Listeria        </i>        infections, that also happens to generate the same type of immunitythat is required when fighting cancer. The live but weakened (attenuated) bacteria stimulate a balanced concert of innate immunetriggers and present the tumor antigen target precisely where it needs to be able to generate potent cancer fighting cells fromwithin the immune system itself. The multitude of accompanying signals serves to broadly mobilize most of the immune system insupport of fighting what seems to be a        <i>         Listeria        </i>        infection, and is then “re-directed” against cancer cell targets.Additionally, the unique intracellular lifecycle of        <i>         Listeria        </i>        avoids the creation of neutralizing antibodies, thereby allowingfor repeat administration as a chronic therapy with a sustained enhancing of tumor antigen-specific T cell immunity.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Lookingback on the last two decades, there have been promising technology advancements to harness and activate killer T cells againstcancers and every day more is learned about the interplay between immunity and cancer that can lead to improved treatments. However,there are still significant unmet needs in the immunotherapy landscape that Advaxis feels        <i>         Lm        </i>        Technology may be able toaddress and complement. Specifically,        <i>         Lm        </i>        Technology has the potential to optimize and expand checkpoint inhibitor activityin combination. It also avoids many of the limitations of previous cancer vaccine attempts by tapping into the pathway reservedfor defense against        <i>         Listeria        </i>        infection while incorporating the best cancer targets science can identify, including neoantigensthat result from mutations in the cancer. To date,        <i>         Lm        </i>        Technology products have a manageable safety profile, do not generateneutralizing antibodies lending themselves to retreatments, and most of the products are designed to be immediately availablefor treatment without the complication and expense of modifying a patient’s own cells in a laboratory.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 5; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           5           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Lm         </i>         Technology: An optimized         <i>          Listeria         </i>         -based antigen delivery system        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Advaxis’        <i>         Listeria        </i>        -based immunotherapies are designed for antigen delivery through a process of insertion of multiple copies ofthe proprietary        <i>         tLLO        </i>        -fusion protein into each extrachromosomal protein expression and secretion plasmid that makes andsecretes the target protein right inside the patient’s antigen presenting cells to initiate and/or boost their immune response.The        <i>         tLLO        </i>        -fusion protein approach was developed at the University of Pennsylvania as an improvement over insertion of asingle copy of the target gene, as an ACT-A (or other        <i>         Lm        </i>        peptide) fusion, within the bacterial genome for four key reasons:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           1.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Multiple    copies of the DNA in the plasmids per bacteria can result in larger amounts of           <i>            tLLO           </i>           -fusion protein being expressed    simultaneously, versus a single copy. This is designed to improve antigen presentation and immunologic priming and increases    the number of T cells generated for a particular treatment.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           2.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            tLLO           </i>           expressed on plasmids (with or without a tumor target protein attached) has been shown preclinically to reduce numbers    and immune suppressive function of Tregs and myeloid-derived suppressor cells, or MDSCs, in the tumor microenvironment. Presented    preclinical data demonstrates that Tregs are destroyed as soon as five days after the first           <i>            Lm           </i>           Technology treatment    and that suppressive M2 tumor-associated macrophages, or TAMs, are replaced by M1 macrophages which support antigen presentation    and adoptive immunity.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    extrachromosal DNA plasmids themselves also contain CpG sequence patterns that trigger TLR-9, which confers additional innate    immune stimulation beyond a listeria without the plasmids.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    multiple copies of bacterial DNA plasmids (up to 80-100 per bacteria) confers additional stimulation of the STING receptor    within APC’s which has been associated with enhancing anti-cancer immunity in patients.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         ClinicalPipeline        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Advaxisis focused on the development and commercialization of proprietary        <i>         Lm        </i>        Technology antigen delivery products. The Companyand its collaborators are currently conducting or are in the planning process for conducting clinical studies of        <i>         Lm        </i>        Technologyimmunotherapies in the following areas:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Disease    focused hotspot/“off-the-shelf” neoantigen-directed therapies          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Human    Papilloma Virus (“HPV”)-associated cancers          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Prostate    cancer (ADXS-PSA)          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany has completed the clinical study report for ADXS-NEO program—its        <i>         Lm        </i>        Technology personalized neoantigen-directedtherapies clinical study and plans to close the related IND for this study shortly. In addition, the Company is winding down itsAIM2CERV Phase 3 clinical trial with axalimogene filolisbac (AXAL) in high-risk locally advanced cervical cancer.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asa clinical-stage biotechnology company with no commercial products, Advaxis is aware of the need for fiscal responsibility, andis focusing its investments in areas that it anticipates will have the highest likelihood of clinical and commercial success.Additionally, the company will continue to be opportunistic by exploring ISTs, licensing and other external opportunities.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         AdvaxisPipeline of Product Candidates        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         <img alt="" src="chart_001.jpg" style="height: 315; width: 670"/>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <!-- Field: Page; Sequence: 6; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           6           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Disease-focused hotspot/‘off -the-shelf’ neoantigen therapies (ADXS-HOT)        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Advaxisis creating a new group of immunotherapy constructs for major solid tumor cancers that combines our optimized        <i>         Lm        </i>        Technologyvector with promising targets designed to generate potent anti-cancer immunity. The ADXS-HOT program is a series of novel cancerimmunotherapies that will target somatic mutations, or hotspots, cancer testis antigens, or CTAs, and oncofetal antigens, or OFAs.These three types of targets form the basis of the ADXS-HOT program because they are designed to be more capable of generatingpotent, tumor specific, and high strength killer T cells, versus more traditional over-expressed native sequence tumor associatedantigens. Most hotspot mutations and OFA/CTA proteins play critical roles in oncogenesis; targeting both at once could significantlyimpair cancer proliferation. The ADXS-HOT products will combine many of the potential high avidity targets that are expressedin all patients with the target disease into one “off-the-shelf”, ready to administer treatment. The ADXS-HOT technologyhas a strong intellectual property, or IP, position, with potential protection into 2037, and an IP filing strategy providingfor broad coverage opportunities across multiple disease platforms and combination therapies.In July 2018, the Company announcedthat the U.S. Food and Drug Administration, or FDA, allowed the Company’s investigational new drug, or IND, applicationfor its ADXS-HOT drug candidate (ADXS-503) for non-small cell lung cancer, or NSCLC. ADXS-503 is currently being evaluated ina Phase 1/2 clinical trial, enrolling patients at five sites. The first two dose-levels with monotherapy in Part A, (1 X10        <sup>         8        </sup>        CFU and 5 X108 CFU) have been completed and Part B and Part C with ADXS-503 (1 X10        <sup>         8        </sup>        CFU) in combination witha checkpoint inhibitor are currently open to enrollment.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany presented updated clinical data from Part B of the ADXS-503 clinical study at ASCO Annual Meeting 2020, which demonstrateddurable clinical benefit in 2 out of 3 evaluable patients with immediate prior progression on KEYTRUDA        <sup>         ®        </sup>        includingone durable response out to 34 weeks with 25% reduction in a target lesion and another sustained response out to 33 weeks witha 60% reduction in site lesions. Clinical benefit was observed after immediate prior progression on KEYTRUDA        <sup>         ®        </sup>        withprevious best responses of stable disease suggest ADXS-503 may re-sensitize or enhance response to KEYTRUDA        <sup>         ®        </sup>        . Bothpatients remain on treatment in Part B, the combination arm with KEYTRUDA        <sup>         ®        </sup>        . The Company has initiated ADXS-503Part B combination arm efficacy expansion which will enroll up to 15 additional patients to evaluate the potential of ADXS-503in combination with KEYTRUDA        <sup>         ®        </sup>        to restore and/or enhance responsiveness to checkpoint inhibitors in PD-1/L-1 refractoryNSCLC patients Advaxis also has initiated the ADXS-503 Part C combination arm to evaluate ADXS-503 in combination with KEYTRUDA®as a first line treatment in patients with NSCLC with PD-L1 expression ≥ 1% or who are unsuitable for chemotherapy       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany expects to report updated clinical and immune response updated data from Part B combination therapy at upcoming scientificmeetings in 2021.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnDecember 3, 2019, Advaxis announced that it submitted an IND to the FDA for the initiation of a Phase 1 clinical study of ADXS-504,its ADXS-HOT drug candidate for prostate cancer. On September 10, 2020, Advaxis was notified that a new IND submitted to the FDAfor the initiation of an Investigator-Sponsored-Trial, a Phase 1 clinical study of ADXS-504 for biochemically recurrent prostatecancer after radical prostatectomy or radical radiotherapy, was accepted by the agency. This study is expected to start at a leadingmedical institution in 1Q2021.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          HPV-RelatedCancers         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany conducted several studies evaluating axalimogene filolisbac, or AXAL, for HPV-related cancers. AXAL is an        <i>         Lm        </i>        -basedantigen delivery product directed against HPV and designed to target cells expressing HPV.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InJune 2019, the Company announced the closing of its AIM2CERV Phase 3 clinical trial with axalimogene filolisbac (AXAL) in high-risklocally advanced cervical cancer. Company estimates showed that the remaining cost to complete the AIM2CERV trial ranged from$80 million to $90 million, and initial efficacy data was not anticipated for at least three years. Therefore, results from theclinical trial were not the basis for the decision to close the study, nor was safety as the trial recently underwent its thirdIndependent Data Monitoring Committee (IDMC) review with no safety issues noted. The Company has unblinded the AIM2CERV clinicaldata generated to date and currently has no plans to present it at any medical conference as the data set is incomplete and inconclusive.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        In2014, Advaxis granted Global BioPharma, or GBP, an exclusive license for the development and commercialization of AXAL in Asia,Africa, and the former USSR territory, exclusive of India and certain other countries. GBP is responsible for all developmentand commercial costs and activities associated with the development in their territories.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Other        <i>         HPV Program Licensing Agreements        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        BioconLimited, or Biocon, our co-development and commercialization partner for AXAL in India and key emerging markets, filed a MAA forlicensure of this immunotherapy in India. The companies will evaluate next steps regarding potential registration in India.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        EspecificosStendhal SA de CV, or Stendhal, the Company’s co-development and commercialization partner for AXAL in Mexico, Brazil, Colombiaand other Latin American countries, agreed to pay $10 million in support payment towards the expense of AIM2CERV over the durationof the trial, contingent upon Advaxis achieving annual project milestones, pursuant to a Co-Development and CommercializationAgreement, or the Stendhal Agreement. The Company was in arbitration proceedings with Stendhal. For more information, see Note9, “Commitments and Contingencies – Legal Proceedings” of the “Notes to the Financial Statements”included in Item 8.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        KnightTherapeutics Inc., or Knight, holds an exclusive license to commercialize AXAL in Canada, as well as other product candidates.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         PersonalizedNeoantigen-directed Therapies (ADXS-NEO)        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        ADXS-NEOis an individualized        <i>         Lm        </i>        Technology antigen delivery product developed using whole-exome sequencing of a patient’stumor to identify neoantigens. ADXS-NEO is designed to work by presenting a large payload of neoantigens directly into dendriticcells within the patient’s immune system and stimulating a T cell response against cancerous cells. In October 2019, theCompany announced that it has dosed its last patient in Part A, in monotherapy, and does not intend to continue into Part B, incombination with a checkpoint inhibitor. As a result, Advaxis is in the process of winding down this study. The Company has completedthe clinical study report from Part A of the ADXS-NEO study and plans to close its ADXS-NEO program IND as next step.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 7; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           7           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         ProstateCancer (ADXS-PSA        </i>        )       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Accordingto the American Cancer Society, prostate cancer is the second most common type of cancer found in American men and is the secondleading cause of cancer death in men, behind only lung cancer. More than 160,000 men are estimated to be diagnosed with prostatecancer in 2018, with approximately 30,000 deaths each year. Unfortunately, in about 10-20% of cases, men with prostate cancerwill go on to develop castration-resistant prostate cancer, or CRPC, which refers to prostate cancer that progresses despite androgendeprivation therapy. Metastatic CRPC, or mCRPC, occurs when the cancer spreads to other parts of the body and there is a risingprostate-specific antigen, PSA, level. This stage of prostate cancer has an average survival of 9-13 months, is associated withdeterioration in quality of life, and has few therapeutic options available.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Recentdata regarding checkpoint inhibitor monotherapy has shown some antitumor activity that provides disease control in a subset ofpatients with bone predominant mCRPC previously treated with next generation hormonal agents and docetaxel. Data from the KEYNOTE-199trial in bone predominant-mCRPC patients treated with KEYTRUDA®, or pembrolizumab, was updated at the ASCO GU meeting in 2019.In this trial, the total stable disease/disease stabilization rate was 39% with no responses reported so far, and only one patientwith ≥50% decrease in the post-baseline PSA value. It is hypothesized that the limited activity in mCRPC may be due to 1) theinability of the checkpoint inhibitor to infiltrate the tumor microenvironment and 2) the presence of an immunosuppressive tumormicro-environment, or TME. The combination therapy with agents—like        <i>         Lm        </i>        constructs—that induce T cell infiltrationwithin the tumor and decrease negative regulators in the TME may improve performance of checkpoints in prostate cancer.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Lm        </i>        Technology constructs demonstrated the ability to induce anti-tumor T cell responses and T cell infiltration in the TME andto reduce the number and suppressive function of Tregs and MDSCs in the TME. For example, destruction of Tregs in the TME hasbeen documented as soon as five days after dosing        <i>         Lm        </i>        constructs in models. This reduction of immune suppression in thetumors has been attributed to our proprietary tLLO-fusion peptides expressed by multiple copies of the plasmids in each bacteria.Because of all these effects, it is hypothesized that        <i>         Lm        </i>        constructs can turn “cold prostate tumors” into “hottumors” that better respond to checkpoint inhibitors. Advaxis believes that the combination of ADXS-PSA, its immunotherapydesigned to target the PSA antigen, with a checkpoint inhibitor may provide an alternative treatment option for patients withmCRPC.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Advaxishas entered into a clinical trial collaboration and supply agreement with Merck to evaluate the safety and efficacy of ADXS-PSAas monotherapy and in combination with KEYTRUDA        <sup>         ®        </sup>        , Merck’s anti PD-1 antibody, in a Phase 1/2, open-label,multicenter, dose determination and expansion trial in patients with previously treated metastatic, castration-resistant prostatecancer (KEYNOTE-046). ADXS-PSA was tested alone or in combination with KEYTRUDA in an advanced and heavily pretreated patientpopulation who had progressed on androgen deprivation therapy. A total of 13 and 37 patients were evaluated on monotherapy andcombination therapy, respectively. For the ADXS-PSA monotherapy dose escalation and determination portion of the trial, cohortswere started at a dose of 1 x 10        <sup>         9        </sup>        cfu (n=7) and successfully escalated to higher dose levels of 5x10        <sup>         9        </sup>        cfu(n=3) and 1x10        <sup>         10        </sup>        cfu (n=3) without achieving a maximum tolerated dose. TEAEs noted at these higher dose levels weregenerally consistent with those observed at the lower dose level (1 x 10        <sup>         9        </sup>        cfu) other than a higher occurrence rateof Grade 2/3 hypotension. The Recommended Phase II Dose of ADXS-PSA monotherapy was determined to be 1x 10        <sup>         9        </sup>        cfu basedon a review of the totality of the clinical data. This dose was used in combination with 200mg of pembrolizumab in a cohort ofsix patients to evaluate the safety of the combination before moving into an expanded cohort of patients. The safety of the combinationwas confirmed and enrollment in the expansion cohort phase was initiated. Enrollment in the study was completed in January 2017.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Atthe final data cutoff of September 16, 2019, median overall survival for 37 patients in the combination arm was 33.6 months (95%CI, range 15.4-33.6 months). This updated median overall survival is an increase from the previous data presented at the AmericanAssociation for Cancer Research Annual Meeting in April 2019, where median overall survival was 21.1 months in the combinationarm. The combination of ADXS-PSA with KEYTRUDA        <sup>         ®        </sup>        , might be associated with prolonged OS in this population, particularlyin patients with unmet medical needs like visceral metastasis (16.4 months, range 4.0 - not reached) and those with prior docetaxel(16 months, range 6.4-34.6). The majority of TEAEs consisted of transient and reversible Grade 1-2 chills/rigors, fever, hypotension,nausea and fatigue. The combination of ADXS-PSA and KEYTRUDA® has appeared to be well-tolerated to date, with no additivetoxicity observed. The Company presented these new data at the ASCO Genitourinary Cancers Symposium in San Francisco, CA. on February2020. The Company is currently seeking potential partners regarding opportunities to expand or advance this mCRPC program.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Other         </i>         Lm         <i>          Technology Products         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font: 10pt Times New Roman, Times, Serif">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         <u>          HER2Expressing Solid Tumors         </u>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        HER2is overexpressed in a percentage of solid tumors including osteosarcoma. According to published literature, up to 60% of osteosarcomasare HER2 positive, and this overexpression is associated with poor outcomes for patients. ADXS-HER2 is an        <i>         Lm        </i>        Technologyantigen delivery product candidate designed to target HER2 expressing solid tumors including human and canine osteosarcoma. ADXS-HER2has received FDA and EMA orphan drug designation for osteosarcoma and has received Fast Track designation from the FDA for patientswith newly-diagnosed, non-metastatic, surgically-resectable osteosarcoma.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InSeptember 2018, the Company announced that it had granted a license to OS Therapies, LLC, or OS Therapies, for the use of ADXS31-164,also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement,OS Therapies, in collaboration with the Children’s Oncology Group, will be responsible for the conduct and funding of aclinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. In December 2020 and January 2021, we receivedan aggregate of $1,345,000 from OS Therapies upon achievement of the $1,550,000 funding milestone set forth in the license agreement.For more information, see Note 15, “Subsequent Events” of the “Notes to the Financial Statements”included in Item 8.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 8; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           8           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         <u>          CanineOsteosarcoma         </u>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnMarch 19, 2014, we entered into a definitive Exclusive License Agreement, or Aratana Agreement, with Aratana Therapeutics, Inc.,or Aratana, where we granted Aratana an exclusive, worldwide, royalty-bearing license, with the right to sublicense, certain ofour proprietary technology that enables Aratana to develop and commercialize animal health products that will be targeted fortreatment of osteosarcoma and other cancer indications in animals. A product license request was filed by Aratana for ADXS-HER2(also known as AT-014 by Aratana) for the treatment of canine osteosarcoma with the United States Department of Agriculture, orUSDA. Aratana received communication in December 2017 that the USDA granted Aratana conditional licensure for AT-014 for the treatmentof dogs diagnosed with osteosarcoma, one year of age or older. Initially, Aratana plans to make the therapeutic available forpurchase at approximately two dozen veterinary oncology practice groups across the United States who participate in the study.Aratana received communication in December 2017 that the USDA granted Aratana conditional licensure for AT-014 for the treatmentof dogs diagnosed with osteosarcoma, one year of age or older. Aratana is currently conducting an extended field study which isa requirement for full USDA licensure. Initially, Aratana plans to make the therapeutic available for purchase at approximatelytwo dozen veterinary oncology practice groups across the United States who participate in the study.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Underthe terms of the Aratana Agreement, Aratana paid an upfront payment to Advaxis in the amount of $1,000,000 upon signing of theAratana Agreement. Aratana will also pay Advaxis: (a) up to $36.5 million based on the achievement of milestone relating to theadvancement of products through the approval process with the USDA in the United States and the relevant regulatory authoritiesin the European Union, or E.U., in all four therapeutic areas and up to an additional $15 million in cumulative sales milestonesbased on achievement of gross sales revenue targets for sales of any and all products for use in non-human animal health applications,or the Aratana Field, (regardless of therapeutic area), and (b) tiered royalties starting at 5% and going up to 10%, which willbe paid based on net sales of any and all products (regardless of therapeutic area) in the Aratana Field in the United States.Royalties for sales of products outside of the United States will be paid at a rate equal to half of the royalty rate payableby Aratana on net sales of products in the United States (starting at 2.5% and going up to 5%). Royalties will be payable on aproduct-by-product and country-by-country basis from first commercial sale of a product in a country until the later of (a) the10th anniversary of first commercial sale of such product by Aratana, its affiliates or sub licensees in such country or (b) theexpiration of the last-to-expire valid claim of our patents or joint patents claiming or covering the composition of matter, formulationor method of use of such product in such country. Aratana will also pay us 50% of all sublicense royalties received by Aratanaand its affiliates. In fiscal year 2019, the Company received approximately $8,000 in royalty revenue from Aratana. Additionally,in July 2019, Aratana announced that their shareholders approved a merger agreement with Elanco Animal Health, or Elanco, wherebyElanco is now the majority shareholder of Aratana. On October 6, 2020, the Company received a notice from Aratana, dated September17, 2020, indicating that Aratana was terminating the Exclusive License Agreement effective December 21, 2020. The Company didnot incur any early termination penalties as a result of the termination. Aratana was required to make all payments to the Companythat were otherwise payable under the Exclusive License Agreement through the effective date of termination.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         CorporateInformation        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wewere originally incorporated in the State of Colorado on June 5, 1987 under the name Great Expectations, Inc. We were a publicly-traded“shell” company without any business until November 12, 2004 when we acquired Advaxis, Inc., a Delaware corporation,through a Share Exchange and Reorganization Agreement, dated as of August 25, 2004, which we refer to as the Share Exchange, byand among Advaxis, the stockholders of Advaxis and us. As a result of the Share Exchange, Advaxis became our wholly-owned subsidiaryand our sole operating company. On December 23, 2004, we amended and restated our articles of incorporation and changed our nameto Advaxis, Inc. On June 6, 2006, our stockholders approved the reincorporation of our company from Colorado to Delaware by mergingthe Colorado entity into our wholly-owned Delaware subsidiary. Our date of inception, for financial statement purposes, is March1, 2002 and the Company was uplisted to Nasdaq in 2014.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourprincipal executive offices and manufacturing facility is located at 305 College Road East, Princeton, New Jersey 08540 and ourtelephone number is (609) 452-9813. We maintain a corporate website at www.advaxis.com which contains descriptions of our technology,our product candidates and the development status of each drug. We make available free of charge through our Internet websiteour annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, and any amendments to these reports,as soon as reasonably practicable after we electronically file such material with, or furnish such material to, the SEC. We arenot including the information on our website as a part of, nor incorporating it by reference into, this report. The SEC maintainsa website that contains annual, quarterly, and current reports, proxy statements, and other information that issuers (includingus) file electronically with the SEC. The SEC’s website address is http://www.sec.gov.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         IntellectualProperty        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Protectionof our intellectual property is important to our business. We have a robust patent portfolio that protects our product candidatesand        <i>         Lm        </i>        -based immunotherapy technology. Currently, we own or have rights to several hundred patents and applications, whichare owned, licensed from, or co-owned with University of Pennsylvania, or Penn, Merck, National Institute of Health, or NIH, and/orAugusta University. We aggressively prosecute and defend our patents and proprietary technology. Our patents and applicationsare directed to the compositions of matter, use, and methods thereof, of our        <i>         Lm        </i>        -LLO immunotherapies for our product candidates,including AXAL, ADXS-PSA, ADXS-HOT, ADXS-HER2. We have and may continue to abandon prosecuting certain patents that are not strategicallyaligned with the direction of the Company.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 9; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           9           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourapproach to the intellectual property portfolio is to create, maintain, protect, enforce and defend our proprietary rights forthe products we develop from our immunotherapy technology platform. We endeavor to maintain a coherent and aggressive strategicapproach to building our patent portfolio with an emphasis in the field of cancer vaccines. Issued patents which are directedto AXAL, ADXS-PSA, and ADXS-HER2 in the United States, will expire between 2020 and 2032. Issued patents directed to our productcandidates AXAL, ADXS-PSA, and ADXS-HER2 outside of the United States, will expire in 2032. Issued patents directed to our        <i>         Lm        </i>        -based immunotherapy platform in the United States, will expire between 2020 and 2031. Issued patents directed to our        <i>         Lm        </i>        -basedimmunotherapy platform outside of the United States, will expire between 2020 and 2033.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave pending patent applications directed to our product candidates AXAL, ADXS-PSA, ADXS-HER2, and ADXS-HOT that, if issued wouldexpire in the United States and in countries outside of the United States between 2020 and 2037. We have pending patent applicationsdirected to methods of using of our product candidates AXAL, ADXS-PSA, ADXS-HOT, ADXS-HER2 directed to the following indicationsand others: prostate cancer and her2/neu-expressing cancer, that, if issued would expire in the United States and in countriesoutside of the United States between 2020 and 2037, depending on the specific indications.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wewill be able to protect our technology from unauthorized use by third parties only to the extent it is covered by valid and enforceablepatents or is effectively maintained as trade secrets. Patents and other proprietary rights are an essential element of our business.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Oursuccess will depend in part on our ability to obtain and maintain proprietary protection for our product candidates, technology,and know-how, to operate without infringing on the proprietary rights of others, and to prevent others from infringing our proprietaryrights. Our policy is to seek to protect our proprietary position by, among other methods, filing U.S. and foreign patent applicationsrelated to our proprietary technology, inventions, and improvements that are important to the development of our business. Wealso rely on trade secrets, know-how, continuing technological innovation, and in-licensing opportunities to develop and maintainour proprietary position.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Anypatent applications which we have filed or will file or to which we have or will have license rights may not issue, and patentsthat do issue may not contain commercially valuable claims. In addition, any patents issued to us or our licensors may not affordmeaningful protection for our products or technology, or may be subsequently circumvented, invalidated, narrowed, or found unenforceable.Our processes and potential products may also conflict with patents which have been or may be granted to competitors, academicinstitutions or others. As the pharmaceutical industry expands and more patents are issued, the risk increases that our processesand potential products may give rise to interferences filed by others in the U.S. Patent and Trademark Office, or to claims ofpatent infringement by other companies, institutions or individuals. These entities or persons could bring legal actions againstus claiming damages and seeking to enjoin clinical testing, manufacturing and marketing of the related product or process. Inrecent years, several companies have been extremely aggressive in challenging patents covering pharmaceutical products, and thechallenges have often been successful. If any of these actions are successful, in addition to any potential liability for damages,we could be required to cease the infringing activity or obtain a license in order to continue to manufacture or market the relevantproduct or process. We may not prevail in any such action and any license required under any such patent may not be made availableon acceptable terms, if at all. Our failure to successfully defend a patent challenge or to obtain a license to any technologythat we may require to commercialize our technologies or potential products could have a materially adverse effect on our business.In addition, changes in either patent laws or in interpretations of patent laws in the United States and other countries may materiallydiminish the value of our intellectual property or narrow the scope of our patent protection.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wealso rely upon unpatented proprietary technology, and in the future may determine in some cases that our interests would be betterserved by reliance on trade secrets or confidentiality agreements rather than patents or licenses. We may not be able to protectour rights to such unpatented proprietary technology and others may independently develop substantially equivalent technologies.If we are unable to obtain strong proprietary rights to our processes or products after obtaining regulatory clearance, competitorsmay be able to market competing processes and products.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Othersmay obtain patents having claims which cover aspects of our products or processes which are necessary for, or useful to, the development,use or manufacture of our services or products. Should any other group obtain patent protection with respect to our discoveries,our commercialization of potential therapeutic products and methods could be limited or prohibited.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         TheDrug Development Process        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theproduct candidates in our pipeline are at various stages of clinical development. The path to regulatory approval includes multiplephases of clinical trials in which we collect data that will ultimately support an application to regulatory authorities to allowus to market a product for the treatment, of a specific type of cancer. There are many difficulties and uncertainties inherentin research and development of new products, resulting in high costs and variable success rates. Bringing a drug from discoveryto regulatory approval, and ultimately to market, takes many years and significant costs.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 10; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           10           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theprocess required by the FDA before product candidates may be marketed in the United States generally involves the following:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           completion    of preclinical laboratory tests, animal studies, and formulation studies in compliance with the FDA’s Good Laboratory    Practice, or GLP, regulations;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           submission    to the FDA of an Investigational New Drug Application, or IND, which must become effective before human clinical trials may    begin at United States clinical trial sites;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           approval    by an Institutional Review Board, or IRB for each clinical site, or centrally, before each trial may be initiated;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           adequate    and well-controlled human clinical trials to establish the product candidate’s safety, purity, and potency for its intended    use, performed in accordance with Good Clinical Practices, or GCPs;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           development    of manufacturing processes to ensure the product candidate’s identity, strength, quality, purity, and potency;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           submission    to the FDA of a Biologics License Application, or BLA;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           satisfactory    completion of an FDA advisory committee review, if applicable;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           satisfactory    completion of an FDA inspection of the manufacturing facility or facilities at which the products are produced to assess compliance    with current Good Manufacturing Practices, or cGMPs, and to assure that the facilities, methods, and controls are adequate    to preserve the therapeutics’ identity, strength, quality, purity, and potency as well as satisfactory completion of    an FDA inspection of selected clinical sites and selected clinical investigators to determine GCP compliance; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           FDA    review and approval of the BLA to permit commercial marketing for particular indications for use.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Preclinicalstudies include laboratory evaluation of chemistry, pharmacology, toxicity, and product formulation, as well as animal studiesto assess potential safety and efficacy. Such studies must generally be conducted in accordance with the FDA’s GLPs. Priorto commencing the first clinical trial at a United States investigational site with a product candidate, an IND sponsor must submitthe results of the preclinical tests and preclinical literature, together with manufacturing information, analytical data, anyavailable clinical data or literature, and proposed clinical study protocols among other things, to the FDA as part of an IND.An IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA notifies the applicant of safety concernsor questions related to one or more proposed clinical trials and places the trial on a clinical hold. In such a case, the INDsponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposedby the FDA at any time before or during trials due to safety concerns or non-compliance. A separate submission to an existingIND must also be made for each successive clinical trial conducted during product development.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Clinicaltesting, known as clinical trials or clinical studies, is either conducted internally by pharmaceutical or biotechnology companiesor managed on behalf of these companies by Clinical Research Organizations, or CROs. The process of conducting clinical studiesis highly regulated by the FDA, as well as by other governmental and professional bodies. In a clinical trial, participants receivespecific interventions according to the research plan or protocol created by the study sponsor and implemented by study investigators.Clinical trials must be conducted in accordance with federal regulations and GCP requirements, which include the requirementsthat all research subjects provide their informed consent in writing for their participation in any clinical trial, as well asreview and approval of the study by an IRB. Additionally, some clinical trials are overseen by an independent data safety monitoringboard, which reviews data and advises the study sponsor on study continuation. A protocol for each clinical trial, and any subsequentprotocol amendments, must be submitted to the FDA as part of the IND.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Clinicaltrials may compare a new medical approach to a standard one that is already available or to a placebo that contains no activeingredients or to no intervention. Some clinical trials compare interventions that are already available to each other. When anew product or approach is being studied, it is not usually known whether it will be helpful, harmful, or no different than availablealternatives. The investigators try to determine the safety and efficacy of the intervention by measuring certain clinical outcomesin the participants.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Phase1        </i>        . Phase 1 clinical trials begin when regulatory agencies allow initiation of clinical investigation of a new drug or productcandidate. They typically involve testing an investigational new drug on a limited number of patients. Phase 1 studies determinea drug’s basic safety, maximum tolerated dose, mechanism of action and how the drug is absorbed by, and eliminated from,the body. Typically, cancer therapies are initially tested on late-stage cancer patients.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Phase2.        </i>        Phase 2 clinical trials involve larger numbers of patients that have been diagnosed with the targeted disease or condition.Phase 2 clinical trials gather preliminary data on effectiveness (where the drug works in people who have a certain disease orcondition) and to determine the common short-term side effects and risks associated with the drug. If Phase 2 clinical trialsshow that an investigational new drug has an acceptable range of safety risks and probable effectiveness, a company will continueto evaluate the investigational new drug in Phase 3 studies.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 11; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           11           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Phase3.        </i>        Phase 3 clinical trials are typically controlled multi-center trials that involve a larger number of patients to ensurethe study results are statistically significant. The purpose is to confirm effectiveness and safety on a large scale and to providean adequate basis for physician labeling. These trials are generally global in nature and are designed to generate clinical datanecessary to submit an application for marketing approval to regulatory agencies. Typically, two Phase 3 trials are required forproduct approval. Under limited circumstances, however, approval may be based upon a single adequate and well-controlled clinicaltrial plus confirmatory evidence or a single large multicenter trial without confirmatory evidence.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        FDAmay also consider additional kinds of data in support of a BLA, such as patient experience data and real world evidence. For geneticallytargeted populations and variant protein targeted products intended to address an unmet medical need in one or more patient subgroupswith a serious or life threatening rare disease or condition, the FDA may allow a sponsor to rely upon data and information previouslydeveloped by the sponsor or for which the sponsor has a right of reference, that was submitted previously to support an approvedapplication for a product that incorporates or utilizes the same or similar genetically targeted technology or a product thatis the same or utilizes the same variant protein targeted drug as the product that is the subject of the application.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Reportsregarding clinical study progress must be submitted to the FDA and IRB on an annual basis. Additional reports are required ifserious adverse events or other significant safety information is found. Certain reports may also be required to be submittedto the IBC. Investigational biologics must additionally be manufactured in accordance with cGMPs, imported in accordance withFDA requirements, and exported in accordance with the requirements of the receiving country as well as FDA.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Additionally,under the Pediatric Research Equity Act, or PREA, BLAs or BLA supplements for a new active ingredient, dosage form, dosage regimen,or route of administration, unless subject to the below requirement for molecularly targeted cancer products, must contain datato assess the safety and effectiveness of the product in all relevant pediatric subpopulations. The FDA may, however, grant deferralsor full or partial waivers of this requirement. PREA does not apply to orphan designated products approved solely for the orphanindication.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifa product is intended for the treatment of adult cancer and is directed at molecular targets that the FDA determines to be substantiallyrelevant to the growth or progression of pediatric cancer, even if the product has orphan designation, the application sponsorsmust submit, reports from molecularly targeted pediatric cancer investigations designed to yield clinically meaningful pediatricstudy data, gathered using appropriate formulations for each applicable age group, to inform potential pediatric labeling. LikePREA, FDA may grant deferrals or waivers of some or all of this data requirement.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Certaingene therapy studies are also subject to the National Institutes of Health’s Guidelines for Research Involving RecombinantDNA Molecules, or NIH Guidelines. The NIH Guidelines include the review of the study by a local institutional committee calledan institutional biosafety committee, or IBC. The IBC assesses the compliance of the research with the NIH Guidelines, assessesthe safety of the research and identifies any potential risk to public health or the environment.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition to the regulations discussed above, there are a number of additional standards that apply to clinical trials involvingthe use of gene therapy. The FDA has issued various guidance documents regarding gene therapies, which outline additional factorsthat the FDA will consider during product development. These include guidance regarding preclinical studies; chemistry, manufacturing,and controls; the measurement of product potency; how FDA will determine whether a gene therapy product is the same as anotherproduct for the purpose of the agency’s orphan drug regulations; and long term patient and clinical study subject followup and regulatory reporting.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         BiologicLicense Application (BLA)        </i>        . During clinical trials, companies usually also complete additional preclinical studies. Companiesfurther develop additional information about the product candidate’s physical characteristics and finalize the cGMP manufacturingprocess. The results of the clinical trials using biologics are submitted to the FDA as part of a BLA. Following the completionof Phase 3 studies, if the sponsor of a potential product in the United States believes it has sufficient information to supportthe safety and effectiveness of the investigational biologic, the sponsor submits a BLA to the FDA requesting marketing approval.The application is a comprehensive filing that includes the results of all preclinical and clinical studies, information aboutthe product’s composition, and the sponsor’s plans for manufacturing, packaging, labeling and testing the investigationalnew product       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Subjectto certain exceptions, the BLA must be accompanied by a substantial user fee at the time of the first submission. FDA has 60 daysfrom its receipt of a BLA to determine whether the application is sufficiently complete for filing and for a substantive review.If the FDA determines that the NDA is incomplete, the FDA may refuse to file the application, in which case the applicant mustaddress the FDA identified deficiencies before refiling. After the BLA is accepted for filing, the FDA reviews the applicationto determine whether the product meets FDA’s approval standards. The FDA aims to complete its review within ten months ofthe 60-day filing date. For products that present significant improvements in the safety or effectiveness of the treatment, diagnosis,or prevention of serious conditions FDA aims to complete its review within 6 months of the 60-day filing date. The FDA, however,does not always meet its review goal. The review goal date may also be extended if FDA requests or the sponsor provides additionalinformation regarding the application. As part of the approval process, FDA will typically inspect one or more clinical sites,as well as the facility or the facilities at which the product is manufactured to ensure GCP and cGMP compliance.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 12; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           12           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        FDAmay also refer an application for review by an independent advisory committee. Specifically, for a product candidate for whichno active ingredient (including any ester or salt of active ingredients) has previously been approved by the FDA, the FDA musteither refer that product candidate to an advisory committee or provide in an action letter, a summary of the reasons why theFDA did not refer the product candidate to an advisory committee. While FDA is not bound by the recommendation of an advisorycommittee, it does carefully consider the committee’s recommendations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Afterevaluating the application, FDA may issue an approval letter, authorizing product marketing, or a Complete Response Letter, orCRL, indicating that the application is not ready for approval. The CRL describes the application’s deficiencies and conditionsthat must be met for product approval. If a CRL is issued, the applicant may resubmit the application, addressing the deficiencies,withdraw the application, or request a hearing. Even with submission of additional information, the FDA ultimately may decidethat the application is not approvable.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifapproval is granted, the FDA may limit the indications for use, including the indicated population, require contraindications,warnings or precautions be included in the product labeling, including black box warnings, or may not approve label statementsnecessary for successful commercialization. FDA may also require, or companies may conduct, additional clinical trials followingapproval, called Phase 4 studies, which can confirm or refute the effectiveness of a product candidate, and can provide importantsafety information. FDA may also require the implementation of a risk evaluation and mitigation strategy, or REMS, which may includerequirements for a medication guide or patient package insert, a communication plan on product risks, or other elements to assuresafe use.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Afterapproval, some types of changes to the approved product, such as adding new indications or label claims, which may themselvesrequire further clinical testing, or changing the manufacturing process are subject to further FDA review and approval. FDA canalso require the implementation REMS or the conduct of phase 4 studies after product approval.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         GovernmentRegulations        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         General        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Governmentauthorities in the United States and other countries extensively regulate, among other things, the preclinical and clinical testing,manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of biopharmaceuticaland drug products. In the United States, the FDA subjects drugs to rigorous review under the Federal Food, Drug and Cosmetic Act,or FDCA, the Public Health Service Act, or PHSA, and implementing regulations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         OrphanDrug Designation        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Underthe Orphan Drug Act, or ODA, the FDA may grant Orphan Drug Designation, or ODD, to a drug or biological product intended to treata rare disease or condition, which means a disease or condition that affects fewer than 200,000 individuals in the United States,or more than 200,000 individuals in the United States, but for which there is no reasonable expectation that the cost of developingand making a drug or biological product available in the United States will be recovered from domestic sales of the product. Additionally,sponsors must present a plausible hypothesis for clinical superiority to obtain ODD if there is a product already approved bythe FDA that that is considered by the FDA to be the same as the already approved product and is intended for the same indication.This hypothesis must be demonstrated to obtain orphan exclusivity.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thebenefits of ODD can be substantial, including research and development tax credits, grants and exemption from user fees. The taxadvantages, however, were limited in the 2017 Tax Cuts and Jobs Act. Moreover, if there is no other product that the FDA considersto be the same product that is approve for the orphan indication, the orphan designated product is eligible for 7 yearsof orphan market exclusivity once the product is approved. During that period, the FDA generally may not approve any other applicationfor the same product for the same indication, although there are exceptions, most notably when the later product is shown to beclinically superior to the product with exclusivity. Other applicants, however, may receive approval of different products forthe orphan indication or the same product for a different indication during the orphan exclusivity period. In order to qualifyfor these incentives, a company must apply for designation of its product as an “Orphan Drug” and obtain approvalfrom the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review andapproval process.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 13; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           13           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wecurrently have ODD with the FDA for AXAL for treatment of anal cancer (granted August 2013), HPV-associated head and neck cancer(granted November 2013); and treatment of Stage II-IV invasive cervical cancer (granted May 2014). We also have ODD with the FDAfor ADXS-HER2 for the treatment of osteosarcoma (granted May 2014).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InEurope, the Committee for Orphan Medicinal Products, COMP, has issued a positive opinion on the application for ODD of AXAL forthe treatment of anal cancer (December 2015) and on the application for ODD of ADXS-HER2 for osteosarcoma (November 2015).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         ExpeditedReview and Approval Programs for Serious Conditions        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Fourcore FDA programs are intended to facilitate and expedite development and review of new biologics to address unmet medical needin the treatment of serious or life-threatening conditions: fast track designation, breakthrough therapy designation, acceleratedapproval, and priority review. We intend to avail ourselves of any and all of these programs as applicable to our products.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        FDAis required to facilitate the development, and expedite the review, of products that are intended for the treatment of a seriousor life-threatening disease or condition, and which demonstrate the potential to address unmet medical needs for the condition.Under the fast track program, the sponsor of a new biologic product candidate may request that FDA designate the drug candidatefor a specific indication as a fast track drug concurrent with, or after, the filing of the IND for the product candidate. FDAmust determine if the product candidate qualifies for Fast Track Designation within 60 days of receipt of the sponsor’srequest. If Fast Track Designation is obtained, sponsors may be eligible for more frequent development meetings and correspondencewith the FDA. FDA may also initiate review of sections of a fast track product’s BLA before the application is complete.This rolling review is available if the applicant provides, and FDA approves, a schedule for the submission of the remaining informationand the applicant pays applicable user fees. However, FDA’s time period goal for reviewing an application does not beginuntil the last section of the BLA is submitted.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        UnderFDA’s accelerated approval programs, FDA may approve a product for a serious or life-threatening illness that provides meaningfultherapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predictclinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonablylikely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity,rarity or prevalence of the condition and the availability or lack of alternative treatments.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inclinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutesfor a direct measurement of how a patient feels, functions or survives. Surrogate endpoints can often be measured more easilyor more rapidly than clinical endpoints. A product candidate approved on this basis is subject to rigorous post-marketing compliancerequirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint.Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow FDAto withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved underaccelerated regulations are subject to prior review by FDA.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Underthe provisions of the Food and Drug Administration Safety and Innovation Act, or FDASIA, enacted in 2012, a sponsor can requestdesignation of a product candidate as a “breakthrough therapy.” A breakthrough therapy is defined as a product thatis intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition,and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies onone or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Productsdesignated as breakthrough therapies are eligible for intensive guidance on an efficient development program beginning as earlyas Phase 1 trials, a commitment from the FDA to involve senior managers and experienced review staff in a proactive collaborativeand cross-disciplinary review, rolling review, and the facilitation of cross-disciplinary review.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Anotherexpedited pathway is the Regenerative Medicine Advanced Therapy, or RMAT, designation. Qualifying products must be a cell therapy,therapeutic tissue engineering product, human cell and tissue product, or a combination of such products, and not a product solelyregulated as a human cell and tissue product. The product must be intended to treat, modify, reverse, or cure a serious or life-threateningdisease or condition, and preliminary clinical evidence must indicate that the product has the potential to address an unmet needfor such disease or condition. Advantages of the RMAT designation include all the benefits of the Fast Track and breakthroughtherapy designation programs, including early interactions with the FDA. These early interactions may be used to discuss potentialsurrogate or intermediate endpoints to support accelerated approval.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Evenif a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditionsfor qualification or decide that the time period for FDA review or approval will not be shortened.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Disclosureof Clinical Trial Information        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Sponsorsof clinical trials of FDA regulated products, including biologics, are required to register and submit certain clinical trialinformation within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their clinicaltrials.govwebsite. Information related to the product, patient population, phase of investigation, Trial sites and investigators and otheraspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the resultsof their clinical trials after completion. Disclosure of the results of these trials can be delayed in certain circumstances forup to two years, depending on the circumstances, after the date of completion of the trial. Competitors may use this publiclyavailable information to gain knowledge regarding the progress of development programs.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Coverage,Pricing and Reimbursement        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Successfulcommercialization of new drug products depends in part on the extent to which reimbursement for those drug products will be availablefrom government health administration authorities, private health insurers and other organizations. Government authorities andthird-party payors, such as private health insurers and health maintenance organizations, decide which drug products they willpay for and establish reimbursement levels. The availability and extent of reimbursement by governmental and private payors isessential for most patients to be able to afford a drug product. Sales of drug products depend substantially, both domesticallyand abroad, on the extent to which the costs of drugs products are paid for by health maintenance, managed care, pharmacy benefitand similar healthcare management organizations, or reimbursed by government health administration authorities, private healthcoverage insurers and other third-party payors.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 14; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           14           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Aprimary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-partypayors have attempted to control costs by limiting coverage and the amount of reimbursement for particular drug products. In manycountries, the prices of drug products are subject to varying price control mechanisms as part of national health systems. Ingeneral, the prices of drug products under such systems are substantially lower than in the United States. Other countries allowcompanies to fix their own prices for drug products, but monitor and control company profits. Accordingly, in markets outsidethe United States, the reimbursement for drug products may be reduced compared with the United States. In the United States, theprincipal decisions about reimbursement for new drug products are typically made by the Centers for Medicare &amp; Medicaid Services,or CMS, an agency within the Department of Health and Human Services, or HHS. CMS decides whether and to what extent a new drugproduct will be covered and reimbursed under certain federal governmental healthcare programs, such as Medicare, and private payorstend to follow CMS to a substantial degree. However, no uniform policy of coverage and reimbursement for drug products existsamong third-party payors and coverage and reimbursement levels for drug products can differ significantly from payor to payor.In the United States, the process for determining whether a third-party payor will provide coverage for a biological product typicallyis separate from the process for setting the price of such product or for establishing the reimbursement rate that the payor willpay for the product once coverage is approved. With respect to biologics, third-party payors may limit coverage to specific productson an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication,or place products at certain formulary levels that result in lower reimbursement levels and higher cost sharing obligation imposedon patients. A decision by a third-party payor not to cover our product candidates could reduce physician utilization of a product.Moreover, a third-party payor’s decision to provide coverage for a product does not imply that an adequate reimbursementrate will be approved. Adequate third-party reimbursement may not be available to enable a manufacturer to maintain price levelssufficient to realize an appropriate return on its investment in product development. Additionally, coverage and reimbursementfor products can differ significantly from payor to payor. One third-party payor’s decision to cover a particular medicalproduct does not ensure that other payors will also provide coverage for the medical product, or will provide coverage at an adequatereimbursement rate. As a result, the coverage determination process usually requires manufacturers to provide scientific and clinicalsupport for the use of their products to each payor separately and is a time-consuming process.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Coveragepolicies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attainedfor one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates maybe implemented in the future. Third-party payors are increasingly challenging the prices charged for medical products and services,examining the medical necessity and reviewing the cost-effectiveness of pharmaceutical products, in addition to questioning safetyand efficacy. If third-party payors do not consider a product to be cost-effective compared to other available therapies, theymay not cover that product after FDA approval or, if they do, the level of payment may not be sufficient to allow a manufacturerto sell its product at a profit.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, in many foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. Therequirements governing drug pricing and reimbursement vary widely from country to country. In the European Union, governmentsinfluence the price of products through their pricing and reimbursement rules and control of national healthcare systems thatfund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems underwhich products may only be marketed once a reimbursement price has been agreed to by the government. To obtain reimbursement orpricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness ofa particular product to currently available therapies. Other member states allow companies to fix their own prices for medicines,but monitor and control company profits. There can be no assurance that any country that has price controls or reimbursement limitationsfor pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. The downwardpressure on healthcare costs in general, particularly prescription products, has become very intense. As a result, increasinglyhigh barriers are being erected to the entry of new products. In addition, in some countries, cross border imports from low-pricedmarkets exert a commercial pressure on pricing within a country (particularly in the EEA where it is illegal to impede such importsfrom elsewhere within the EEA).       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         OtherHealthcare Laws        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Manufacturing,sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authoritiesin the United States in addition to the FDA, including CMS, the HHS Office of Inspector General and HHS Office for Civil Rights,other divisions of the HHS and the Department of Justice.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Healthcareproviders, physicians, and third-party payors will play a primary role in the recommendation and prescription of any productsfor which we obtain marketing approval. Our current and future arrangements with third-party payors, healthcare providers andphysicians may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain thebusiness or financial arrangements and relationships through which we market, sell and distribute any drugs for which we obtainmarketing approval. In the United States, these laws include, without limitation, state and federal anti-kickback, false claims,physician transparency, and patient data privacy and security laws and regulations, including but not limited to those describedbelow.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheU.S. federal Anti-Kickback Statute, or AKS, prohibits, among other things, any person or entity from knowingly and willfully offering,paying, soliciting, receiving or providing any remuneration, directly or indirectly, overtly or covertly, to induce or in returnfor purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any good, facility, item orservice reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term “remuneration”has been broadly interpreted to include anything of value. The AKS has been interpreted to apply to arrangements between pharmaceuticaland medical device manufacturers on the one hand and prescribers, purchasers, formulary managers and beneficiaries on the otherhand. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution,the exceptions and safe harbors are drawn narrowly. Failure to meet all of the requirements of a particular applicable statutoryexception or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangementwill be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts haveinterpreted the statute’s intent requirement to mean that if any one purpose of an arrangement involving remuneration isto induce referrals of federal healthcare covered business, the statute has been violated. In addition, a person or entity doesnot need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Moreover,a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposesof the federal civil False Claims Act.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 15; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           15           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Althoughwe would not submit claims directly to payors, drug manufacturers can be held liable under the federal False Claims Act, whichimposes civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities (includingmanufacturers) for, among other things, knowingly presenting, or causing to be presented to federal programs (including Medicareand Medicaid) claims for items or services, including drugs, that are false or fraudulent, claims for items or services not providedas claimed, or claims for medically unnecessary items or services. The government may deem manufacturers to have “caused”the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customersor promoting a product off-label. Several biopharmaceutical, medical device and other healthcare companies have been prosecutedunder federal false claims and civil monetary penalty laws for, among other things, allegedly providing free product to customerswith the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted forcausing false claims to be submitted because of the companies’ marketing of products for unapproved (e.g., or off-label),and thus non-covered, uses. In addition, the civil monetary penalties statute imposes penalties against any person who is determinedto have presented or caused to be presented a claim to a federal health program that the person knows or should know is for anitem or service that was not provided as claimed or is false or fraudulent. Claims which include items or services resulting froma violation of the federal AKS are false or fraudulent claims for purposes of the False Claims Act.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourfuture marketing and activities relating to the reporting of wholesaler or estimated retail prices for our products, if approved,the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state and third-partyreimbursement for our products, and the sale and marketing of our product candidates, are subject to scrutiny under these laws.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       The federal Health InsurancePortability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among otheractions, knowingly and wilfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of falseor fraudulent pretences, representations or promises, any money or property owned by, or under the control or custody of,any healthcare benefit program, including private third-party payors, knowingly and wilfully embezzling or stealing froma healthcare benefit program, wilfully obstructing a criminal investigation of a healthcare offense and knowingly and wilfullyfalsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement inconnection with the delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal Anti-KickbackStatute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order tohave committed a violation.      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, there has been a recent trend of increased federal and state regulation of payments made to physicians and certain otherhealthcare providers. The Affordable Care Act, or the ACA, imposed, among other things, new annual reporting requirements throughthe Physician Payments Sunshine Act for covered manufacturers for certain payments and “transfers of value” providedto physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate familymembers. Failure to submit timely, accurately and completely the required information for all payments, transfers of value andownership or investment interests may result in civil monetary penalties. Covered manufacturers must submit reports by the 90thday of each subsequent calendar year and the reported information is publicly made available on a searchable website.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wemay also be subject to data privacy and security regulation by both the federal government and the states in which we conductour business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and theirrespective implementing regulations, including the Final HIPAA Omnibus Rule published on January 25, 2013, impose specified requirementsrelating to the privacy, security and transmission of individually identifiable health information held by covered entities andtheir business associates. Among other things, HITECH made HIPAAs security standards directly applicable to “business associates,”defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health informationin connection with providing a service for or on behalf of a covered entity, although it is unclear that we would be considereda “business associate” in the normal course of our business. HITECH also increased the civil and criminal penaltiesthat may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys generalnew authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney’sfees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of healthinformation in certain circumstances, many of which differ from each other in significant ways and may not have the same requirements,thus complicating compliance efforts.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Similarstate and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, may apply to salesor marketing arrangements and claims involving healthcare items or services. Such laws are generally broad and are enforced byvarious state agencies and private actions. Also, many states have similar fraud and abuse statutes or regulations that may bebroader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other stateprograms. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary complianceguidelines and the relevant federal government compliance guidance, and require drug manufacturers to report information relatedto payments and other transfers of value to physicians and other healthcare providers, marketing expenditures or drug pricing.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 16; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           16           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inorder to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesaledistributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who shipproducts into the state even if such manufacturers or distributors have no place of business within the state. Some states alsoimpose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, includingsome states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it movesthrough the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies toestablish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing,pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmaciesand other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companiesfor use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentiallysubject to federal and state consumer protection and unfair competition laws.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thescope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcarereform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recentlyincreased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations,prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities will concludethat our business practices may not comply with current or future statutes, regulations or case law involving applicable fraudand abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or anyother governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties,damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, imprisonment, exclusionof drugs from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of ouroperations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreementor other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability tooperate our business and our financial results. If any of the physicians or other healthcare providers or entities with whom weexpect to do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civilor administrative sanctions, including exclusions from government funded healthcare programs. Ensuring business arrangements complywith applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- andresource-consuming and can divert a company’s attention from the business.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Currentand Future Legislation        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inthe United States and foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changesregarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulatepost-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in morerigorous coverage criteria and additional downward pressure on the price that we, or any collaborators, may receive for any approvedproducts.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheACA, for example, contains provisions that subject biological products to potential competition by lower-cost biosimilars andmay reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extend Medicaidrebates to Medicaid managed care plans, provide for mandatory discounts for certain Medicare Part D beneficiaries and annual feesbased on pharmaceutical companies’ share of sales to federal healthcare programs. With the President Trump administrationand current Congress, there will likely be additional administrative or legislative changes, including modification, repeal orreplacement of all, or certain provisions of the ACA, which may impact reimbursement for drugs and biologics. On January 20, 2017,President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the ACA to waive,defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatoryburden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices.On October 13, 2017, President Trump signed an Executive Order terminating the cost-sharing subsidies that reimburse insurersunder the ACA. Several state Attorneys General filed suit to stop the administration from terminating the subsidies, but theirlawsuit was dismissed by a federal judge in California on July 18, 2018. In addition, CMS has recently finalized regulations thatwould give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, whichmay have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces.Further, each chamber of Congress has put forth multiple bills, and may do so again in the future, designed to repeal or repealand replace portions of the ACA.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        WhileCongress has not passed repeal legislation, the Tax Reform Act includes a provision that repealed, effective January 1, 2019,the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coveragefor all or part of a year that is commonly referred to as the “individual mandate.” Further, the Bipartisan BudgetAct of 2018, or the BBA, among other things, amended the ACA, effective January 1, 2019, to increase from 50 percent to 70 percentthe point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coveragegap in most Medicare drug plans, commonly referred to as the “donut hole.” Congress may consider other legislationto repeal and replace elements of the ACA. On December 14, 2018, a U.S. District Court judge in the Northern District of Texasruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore becausethe mandate was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. The Trumpadministration and CMS have both stated that the ruling will have no immediate effect, and on December 30, 2018 the same judgeissued an order staying the judgment pending appeal. A Fifth Circuit U.S. Court of Appeals hearing to determine whether certainstates and the House of Representatives have standing to appeal the lower court decision was held on July 9, 2019, but it is unclearwhen a Court will render its decision on this hearing, and what effect it will have on the status of the ACA. Litigation and legislationover the ACA are likely to continue, with unpredictable and uncertain results.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 17; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           17           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Additionally,other federal health reform measures have been proposed and adopted in the United States since the ACA was enacted:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee    on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through    2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government    programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which    went into effect in April 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain    in effect through 2027, unless additional Congressional action is taken.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers, and increased the    statute of limitations period for the government to recover overpayments to providers from three to five years.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    Middle Class Tax Relief and Job Creation Act of 2012 required that CMS reduce the Medicare clinical laboratory fee schedule    by 2% in 2013, which served as a base for 2014 and subsequent years. In addition, effective January 1, 2014, CMS also began    bundling the Medicare payments for certain laboratory tests ordered while a patient received services in a hospital outpatient    setting.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Further,there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products,which have resulted in several recent Congressional inquiries and proposed and enacted bills designed to, among other things,bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reformgovernment program reimbursement methodologies for products. In addition, the U.S. government, state legislatures, and foreigngovernments have shown significant interest in implementing cost containment programs, including price-controls, restrictionson reimbursement and requirements for substitution of generic products for branded prescription drugs to limit the growth of governmentpaid healthcare costs. For example, the U.S. government has passed legislation requiring pharmaceutical manufacturers to providerebates and discounts to certain entities and governmental payors to participate in federal healthcare programs. Further, Congressand the current administration have each indicated that it will continue to seek new legislative and/or administrative measuresto control drug costs, and the current administration recently released a “Blueprint”, or plan, to reduce the costof drugs. The Blueprint contains certain measures that the U.S. Department of Health and Human Services is already working toimplement. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapyfor Part B drugs beginning January 1, 2020. This final rule codified CMS’s policy change that was effective January 1, 2019.Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrativemeasures to control drug costs. Individual states in the United States have also been increasingly passing legislation and implementingregulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints,discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases,designed to encourage importation from other countries and bulk purchasing.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Non-U.S.Regulation        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Beforeour products can be marketed outside the United States, they are subject to regulatory approval of the respective authoritiesin the country in which the product should be marketed. The requirements governing the conduct of clinical trials, product licensing,pricing and reimbursement vary widely from country to country. No action can be taken to market any product in a country untilan appropriate application has been approved by the regulatory authorities in that country. The time spent in gaining approvalvaries from that required for FDA approval, and in certain countries, the sales price of a product must also be approved. Thepricing review period often begins after market approval is granted. Even if a product is approved by a regulatory authority,satisfactory prices might not be approved for such product.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Collaborations,Partnerships and Agreements        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Collaborations,partnerships and agreements are a key component of Advaxis’ corporate strategy. As a clinical stage biotechnology companywithout sales revenue, partnerships are an essential part of the ongoing strategy. Additionally, the evolution of the field ofimmunotherapy has resulted in combination treatments becoming ubiquitous; ongoing clinical studies and agreements with many ofthe leading, large oncology pharmaceutical companies helps validate that        <i>         Lm        </i>        Technology may play a key role in the cancertreatment protocols of the future.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourcollaborators and partners include Merck, Aratana, OS Therapies, Biocon, Global BioPharma, Knight, and others. For more information,see Note 8, “Collaboration and Licensing Agreements” of the “Notes to the Financial Statements” includedin Item 8.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weentered into an exclusive worldwide license agreement with Penn, on July 1, 2002 with respect to the innovative work of YvonnePaterson, Ph.D., Associate Dean for Research at the School of Nursing at Penn, and former Professor of Microbiology at Penn, inthe area of innate immunity, or the immune response attributed to immune cells, including dendritic cells, macrophages and naturalkiller cells, that respond to pathogens non-specifically (subject to certain U.S. government rights). This agreement was amendedand restated as of February 13, 2007, and, thereafter, has been amended from time to time.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 18; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           18           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thislicense, unless sooner terminated in accordance with its terms, terminates upon the latter of (a) the expiration of the last toexpire of the Penn patent rights; or (b) twenty years after the effective date of the license. Penn may terminate the licenseagreement early upon the occurrence of certain defaults by us, including, but not limited to, a material breach by us of the Pennlicense agreement that is not cured within 60 days after notice of the breach is provided to us.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thelicense provides us with the exclusive commercial rights to the patent portfolio developed by Penn as of the effective date ofthe license, in connection with Dr. Paterson and requires us to pay various milestone, legal, filing and licensing payments tocommercialize the technology. In exchange for the license, Penn received shares of our Common Stock. In addition, Penn is entitledto receive a non-refundable initial license fee, royalty payments and milestone payments based on net sales and percentages ofsublicense fees and certain commercial milestones. Under the amended licensing agreement, Penn is entitled to receive 2.5% ofnet sales in the territory. Should annual net sales exceed $250 million, the royalty rate will increase to 2.75%, but only withrespect to those annual net sales in excess of $250 million. Additionally, Penn will receive tiered sales milestone payments uponthe achievement of cumulative global sales ranging between $250 million and $2 billion, with the maximum aggregate amounts payableto Penn in the event that maximum sales milestones are achieved is $40 million. Notwithstanding these royalty rates, upon firstin-human commercial sale (U.S. &amp; E.U.), we have agreed to pay Penn a total of $775,000 over a four-year period as an advanceminimum royalty, which shall serve as an advance royalty in conjunction with the above terms. In addition, under the license,we are obligated to pay an annual maintenance fee of $100,000 commencing on December 31, 2010, and each December 31st thereafterfor the remainder of the term of the agreement until the first commercial sale of a Penn licensed product. We are responsiblefor filing new patents and maintaining and defending the existing patents licensed to us and we are obligated to reimburse Pennfor all attorney’s fees, expenses, official fees and other charges incurred in the preparation, prosecution and maintenanceof the patents licensed from Penn.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Uponfirst regulatory approval in humans (US or EU), Penn will be entitled to a milestone payment of $600,000. Furthermore, upon theachievement of the first sale of a product in certain fields, Penn will be entitled to certain milestone payments, as follows:$2.5 million will be due upon the first in-human commercial sale (US or EU) of the first product in the cancer field and $1.0million will be due upon the date of first in-human commercial sale (US or EU) of a product in each of the secondary strategicfields sold.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Manufacturing        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        cGMPs,are the standards identified to conform to requirements by governmental agencies that control authorization and licensure formanufacture and distribution of biologic products for either clinical investigations or commercial sale. GMPs identify the requirementsfor procurement, manufacturing, testing, storage, distribution and the supporting quality systems to ensure that a drug productis safe for its intended application. cGMPs are enforced in the United States by the FDA, under the authorities of the FederalFood, Drug and Cosmetic Act and its implementing regulations and use the phrase “current good manufacturing practices”to describe these standards.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Eachof Advaxis’ wholly owned product candidates is manufactured using a platform process, with uniform methods and testing procedures.This allows for an expedited pathway from construct discovery to clinical product delivery, while helping to keep cost of goodslow.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Advaxishas entered into agreements with multiple third-party organizations, or CMOs, to handle the manufacturing, testing, and distributionof product candidates. These organizations have extensive experience within the biologics space and with the production of clinicaland commercial GMP supplies.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Advaxishas constructed a state-of-the-art manufacturing facility and laboratory to develop and manufacture clinical-grade products, supportingthe clinical trials and future potential commercialization of the Company’s therapeutics. Increased manufacturing capabilityand capacity allows Advaxis to manufacture its own material and reduce reliance on CMOs, and improve supply flexibility, scalability,lead times, and costs of goods. The Company’s long-term manufacturing strategy is to leverage both their partners’capabilities and their internal capabilities in order to build a supply chain that is reliable, flexible, and cost competitive.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Competition        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thebiotechnology and biopharmaceutical industries are characterized by rapid technological developments and a high degree of competition.As a result, our actual or proposed immunotherapies could become obsolete before we recoup any portion of our related researchand development expenses. While we believe that our product candidates, technology, knowledge and experience provide us with competitiveadvantages, we face competition from established and emerging pharmaceutical and biotechnology companies, among others. The biotechnologyand biopharmaceutical industries are highly competitive, and this competition comes from both biotechnology firms and from majorpharmaceutical companies, including: BioNtech, Moderna, Gritstone, BMS, AstraZeneca, Merck, Neon Therapeutics, et al., each ofwhich is pursuing cancer vaccines and/or immunotherapies.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Manyof these companies have substantially greater financial, marketing, and human resources than we do (including, in some cases,substantially greater experience in clinical testing, manufacturing, and marketing of pharmaceutical products). We also experiencecompetition in the development of our immunotherapies from universities and other research institutions and compete with othersin acquiring technology from such universities and institutions. In addition, certain of our immunotherapies may be subject tocompetition from investigational new drugs and/or products developed using other technologies, some of which have completed numerousclinical trials.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 19; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           19           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourcompetition will be determined in part by the potential indications for which drugs are developed and ultimately approved by regulatoryauthorities. Additionally, the timing of market introduction of some of our potential immunotherapies or of competitors’products may be an important competitive factor. Accordingly, the speed with which we can develop immunotherapies, complete preclinicaltesting, clinical trials and approval processes and supply commercial quantities to market are expected to be important competitivefactors. We expect that competition among products approved for sale will be based on various factors, including product efficacy,safety, administration, reliability, acceptance, availability, price and patent position.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Experienceand Expertise        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourmanagement team has extensive experience in oncology development, including contract research, development, manufacturing andcommercialization across a board range of science, technologies, and process operations. We have built internal capabilities supportingresearch, clinical, medical, manufacturing and compliance operations and have extended our expertise with collaborations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Employees        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof October 31, 2020, we had 18 employees, 17 of which were full time employees. Of our full-time employees, 1 holds a Ph.D. degree.None of our employees are represented by a labor union, and we consider our relationship with our employees to be good.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wewill continue to rent necessary offices and laboratories to support our business.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_018">         </a>         Item1A. Risk Factors.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Summaryof Risk Factors        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Belowis a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does notaddress all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risksthat we face, can be found below under the heading “Risk Factors” and should be carefully considered, together withother information in this Form 10-K and our other filings with the SEC, before making an investment decision regarding our commonstock.        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           We    have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable    future.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           We    will require additional capital to fund our operations and if we fail to obtain necessary financing we will not be able to    complete the development and commercialization of our product candidates.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           We    are significantly dependent on the success of our Lm Technology platform and our product candidates based on this platform.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           If    we are unable to establish, manage or maintain strategic collaborations in the future, our revenue and drug development may    be limited.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           We    are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade    laws and regulations. We can face serious consequences for violations.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           We    need to attract and retain highly skilled personnel; we may be unable to effectively manage growth with our limited resources.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           We    depend upon our senior management and key consultants and their loss or unavailability could put us at a competitive disadvantage.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    biotechnology and immunotherapy industries are characterized by rapid technological developments and a high degree of competition.    We may be unable to compete with more substantial enterprises.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           As    a matter of course, we are reviewing strategic transactions for our company. We may not be successful in identifying or completing    any strategic transaction and any such strategic transaction completed may not yield additional value for stockholders.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           We    can provide no assurance that our clinical product candidates will obtain regulatory approval or that the results of clinical    studies will be favorable.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Drug    discovery and development is a complex, time-consuming and expensive process that is fraught with risk and a high rate of    failure.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           We    may face legal claims; legal disputes are expensive and we may not be able to afford the costs.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           We    can provide no assurance of the successful and timely development of new products.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Our    employees, independent contractors, consultants, commercial partners, principal investigators, or CROs may engage in misconduct    or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material    adverse effect on our business.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           We    must comply with significant government regulations.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Ongoing    healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           We    rely upon patents to protect our technology. We may be unable to protect our intellectual property rights and we may be liable    for infringing the intellectual property rights of others.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 20; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           20           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    price of our common stock and warrants may be volatile.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    market prices for our common stock may be adversely impacted by future events.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           A    limited public trading market may cause volatility in the price of our common stock.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           We    are not currently in compliance with the continued listing requirements for Nasdaq. If the price of our common stock continues    to trade below $1.00 per share for a sustained period or we do not meet other continued listing requirements, our common stock    may be delisted from the Nasdaq Capital Market, which could affect the market price and liquidity for our common stock and    reduce our ability to raise additional capital.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           We    may be at an increased risk of securities litigation, which is expensive and could divert management attention           <b>            .           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Our    certificate of incorporation, bylaws and Delaware law have anti-takeover provisions that could discourage, delay or prevent    a change in control, which may cause our stock price to decline.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <u>          RiskFactors         </u>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Youshould carefully consider the risks described below as well as other information provided to you in this annual report, includinginformation in the section of this document entitled “Forward-Looking Statements.” The risks and uncertainties describedbelow are not the only ones facing us. Additional risks and uncertainties not presently known to us or that we currently believeare immaterial may also impair our business operations. If any of the following risks actually occur, our business, financialcondition or results of operations could be materially adversely affected, the value of our common stock could decline, and youmay lose all or part of your investment.        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         RisksRelated to Our Financial Position and Capital Needs        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wehave incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeablefuture.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weare a clinical-stage biotechnology company. Investment in biotechnology product development is highly speculative because it entailssubstantial upfront capital expenditures and significant risk that a product candidate will fail to gain regulatory approval orbecome commercially viable. We have not generated any revenue from product sales to date, and we continue to incur significantdevelopment and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred lossesin each period since our inception.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weexpect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our developmentof, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products. We may encounterunforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. Thesize of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues.If any of our product candidates fails in clinical studies or do not gain regulatory approval, or if approved, fails to achievemarket acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustainprofitability in subsequent periods. Our prior losses and expected future losses have had and will continue to have an adverseeffect on our stockholders’ (deficit) equity and working capital.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wewill require additional capital to fund our operations and if we fail to obtain necessary financing we will not be able to completethe development and commercialization of our product candidates.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theresearch and development of our products has consumed substantial amounts of cash since inception. We expect to continue to investin advancing the clinical development of our product candidates and to commercialize any product candidates for which we receiveregulatory approval. As of October 31, 2020, we had cash and cash equivalents of about $25.178 million. We will require additionalcapital for the further development of our product candidates. We are pursuing various ways to support our development effortsincluding debt and/or equity financing as well as targeting potential collaborators of our products.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 21; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           21           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wecannot be certain that additional funding will be available on acceptable terms, or at all. If we are unable to raise additionalcapital in sufficient amounts or on terms acceptable to us we may have to significantly delay, scale back or discontinue the developmentor commercialization of one or more of our products or product candidates or one or more of our other research and developmentinitiatives. Our forecast of the period of time through which our financial resources will be adequate to support our operationsis a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number offactors, including the factors discussed elsewhere in this “Risk Factors” section. We have based this estimate onassumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           The    progress, timing, costs and results of the clinical studies underway;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           future    clinical development plans we establish for our product candidates;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    number and characteristics of product candidates that we develop or may in-license;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    outcome, timing and cost of meeting regulatory requirements established by the FDA and comparable foreign regulatory authorities,    including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than    those that we currently expect;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us    or our product candidates;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    effect of competing technological and market developments;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    cost and timing of completion of commercial-scale outsourced manufacturing activities; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory    approval in regions where we choose to commercialize our products on our own.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         RisksRelated to Our Business, Industry and Strategy        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Weare a clinical stage company.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weare a clinical stage biotechnology company with a history of losses and can provide no assurance as to future operating results.As a result of losses that will continue throughout our clinical stage, we may exhaust our financial resources and be unable tocomplete the development of our products. We anticipate that we will continue to incur significant operational costs as we executeon our clinical development strategy. Our deficit will continue to grow during our drug development period.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave sustained losses from operations in each fiscal year since our inception, and we expect losses to continue for the foreseeablefuture due to our substantial investment in research and development. As of October 31, 2020, we had an accumulated deficit ofapproximately $410.7 million and stockholders’ equity of approximately $30.18 million. We expect to spend substantial additionalsums on the continued administration and research and development of proprietary products and technologies with no certainty thatour immunotherapies will become commercially viable or profitable as a result of these expenditures. If we fail to raise a significantamount of capital, we may need to significantly curtail operations or cease operations in the near future. If any of our productcandidates fail in clinical trials or does not gain regulatory approval, we may never become profitable. Even if we achieve profitabilityin the future, we may not be able to sustain profitability in subsequent periods.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 22; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           22           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Weare significantly dependent on the success of our         </i>         Lm         <i>          Technology platform and our product candidates based on this platform.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave invested, and we expect to continue to invest, significant efforts and financial resources in the development of productcandidates based on our        <i>         Lm        </i>        Technology. Our ability to generate meaningful revenue, which may not occur for the foreseeablefuture, if ever, will depend heavily on the successful development, regulatory approval and commercialization of one or more ofthese product candidates, and such regulatory approval and commercialization may never occur.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Thesuccessful development of immunotherapies is highly uncertain.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Successfuldevelopment of immunotherapies is highly uncertain and is dependent on numerous factors, many of which are beyond our control.Immunotherapies that appear promising in the early phases of development may fail to reach, or be delayed in reaching, the marketfor several reasons including:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           preclinical    study results that may show the immunotherapy to be less effective than desired (e.g., the study failed to meet its primary    objectives) or to have harmful or problematic side effects;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           clinical    study results that may show the immunotherapy to be less effective than expected (e.g., the study failed to meet its primary    endpoint) or to have unacceptable side effects;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           failure    to receive the necessary regulatory approvals or a delay in receiving such approvals. Among other things, such delays may    be caused by slow enrollment in clinical studies, length of time to achieve study endpoints, delays in receiving the necessary    products or supplies for the conduct of clinical or pre-clinical trials, additional time requirements for data analysis, or    Biologics License Application preparation, discussions with the FDA, an FDA request for additional preclinical or clinical    data, FDA delays in inspecting manufacturing establishments, failure to receive FDA approval for manufacturing processes or    facilities, or unexpected safety or manufacturing issues;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           manufacturing    costs, formulation issues, pricing or reimbursement issues, or other factors that make the immunotherapy uneconomical; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    proprietary rights of others and their competing products and technologies that may prevent the immunotherapy from being commercialized.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Successin preclinical and early clinical studies does not ensure that large-scale clinical studies will be successful. Clinical resultsare frequently susceptible to varying interpretations that may delay, limit or prevent regulatory approvals. The length of timenecessary to complete clinical studies and to submit an application for marketing approval for a final decision by a regulatoryauthority varies significantly from one immunotherapy to the next and may be difficult to predict.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Evenif our product candidates are approved, they may be subject to limitations on the indicated uses and populations for which theymay be marketed. They may also be subject to other conditions of approval, may contain significant safety warnings, includingboxed warnings, contraindications, and precautions, may not be approved with label statements necessary or desirable for successfulcommercialization, or may contain requirements for costly post-market testing and surveillance, or other requirements, includingthe submission of a REMS, to monitor the safety or efficacy of the products. If we do not receive FDA approval for, and successfullycommercialize our product candidates, we will not be able to generate revenue from these product candidates in the United Statesin the foreseeable future, or at all. Any significant delays in obtaining approval for and commercializing our product candidateswill have a material adverse impact on our business and financial condition.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Weare limited in our manufacturing capabilities and we must rely upon third parties for such services.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wecurrently have agreements with third party manufacturing facilities for production of many of our immunotherapies for researchand development and testing purposes. While we have built our own manufacturing facility onsite in Princeton, New Jersey to manufactureclinical materials for some of our products, we depend on third-party manufacturers to supply most of our clinical materials.Third-party manufacturers must be able to meet our deadlines as well as adhere to quality standards and specifications. Our predominantreliance on third parties for the manufacture of our drug substance, investigational new drugs and, in the future, any approvedproducts, creates a dependency that could severely disrupt our research and development, our clinical testing, and ultimatelyour sales and marketing efforts if the source of such supply proves to be unreliable or unavailable. For instance, manufacturersmay experience unforeseen problems, such as material or personnel shortages, temporary or permanent facility closures, or scaleup challenges. If our own manufacturing operation or any contracted manufacturing operation is unreliable or unavailable, we maynot be able to manufacture clinical drug supplies of our immunotherapies, and our preclinical and clinical testing programs maynot be able to move forward and our entire business plan could fail. If we are able to commercialize our products in the future,there is no assurance that our own manufacturing operation or any third-party manufacturers will be able to meet commercializedscale production requirements in a timely manner.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 23; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           23           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thereis also no guarantee that our third party manufacturers will be able to manufacture our product candidates in accordance withapplicable standards or cGMPs. Poor control of production processes can lead to the introduction of adventitious agents or othercontaminants, or to inadvertent changes in the properties or stability of a product candidate that may not be detectable in finalproduct testing. If these third party manufacturers are not able to comply with cGMPs, we may not be able to conduct clinicaltrials, may need to conduct additional studies, and may not, eventually, receive and maintain FDA approval of our manufacturingprocesses and facilities. Deviations from manufacturing requirements may also require remedial measures that may be costly and/ortime-consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical trialor commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon or by us or thirdparties with whom we contract could materially harm our business. A failure to comply with the applicable regulatory requirementsmay also result in regulatory enforcement actions against our manufacturers or us.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Whilewe are ultimately responsible for the manufacture of our product candidates, other than through our contractual arrangements,we have little control over our manufacturers’ compliance with these regulations and standards. If we or our manufacturersencounter manufacturing difficulties, including cGMP compliance, we may need to find alternative manufacturing facilities, whichwe may not be able to on favorable terms or at all, and which would significantly impact our ability to develop, obtain and maintainregulatory approval for or market our product candidates, if approved. Any new manufacturers would need to either obtain or developthe necessary manufacturing know-how, and obtain the necessary equipment and materials, which may take substantial time and investment.We must also receive FDA approval for the use of any new manufacturers for commercial supply.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ifwe are unable to establish, manage or maintain strategic collaborations in the future, our revenue and drug development may belimited.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourstrategy includes eventual substantial reliance upon strategic collaborations for marketing and commercialization of our clinicalproduct candidates, and we may rely even more on strategic collaborations for research, development, marketing and commercializationfor some of our immunotherapies. To date, we have been heavily reliant upon third party outsourcing for our clinical trials executionand production of drug supplies for use in clinical trials. Establishing strategic collaborations is difficult and time-consuming.Our discussions with potential collaborators may not lead to the establishment of collaborations on favorable terms, if at all.For example, potential collaborators may reject collaborations based upon their assessment of our financial, clinical, regulatoryor intellectual property position. Our current collaborations, as well as any future new collaborations, may never result in thesuccessful development or commercialization of our immunotherapies or the generation of sales revenue. To the extent that we haveentered or will enter into co-promotion or other collaborative arrangements, our product revenues are likely to be lower thanif we directly marketed and sold any products that we may develop.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 24; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           24           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Managementof our relationships with our collaborators will require:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           significant    time and effort from our management team;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           financial    funding to support said collaboration;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           coordination    of our research and development programs with the research and development priorities of our collaborators; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           effective    allocation of our resources to multiple projects.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifwe continue to enter into research and development collaborations at the early phases of drug development, our success will inpart depend on the performance of our corporate collaborators. We will not directly control the amount or timing of resourcesdevoted by our corporate collaborators to activities related to our immunotherapies and our collaborations may terminate at anytime. Our corporate collaborators may not commit sufficient resources to our research and development programs or the commercialization,marketing or distribution of our immunotherapies. If any corporate collaborator fails to commit sufficient resources or terminatetheir collaborations with us, our preclinical or clinical development programs related to this collaboration could be delayedor terminated.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Further,our collaborators may pursue existing or other development-stage products or alternative technologies in preference to those beingdeveloped in collaboration with us. Collaborators may also fail to comply with the applicable regulatory requirements, which maysubject them or us to regulatory enforcement actions. Finally, if we fail to make required milestone or royalty payments to ourcollaborators or to observe other obligations in our agreements with them, our collaborators may have the right to terminate thoseagreements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Changesin product candidate manufacturing or formulation may result in additional costs or delay.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inan effort to optimize processes and results, it is common that various aspects of the development program, such as manufacturingmethods, manufacturing sites, and formulation, are altered as product candidates are developed from preclinical studies to late-stageclinical trials toward approval and commercialization. Any of these changes could cause our product candidates to perform differentlyand affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. Such changesmay also require additional testing, regulatory disclosure, or prior approval from the FDA. For instance, the FDA may requirethat we conduct a comparability study that evaluates the potential differences in the product candidate resulting from the change.Delays in designing and completing such a study to the satisfaction of the FDA could delay or preclude our development and commercializationplans, and the regulatory approval of our product candidates. It may also require the repetition of one or more clinical trials,increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence product sales andgenerate revenue. Any of the foregoing could limit our future revenues and growth. Any changes would also require that we devotetime and resources to manufacturing development, including with third-party manufacturers, and would also likely require additionaltesting and regulatory actions on our part, which may delay the development of our product candidates.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wemay incur significant costs complying with environmental laws and regulations.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weand our contracted third parties use hazardous materials, including chemicals and biological agents and compounds that could bedangerous to human health and safety or the environment. As appropriate, we store these materials and wastes resulting from theiruse at our or our outsourced laboratory facility pending their ultimate use or disposal. We contract with a third party to properlydispose of these materials and wastes. We are subject to a variety of federal, state and local laws and regulations governingthe use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with such laws andregulations may be costly.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Additionallaws and regulations governing international operations could negatively impact or restrict our operations.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifwe further expand our operations outside of the United States, we must dedicate additional resources to comply with numerous lawsand regulations in each jurisdiction in which we plan to operate. The U.S. Foreign Corrupt Practices Act, or FCPA, prohibits anyU.S. individual or business from paying, offering, authorizing payment or offering anything of value, directly or indirectly,to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entityin order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securitiesare listed in the United States to comply with certain accounting provisions requiring the company to maintain books and recordsthat accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise andmaintain an adequate system of internal accounting controls for international operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">      </p>      <!-- Field: Page; Sequence: 25; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           25           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Compliancewith the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition,the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated bythe government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connectionwith clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcementactions.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Variouslaws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing withcertain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technicaldata relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additionalresources to comply with these laws, and these laws may preclude us from developing, manufacturing or selling certain productsand product candidates outside of the United States, which could limit our growth potential and increase our development costs.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefailure to comply with laws governing international business practices may result in substantial civil and criminal penaltiesand suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S.exchanges for violations of the FCPA’s accounting provisions.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Weare subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade lawsand regulations. We can face serious consequences for violations.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Amongother matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations,which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations,legal counsel, accountants, consultants, contractors and other partners from authorizing, promising, offering, providing, solicitingor receiving, directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the publicor private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the lossof trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, exclusion from public tenders, reputationalharm and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliatedhospitals, universities and other organizations. We plan to engage third parties for clinical trials and/or to obtain necessarypermits, licenses, patent registrations and other regulatory approvals and we can be held liable for the corrupt or other illegalactivities of our personnel, agents or partners, even if we do not explicitly authorize or have prior knowledge of such activities.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 26; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           26           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ifwe use biological materials in a manner that causes injury, we may be liable for damages.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourresearch and development activities involve the use of biological and hazardous materials. Although we believe our safety proceduresfor handling and disposing of these materials complies with federal, state and local laws and regulations, we cannot entirelyeliminate the risk of accidental injury or contamination from the use, storage, handling or disposal of these materials. We donot carry specific biological waste or pollution liability or remediation insurance coverage, nor do our workers’ compensation,general liability, and property and casualty insurance policies provide coverage for damages and fines/penalties arising frombiological exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damagesor penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspendedor terminated.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Weneed to attract and retain highly skilled personnel; we may be unable to effectively manage growth with our limited resources.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof October 31, 2020, we had 18 employees, 17 of which were full time employees. Our ability to attract and retain highly skilledpersonnel is critical to our operations and expansion. We face competition for these types of personnel from other technologycompanies and more established organizations, many of which have significantly larger operations and greater financial, technical,human and other resources than we have. We may not be successful in attracting and retaining qualified personnel on a timely basis,on competitive terms, or at all. If we are not successful in attracting and retaining these personnel, or integrating them intoour operations, our business, prospects, financial condition and results of operations will be materially adversely affected.In such circumstances we may be unable to conduct certain research and development programs, unable to adequately manage our clinicaltrials and other products, unable to commercialize any products, and unable to adequately address our management needs.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wedepend upon our senior management and key consultants and their loss or unavailability could put us at a competitive disadvantage.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wedepend upon the efforts and abilities of our senior executives, as well as the services of several key consultants. The loss orunavailability of the services of any of these individuals for any significant period of time could have a material adverse effecton our business, prospects, financial condition and results of operations. We have not obtained, do not own, nor are we the beneficiaryof, key-person life insurance.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Thebiotechnology and immunotherapy industries are characterized by rapid technological developments and a high degree of competition.We may be unable to compete with more substantial enterprises.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thebiotechnology and biopharmaceutical industries are characterized by rapid technological developments and a high degree of competition.As a result, our actual or proposed immunotherapies could become obsolete before we recoup any portion of our related researchand development and commercialization expenses. Competition in the biopharmaceutical industry is based significantly on scientificand technological factors. These factors include the availability of patent and other protection for technology and products,the ability to commercialize technological developments and the ability to obtain governmental approval for testing, manufacturingand marketing. We compete with specialized biopharmaceutical firms in the United States, Europe and elsewhere, as well as a growingnumber of large pharmaceutical companies that are applying biotechnology to their operations. Many biopharmaceutical companieshave focused their development efforts in the human therapeutics area, including cancer. Many major pharmaceutical companies havedeveloped or acquired internal biotechnology capabilities or made commercial arrangements with other biopharmaceutical companies.These companies, as well as academic institutions and governmental agencies and private research organizations, also compete withus in recruiting and retaining highly qualified scientific personnel and consultants. Our ability to compete successfully withother companies in the pharmaceutical field will also depend to a considerable degree on the continuing availability of capitalto us.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weare aware of certain investigational new products under development or approved products by competitors that are used for theprevention, diagnosis, or treatment of certain diseases we have targeted for product development. Various companies are developingbiopharmaceutical products that have the potential to directly compete with our immunotherapies even though their approach maybe different. The biotechnology and biopharmaceutical industries are highly competitive, and this competition comes from bothbiotechnology firms and major pharmaceutical companies, including companies like: Gritstone, Moderna, BMS, Merck and Neon Therapeutics,among others, each of which is pursuing cancer vaccines and/or immunotherapies. Many of these companies have substantially greaterfinancial, marketing, and human resources than we do (including, in some cases, substantially greater experience in clinical testing,manufacturing, and marketing of pharmaceutical products). We also experience competition in the development of our immunotherapiesfrom universities and other research institutions and compete with others in acquiring technology from such universities and institutions.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 27; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           27           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, certain of our immunotherapies may be subject to competition from investigational new drugs and/or products developedusing other technologies, some of which have completed numerous clinical trials.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Asa matter of course, we are reviewing strategic transactions for our company. We may not be successful in identifying or completingany strategic transaction and any such strategic transaction completed may not yield additional value for stockholders.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asa matter of course, we are reviewing strategic transactions and alternatives and there can be no assurance that we will be successfulin identifying or completing any strategic transactions, that any such strategic transaction will result in additional value forour stockholders or that the process will not have an adverse impact on our business. These transactions could include, but arenot limited to, collaboration agreements, co-development agreements, strategic mergers, reverse mergers, the issuance or buybackof public shares, or the purchase, in-license or out-license or sale of specific assets, in addition to other potential actionsaimed at increasing stockholder value. There can be no assurance that the review of strategic transactions will result in theidentification or consummation of any transaction. Our Board of Directors may also determine that our most effective strategyis to continue to effectuate our current business plan. The process of reviewing strategic transactions may be time consumingand disruptive to our business operations and, if we are unable to effectively manage the process, our business, financial conditionand results of operations could be adversely affected. We could incur substantial expenses associated with identifying and evaluatingpotential strategic alternatives. No decision has been made with respect to any transaction and we cannot assure you that we willbe able to identify and undertake any transaction that allows our shareholders to realize an increase in the value of their commonstock or provide any guidance on the timing of such action, if any.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wealso cannot assure you that any potential strategic transaction or other alternative transaction, if identified, evaluated andconsummated, will provide greater value to our stockholders than that reflected in the current price of our common stock. Anypotential transaction would be dependent upon a number of factors that may be beyond our control, including, but not limited to,market conditions, industry trends, the interest of third parties in our business and the availability of financing to potentialbuyers on reasonable terms. We do not intend to comment regarding the evaluation of strategic alternatives until such time asour Board of Directors has determined the outcome of the process or otherwise has deemed that disclosure is appropriate or requiredby applicable law. As a consequence, perceived uncertainties related to our future may result in the loss of potential businessopportunities and volatility in the market price of our common stock and may make it more difficult for us to attract and retainqualified personnel and business partners.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Aglobal health crisis such as a pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, may materially and adverselyaffect our business and operations.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCOVID-19 pandemic is affecting the United States and global economies and has affected, and may continue to affect, our operationsand those of third parties on which we rely, including by causing disruptions in our raw material supply and the manufacturingof our product candidates. In addition, the COVID-19 pandemic has affected the operations of the U.S. Food and Drug Administrationand other health authorities, which can result in delays of reviews and approvals, including with respect to our product candidates.The evolving COVID-19 pandemic has, and may continue to, directly or indirectly affect the pace of enrollment in our clinicaltrials as patients may avoid or may not be able to travel to healthcare facilities and physicians’ offices unless due toa health emergency and clinical trial staff can no longer get to the clinic. Additionally, such facilities and offices have beenand may continue to be required to focus limited resources on non-clinical trial matters, including treatment of COVID-19 patients,thereby decreasing availability, in whole or in part, for clinical trial services. In addition, employee disruptions and remoteworking environments related to the COVID-19 pandemic and the federal, state and local responses to such virus, could materiallyaffect the efficiency and pace with which we work and develop our product candidates and the manufacturing of our product candidates.In addition, COVID-19 infection of our workforce could result in a temporary disruption in our business activities, includingmanufacturing and other functions. Further, while the potential economic impact brought by, and the duration of, the COVID-19pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce ourability to access capital, which could negatively affect our short-term and long-term liquidity. Additionally, the stock markethas been unusually volatile during the COVID-19 outbreak and such volatility may continue. The ultimate impact of the COVID-19pandemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business,financing or clinical trial activities, or on healthcare systems or the global economy as a whole. However, these effects couldhave a material impact on our liquidity, capital resources, operations and business and those of the third parties on which werely.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         RisksRelated to the Development and Regulatory Approval of Our Product Candidates        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wecan provide no assurance that our clinical product candidates will obtain regulatory approval or that the results of clinicalstudies will be favorable.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weare currently evaluating the safety and efficacy of our product candidates in clinical trials. However, even though the initiationand conduct of the clinical trials is in accordance with the governing regulatory authorities in each country, as with any investigationalnew drug (under an IND in the United States, or the equivalent in countries outside of the United States), we are at risk of aclinical hold at any time based on the evaluation of the data and information submitted to the governing regulatory authorities.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 28; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           28           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Therecan be delays in obtaining FDA and/or other necessary regulatory approvals in the United States and in countries outside the UnitedStates for any investigational new drug and failure to receive such approvals would have an adverse effect on the investigationalnew drug’s potential commercial success and on our business, prospects, financial condition and results of operations. Thetime required to obtain approval by the FDA and non-U.S. regulatory authorities is unpredictable but typically takes many yearsfollowing the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatoryauthorities. For example, the FDA or non-U.S. regulatory authorities may disagree with the design or implementation of our clinicaltrials or study endpoints; or we may be unable to demonstrate that a product candidate’s clinical and other benefits outweighits safety risks. In addition, the FDA or non-U.S. regulatory authorities may disagree with our interpretation of data from preclinicalstudies or clinical trials or the data collected from clinical trials of our product candidates may not be sufficient to supportthe submission of a BLA or New Drug Application, or NDA or other submission or to obtain regulatory approval in the United Statesor elsewhere. The FDA or non-U.S. regulatory authorities may fail to approve the manufacturing processes or facilities of third-partymanufacturers with which we contract for clinical and commercial supplies; and the approval policies or regulations of the FDAor non-U.S. regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition to the foregoing, approval policies, regulations, or the type and amount of clinical data necessary to gain approvalmay change during the course of a product candidate’s clinical development and may vary among jurisdictions. We have notsubmitted for nor obtained regulatory approval for any product candidate in-humans (US &amp; EU) and it is possible that noneof our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatoryapproval.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Drugdiscovery and development is a complex, time-consuming and expensive process that is fraught with risk and a high rate of failure.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Productcandidates are subject to extensive pre-clinical testing and clinical trials to demonstrate their safety and efficacy in humans.Conducting pre-clinical testing and clinical trials is a lengthy, time-consuming and expensive process that takes many years.We cannot be sure that pre-clinical testing or clinical trials of any of our product candidates will demonstrate the safety, efficacyand benefit-to-risk profile necessary to obtain marketing approvals. In addition, product candidates that experience success inpre-clinical testing and early-stage clinical trials will not necessarily experience the same success in larger or late-stageclinical trials, which are required for marketing approval.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Evenif we are successful in advancing a product candidate into the clinical development stage, before obtaining regulatory and marketingapprovals, we must demonstrate through extensive human clinical trials that the product candidate is safe and effective for itsintended use. Human clinical trials must be carried out under protocols that are acceptable to regulatory authorities and to theindependent committees responsible for the ethical review of clinical studies. There may be delays in preparing protocols or receivingapproval for them that may delay the start or completion of the clinical trials. In addition, clinical practices vary globally,and there is a lack of harmonization among the guidance provided by various regulatory bodies of different regions and countrieswith respect to the data that is required to receive marketing approval, which makes designing global trials increasingly complex.There are a number of additional factors that may cause our clinical trials to be delayed, prematurely terminated or deemed inadequateto support regulatory approval, such as:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           safety    issues up to and including patient death (whether arising with respect to trials by third parties for compounds in a similar    class as tour product or product candidate), inadequate efficacy, or an unacceptable risk-benefit profile observed at any    point during or after completion of the trials;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           slower    than expected rates of patient enrollment, which could be due to any number of factors, including failure of our third-party    vendors, including our CROs, to effectively perform their obligations to us, a lack of patients who meet the enrollment criteria    or competition from clinical trials in similar product classes or patient populations, or onerous treatment administration    requirements;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 29; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           29           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           subjects    may drop out of our clinical trials, be lost to follow-up at a higher rate than we anticipate, or not comply with the required    clinical trial procedures;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           we    may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols    with prospective trial sites and our CROs;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            thecost of clinical trials may be greater than we anticipate or we may have insufficient funds for a clinical trial or to pay thesubstantial FDA user fees;           </font>          </p>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    FDA or comparable foreign regulatory authorities may disagree with our study design, including endpoints, our intended indications,    or our interpretation of data;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    risk of failure of our clinical investigational sites and related facilities, including our suppliers and CROs, to maintain    compliance with the FDA’s cGMP and GCP regulations or similar regulations in countries outside of the U.S., including    the risk that these sites fail to pass inspections by the appropriate governmental authority, which could invalidate the data    collected at that site or place the entire clinical trial at risk;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           any    inability to reach agreement or lengthy discussions with the FDA, equivalent regulatory authorities, or ethical review committees    on trial design that we are able to execute or we may be required to modify our trial design such that studies are impracticable;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           regulators    may require us to perform additional or unanticipated clinical trials to obtain approval or we may be subject to additional    post-marketing testing, surveillance, or REMS requirements to maintain regulatory approval;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           FDA    refusal to accept the data from foreign clinical trial sites, to the extent we use such sites;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           changes    in laws, regulations, regulatory policy or clinical practices, especially if they occur during ongoing clinical trials or    shortly after completion of such trials; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           clinical    trial record keeping or data quality and accuracy issues.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Anydeficiency in the design, implementation or oversight of our development programs could cause us to incur significant additionalcosts, conduct additional trials, experience significant delays, prevent us from obtaining marketing approval for any productcandidate or abandon development of certain product candidates, any of which could harm our business and cause our stock priceto decline.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wemay face legal claims; legal disputes are expensive and we may not be able to afford the costs.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wemay face legal claims involving stockholders, consumers, clinical trial subjects, competitors, regulators and other parties. Asdescribed in “Legal Proceedings” in Part I Item 3 of this Form 10-K, we are engaged in legal proceedings. Litigationand other legal proceedings are inherently uncertain, and adverse rulings could occur, including monetary damages, or an injunctionstopping us from engaging in business practices, or requiring other remedies, including, but not limited to, compulsory licensingof patents.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thecosts of litigation or any proceeding, including, but not limited to, those relating to our intellectual property or contractualrights, could be substantial, even if resolved in our favor. Some of our competitors or financial funding sources have far greaterresources than we do and may be better able to afford the costs of complex litigation. Also, a lawsuit, even if frivolous, willrequire considerable time commitments on the part of management, our attorneys and consultants. Defending these types of proceedingsor legal actions involve considerable expense and could negatively affect our financial results. Legal claims may also adverselyimpact us in other ways, such as the withdrawal or slower enrollment in or from our clinical trials, regulatory enforcement actions,and negative media attention, any of which could materially and negatively harm us and our operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 30; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           30           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wecan provide no assurance of the successful and timely development of new products.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourimmunotherapies are at various stages of development. Further development and extensive testing will be required to determinetheir technical feasibility and commercial viability. We will need to complete significant additional clinical trials demonstratingthat our product candidates are safe and effective to the satisfaction of the FDA and other non-U.S. regulatory authorities. Thedrug approval process is time-consuming, involves substantial expenditures of resources, and depends upon a number of factors,including the severity of the illness in question, the availability of alternative treatments, and the risks and benefits demonstratedin the clinical trials. Our success will depend on our ability to achieve scientific and technological advances and to translatesuch advances into licensable, FDA-approvable, commercially competitive products on a timely basis. Failure can occur at any stageof the process. If such programs are not successful, we may invest substantial amounts of time and money without developing revenue-producingproducts. As we enter a more extensive clinical program for our product candidates, the data generated in these studies may notbe as compelling as the earlier results.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theproposed development schedules for our immunotherapies may be affected by a variety of factors, including technological difficulties,clinical trial failures, regulatory hurdles, clinical holds, competitive products, intellectual property challenges and/or changesin governmental regulation, many of which will not be within our control. Any delay in the development, introduction or marketingof our products could result either in such products being marketed at a time when their cost and performance characteristicswould not be competitive in the marketplace or in the shortening of their commercial lives. In light of the long-term nature ofour projects, the unproven technology involved and the other factors described elsewhere in this section, there can be no assurancethat we will be able to successfully complete the development or marketing of any new products which could materially harm ourbusiness, results of operations and prospects.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ourresearch and development expenses are subject to uncertainty.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Factorsaffecting our research and development expenses include, but are not limited to:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           competition    from companies that have substantially greater assets and financial resources than we have;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           need    for market acceptance of our immunotherapies if we receive regulatory approval;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ability    to anticipate and adapt to a competitive market and rapid technological developments;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ability    to raise sufficient capital to fund our research and development activities;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           amount    and timing of operating costs and capital expenditures relating to expansion of our business, operations and infrastructure;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           need    to rely on multiple levels of outside funding due to the length of drug development cycles and governmental approved protocols    associated with the pharmaceutical industry; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           dependence    upon key personnel including key independent consultants and advisors.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Therecan be no guarantee that our research and development expenses will be consistent from period to period. We may be required toaccelerate or delay incurring certain expenses depending on the results of our studies and the availability of adequate funding.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wemay be required to suspend or discontinue clinical trials for a number of reasons, which could preclude approval of any of ourproduct candidates.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourclinical trials may be suspended at any time for a number of reasons. A clinical trial may be suspended or terminated by us, anIRB, the FDA or other regulatory authorities due to a failure to conduct the clinical trial in accordance with regulatory requirementsor our clinical protocols, presentation or identification of unforeseen safety signals or issues, failure to demonstrate a benefitfrom using the investigational drug, changes in governmental regulations or administrative actions, lack of adequate funding tocontinue the clinical trial, or for other business-related reasons. For example, in June 2019, we announced that we were closingour AIM2CERV Phase 3 clinical trial with AXAL in cervical cancer due to the delays we incurred as a result of the recent FDA partialclinical hold on the trial, as well as the estimated cost and time to completion of the trial. Furthermore, the Company has completedthe clinical study report from Part A of the ADXS-NEO study and plans to close its ADXS-NEO program IND as next step. In addition,clinical trials for our product candidates could be suspended due to adverse side effects. Drug-related side effects could affectpatient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims.We may also voluntarily suspend or terminate our clinical trials if at any time we believe that they present an unacceptable riskto patients or do not demonstrate clinical benefit. If we elect or are forced to suspend or terminate any clinical trial of anyproduct candidates that we develop, the commercial prospects of such product candidates will be harmed and our ability to generateproduct revenues from any of these product candidates will be delayed or eliminated. Any of these occurrences may significantlyharm our business, financial condition, results of operations and prospects.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <!-- Field: Page; Sequence: 31; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           31           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Preliminaryor interim results of a clinical trial are not necessarily predictive of future or final results.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Interimor preliminary data from clinical trials that we may conduct may not be indicative of the final results of the trial and are subjectto the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient databecome available. Interim or preliminary data also remain subject to audit and verification procedures that may result in thefinal data being materially different from the interim or preliminary data. As a result, interim or preliminary data should beviewed with caution until the final data are available. Even if our clinical trials are completed as planned, we cannot be certainthat their results will support our proposed indications.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Weare subject to numerous risks inherent in conducting clinical trials.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weoutsource the management of our clinical trials to third parties. Agreements with CROs, clinical investigators and medical institutionsfor clinical testing and data management services, place substantial responsibilities on these parties that, if unmet, could resultin delays in, or termination of, our clinical trials. For example, if any of our clinical trial sites or CROs fail to comply withFDA-approved good clinical practices, we may be unable to use the data gathered at those sites. If these clinical investigators,medical institutions or other third parties do not carry out their contractual duties or regulatory obligations or fail to meetexpected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhereto our clinical protocols or for other reasons, our clinical trials may be extended, delayed or terminated, and we may be unableto obtain regulatory approval for, or successfully commercialize, our agents. We are not certain that we will successfully recruitenough patients to complete our clinical trials nor that we will reach our primary endpoints. Delays in recruitment, lack of clinicalbenefit or unacceptable side effects would delay or prevent the initiation of future development of our agents.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Whilewe have agreements governing the activities of such third parties and are responsible for our third party service provider’sactivities and regulatory compliance, we have limited influence and control over their actual performance and activities and cannotcontrol whether or not they devote sufficient time and resources to our ongoing clinical, non-clinical, and preclinical programsand cannot control whether they maintain regulatory compliance. Our third-party service providers may also have relationshipswith other entities, some of which may be our competitors, for whom they may also be conducting trials or other therapeutic developmentactivities that could harm our competitive position.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Agreementswith third parties conducting or otherwise assisting with our clinical or preclinical studies might terminate for a variety ofreasons, including a failure to perform by the third parties. If any of our relationships with these third parties terminate,we may not be able to enter into arrangements with alternative providers or to do so on commercially reasonable terms. Switchingor adding additional third parties involves additional cost and requires management time and focus. In addition, there is a naturaltransition period when a new third party commences work. As a result, if we need to enter into alternative arrangements, it coulddelay our product development activities and adversely affect our business. Though we carefully manage our relationships withour third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delaysor challenges will not have a material adverse impact on our business, financial condition and prospects, and results of operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weor our regulators may suspend or terminate our clinical trials for a number of reasons. We may voluntarily suspend or terminateour clinical trials if at any time we believe they present an unacceptable risk to the patients enrolled in our clinical trialsor do not demonstrate clinical benefit. In addition, regulatory agencies may order the temporary or permanent discontinuationof our clinical trials, or place our products on temporary or permanent hold, at any time if they believe that the clinical trialsare not being conducted in accordance with applicable regulatory requirements or that they present an unacceptable safety riskto the patients enrolled in our clinical trials.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourclinical trial operations are subject to regulatory inspections at any time. If regulatory inspectors conclude that we or ourclinical trial sites are not in compliance with applicable regulatory requirements for conducting clinical trials, we may receivereports of observations or warning letters detailing deficiencies, and we will be required to implement corrective actions. Ifregulatory agencies deem our responses to be inadequate or are dissatisfied with the corrective actions we or our clinical trialsites have implemented, our clinical trials may be temporarily or permanently discontinued, we may be fined, we or our investigatorsmay be precluded from conducting any ongoing or any future clinical trials, the government may refuse to approve our marketingapplications or allow us to manufacture or market our products, and we may be criminally prosecuted.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thelengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtainregulatory approval for our product candidates, which would materially harm our business, results of operations and prospects.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ouremployees, independent contractors, consultants, commercial partners, principal investigators, or CROs may engage in misconductor other improper activities, including noncompliance with regulatory standards and requirements, which could have a materialadverse effect on our business.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weare exposed to the risk of employee and third party fraud or other misconduct. Misconduct by employees, independent contractors,consultants, commercial partners, manufacturers, investigators, or CROs could include intentional, reckless, negligent, or unintentionalfailures to comply with FDA regulations, comply with applicable fraud and abuse laws, provide accurate information to the FDA,properly calculate pricing information required by federal programs, comply with federal procurement rules or contract terms,report financial information or data accurately or disclose unauthorized activities to us. This misconduct could also involvethe improper use or misrepresentation of information obtained in the course of clinical trials, which could result in regulatorysanctions and serious harm to our reputation. It is not always possible to identify and deter this type of misconduct, and theprecautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or lossesor in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliancewith such laws or regulations. Moreover, it is possible for a whistleblower to pursue a False Claims Act case against us evenif the government considers the claim unmeritorious and declines to intervene, which could require us to incur costs defendingagainst such a claim. Further, due to the risk that a judgment in an FCA case could result in exclusion from federal health programsor debarment from government contracts, whistleblower cases often result in large settlements. If any such actions are institutedagainst us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impacton our business, financial condition, and results of operations, including the imposition of significant fines or other sanctions.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 32; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           32           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wemust comply with significant government regulations.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theresearch and development, manufacturing and marketing of human therapeutic and diagnostic products are subject to regulation,primarily by the FDA in the United States and by comparable authorities in other countries. These national agencies and otherfederal, state, local and foreign entities regulate, among other things, research and development activities (including testingin animals and in humans) and the testing, manufacturing, handling, labeling, storage, record keeping, approval, distribution,advertising and promotion of the products that we are developing. If we obtain approval for any of our product candidates, ouroperations will be directly or indirectly through our customers, subject to various federal and state fraud and abuse laws, including,without limitation, the federal Anti-Kickback Statue and the federal False Claims Act, and privacy laws. We, our product candidates,and our products, if we receive marketing approval are and will continue to be subject to extensive governmental regulation andregulatory authorities do and will continue to closely monitor our and our contractor’s compliance through, among othermethods, inspections. Noncompliance with applicable laws and requirements can result in various adverse consequences and regulatoryenforcement actions, including delay in approving or refusal to approve product licenses or other applications, suspension ortermination of clinical investigations, revocation of approvals previously granted, fines, criminal prosecution, civil and criminalpenalties, restitution or disgorgement of profits, recall or seizure of products, exclusion from having our products reimbursedby federal health care programs, the curtailment or restructuring of our operations, corporate integrity agreements or consentdecrees, refusal ot permit product import or export, modifications to labeling or promotional materials, issuance of correctiveinformation, regulatory authority public statements, warning, untitled, or cyber letters, requirements for post-market studiesor REMS, injunctions against shipping products and total or partial suspension of production and/or refusal to allow a companyto enter into governmental supply contracts. Any of these events could prevent us from achieving or maintaining product approvaland market acceptance of the particular product candidate, if approved, or could substantially increase the costs and expensesof developing and commercializing such product, which in turn could delay or prevent us from generating significant revenues fromits sale. Any of these events could further have other material and adverse effects on our operations and business and could adverselyimpact our stock price and could significantly harm our business, financial condition, results of operations, and prospects.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theprocess of obtaining requisite FDA approval has historically been costly and time-consuming. Current FDA requirements for a newhuman biological product to be marketed in the United States include: (1) the successful conclusion of preclinical laboratoryand animal tests, if appropriate, to gain preliminary information on the product’s safety; (2) filing with the FDA of anIND to conduct human clinical trials for drugs or biologics; (3) the successful completion of adequate and well-controlled humanclinical trials to establish the safety and efficacy of the investigational new drug for its recommended use; and (4) filing bya company and acceptance and approval by the FDA of a BLA for marketing approval of a biologic, to allow commercial distributionof a biologic product. The FDA also requires that any drug or formulation to be tested in humans be manufactured in accordancewith its cGMP regulations. This has been extended to include any drug that will be tested for safety in animals in support ofhuman testing. The cGMPs set certain minimum requirements for procedures, record-keeping and the physical characteristics of thelaboratories used in the production of these drugs. A delay in one or more of the procedural steps outlined above could be harmfulto us in terms of getting our immunotherapies through clinical testing and to market.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 33; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           33           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wemay not obtain or maintain the benefits associated with orphan drug designation, including market exclusivity.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Althoughwe have been granted FDA orphan drug designation for AXAL for use in the treatment of anal cancer, HPV-associated head and neckcancer, Stage II-IV invasive cervical cancer and for ADXS-HER2 for the treatment of osteosarcoma in the United States, as wellas EMA orphan drug designation for AXAL for the treatment of anal cancer and for ADXS-HER2 for the treatment of osteosarcoma inthe EU, we may not receive the benefits associated with orphan drug designation. This may result from a failure to maintain orphandrug status or result from a competing product reaching the market that has an orphan designation for the same disease indication.Moreover, while orphan drug designation does provide us with certain advantages, it neither shortens the development time or regulatoryreview time of a product candidate nor gives the product candidate any advantage in the regulatory review or approval process.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        UnderU.S. rules for orphan drugs, if such a competing product reaches the market before ours does, if such product is considered byFDA to be the same as ours, and if such product is intended for the same orphan indication, the competing product could potentiallyobtain a scope of market exclusivity that limits or precludes our product from being sold in the United States for seven yearsunless we can demonstrate that our product is clinically superior. Even if we obtain exclusivity, the FDA could subsequently approvethe same drug for the same condition if the FDA concludes that the later drug is clinically superior to ours in that it is shownto be safer, more effective or makes a major contribution to patient care. A competitor also may receive approval of differentproducts for the same indication for which our orphan product has exclusivity or obtain approval for the same product but fora different indication for which the orphan product has exclusivity. Moreover, we may not be able to maintain our orphan drugdesignation or exclusivity and our product candidates would not be eligible for exclusivity if the approved indication is broaderthan the orphan drug designation.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, if and when we request orphan drug designation in Europe, the European exclusivity period is ten years but can be reducedto six years if the drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable sothat market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMEA determines that the requestfor designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet theneeds of patients with the rare disease or condition.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wemay incur substantial liabilities from any product liability claims if our insurance coverage for those claims is inadequate.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weface an inherent risk of product liability exposure related to the testing of our immunotherapies in human clinical trials andwill face an even greater risk if the approved products are sold commercially. An individual may bring a liability claim againstus if one of the immunotherapies causes, or merely appears to have caused, an injury. If we cannot successfully defend ourselvesagainst the product liability claim, we will incur substantial liabilities. Regardless of merit or eventual outcome, liabilityclaims may result in:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           decreased    demand for our immunotherapies;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           damage    to our reputation;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           withdrawal    of clinical trial participants;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           costs    of related litigation;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 34; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           34           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           substantial    monetary awards to patients or other claimants;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           loss    of revenues;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    inability to commercialize immunotherapies; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           increased    difficulty in raising required additional funds in the private and public capital markets.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave Product Liability and Clinical Trial Liability insurance coverage for each clinical trial. We do not have product liabilityinsurance for sold commercial products because we do not have products on the market. We plan to expand such coverage to includethe sale of commercial products if marketing approval is obtained for any of our immunotherapies. However, insurance coverageis increasingly expensive and we may not be able to maintain insurance coverage at a reasonable cost. Further, we may not be ableto obtain insurance coverage that will be adequate to satisfy any liability that may arise.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wemay not receive Fast Track Designation, Breakthrough Therapy Designation or any other designation that we may apply for from theFDA and, if granted, such designations may not actually lead to a faster development or regulatory review or approval process.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheFDA has granted Fast Track Designation for AXAL for adjuvant therapy for high-risk locally advanced cervical cancer patients,and has granted Fast Track Designation for ADXS-HER2 for patients with newly-diagnosed, non-metastatic, surgically-resectableosteosarcoma. We may seek Breakthrough Therapy Designation for our product candidates or Fast Track Designation for certain ofour other product candidates. There is no guarantee, however, that we will be able to obtain or maintain such designations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheFDA has broad discretion whether or not to grant any special designation, so even if we believe one of our product candidatesis eligible for this designation, we cannot assure you that the FDA would decide to grant it. Additionally, even if we do receivea special designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures.The FDA may also withdraw the designation if it believes that the designation is no longer supported by data from our clinicaldevelopment program.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 35; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           35           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Theresults of clinical trials conducted at clinical trial sites outside the United States might not be accepted by the FDA, and datadeveloped outside of a foreign jurisdiction similarly might not be accepted by such foreign regulatory authority.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Someof the clinical trials for our product candidates that are being or will be conducted through our partnerships and collaborationsmay be conducted outside the United States, and we intend in the future to conduct additional clinical trials outside the UnitedStates. Although the FDA, European Medicines Agency (“EMA”) or comparable foreign regulatory authorities may acceptdata from clinical trials conducted outside the relevant jurisdiction, acceptance of these data is subject to certain conditions.For example, the FDA requires that the clinical trial must be well designed and conducted and performed by qualified investigatorsin accordance with ethical principles such as IRB or ethics committee approval and informed consent, the trial population mustadequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice inways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws,acceptance of the data by the FDA will be dependent upon its determination that the trials were conducted consistent with allapplicable U.S. laws and regulations. There can be no assurance that the FDA will accept data from trials conducted outside ofthe United States as adequate support of a marketing application. Similarly, we must also ensure that any data submitted to foreignregulatory authorities adheres to their standards and requirements for clinical trials and there can be no assurance a comparableforeign regulatory authority would accept data from trials conducted outside of its jurisdiction.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ourrelationships with healthcare providers and physicians and third-party payors will be subject to applicable anti-kickback, fraudand abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractualdamages, reputational harm and diminished profits and future earnings.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Healthcareproviders, physicians and third-party payors in the United States and elsewhere play a primary role in the recommendation andprescription of pharmaceutical products. Arrangements with third-party payors and customers can expose pharmaceutical manufacturersto broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-KickbackStatute and the federal False Claims Act, or FCA, which may constrain the business or financial arrangements and relationshipsthrough which such companies sell, market and distribute pharmaceutical products. In particular, the research of our product candidates,as well as the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in thehealthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices.These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuringand commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to theselaws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. The applicablefederal, state and foreign healthcare laws and regulations that may affect our ability to operate include, but are not limitedto:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering    or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash    or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation    of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program,    such as the Medicare and Medicaid programs. A person or entity can be found guilty of violating the statute without actual    knowledge of the statute or specific intent to violate it. In addition, a claim including items or services resulting from    a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. The Anti-Kickback    Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers,    purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting    some common activities from prosecution;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    federal civil and criminal false claims laws and civil monetary penalty laws, including the FCA, which prohibit, among other    things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment    to, or approval by Medicare, Medicaid or other federal healthcare programs, knowingly making, using or causing to be made    or used a false record or statement material to a false or fraudulent claim or an obligation to pay or transmit money to the    federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing or concealing an obligation    to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims    directly to government payors if they are deemed to “cause” the submission of false or fraudulent claims. The    government may deem manufacturers to have “caused” the submission of false or fraudulent claims by, for example,    providing inaccurate billing or coding information to customers or promoting a product off-label. The FCA also permits a private    individual acting as a “whistleblower” to bring actions on behalf of the federal government alleging violations    of the FCA and to share in any monetary recovery;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes    that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program    or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by,    or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and    knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially    false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare    matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual    knowledge of the statute or specific intent to violate it;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 36; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           36           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           HIPAA,    as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective    implementing regulations, which impose, among other things, requirements on certain healthcare providers, health plans and    healthcare clearinghouses, known as covered entities, as well as their respective business associates, independent contractors    that perform services for covered entities that involve the use, or disclosure of, individually identifiable health information,    relating to the privacy, security and transmission of individually identifiable health information. HITECH also created new    tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates,    and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce    the federal HIPAA laws and seek attorneys’ fees and costs associated with pursuing federal civil actions;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    federal Physician Payments Sunshine Act, created under the Patient Protection and Affordable Care Act, as amended, or ACA,    and its implementing regulations, which require some manufacturers of drugs, devices, biologicals and medical supplies for    which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions)    to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, of the U.S. Department of Health and Human    Services, or HHS, information related to payments or other transfers of value made to physicians (defined to include doctors,    dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests    held by physicians and their immediate family members; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           analogous    state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing    arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including    private insurers, and may be broader in scope than their federal equivalents; state and foreign laws that require pharmaceutical    companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance    promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign    laws that require drug manufacturers to report information related to payments and other transfers of value to physicians    and other healthcare providers, marketing expenditures or drug pricing; state and local laws that require the registration    of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information    in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus    complicating compliance efforts.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thedistribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping,licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. Pharmaceuticalcompanies may also be subject to federal consumer protection and unfair competition laws, which broadly regulate marketplace activitiesand activities that potentially harm consumers.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thescope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcarereform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies continueto closely scrutinize interactions between healthcare companies and healthcare providers, which has led to a number of investigations,prosecutions, convictions and settlements in the healthcare industry. Ensuring business arrangements comply with applicable healthcarelaws, as well as responding to possible investigations by government authorities, can be time and resource-consuming and can diverta company’s attention from the business.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Itis possible that governmental and enforcement authorities will conclude that our business practices may not comply with currentor future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations.If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, thoseactions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties,damages, fines, disgorgement, imprisonment, exclusion from participation in federal and state funded healthcare programs, contractualdamages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if webecome subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws.Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to benot in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, includingexclusions from government funded healthcare programs. Any action for violation of these laws, even if successfully defended,could cause a biopharmaceutical manufacturer to incur significant legal expenses and divert management’s attention fromthe operation of the business. Prohibitions or restrictions on sales or withdrawal of future marketed products could materiallyaffect business in an adverse way.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 37; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           37           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Obtainingand maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful inobtaining regulatory approval of our product candidates in other jurisdictions.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Obtainingand maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtainor maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdictionmay have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approvalof a product candidate, the EMA or comparable foreign regulatory authorities must also approve the manufacturing, marketing andpromotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirementsand administrative review periods different from, and greater than, those in the United States, including additional preclinicalstudies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities inother jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement beforeit can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subjectto approval.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wemay also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United Stateshave requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtainingforeign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficultiesand costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with theregulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reducedand our ability to realize the full market potential of our product candidates will be harmed.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Evenif we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continuedregulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to complywith regulatory requirements or experience unanticipated problems with our product candidates.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifany of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling,packaging, storage, advertising, promotion, distribution, sampling, record-keeping, conduct of post-marketing studies and submissionof safety, efficacy and other post-market information, including both federal and state requirements in the United States andrequirements of comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with cGMP andGCP requirements for any clinical trials that we conduct post-approval.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Manufacturersand manufacturers’ facilities are required to comply with extensive FDA, EMA and comparable foreign regulatory authorityrequirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we andour contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence tocommitments made in any BLA, other marketing application and previous responses to inspection observations. Accordingly, we andothers with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing,production and quality control.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Anyregulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses forwhich the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketingtesting, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. Certainendpoint data we hope to include in any approved product labeling also may not make it into such labeling, including exploratoryor secondary endpoint data such as patient-reported outcome measures. The FDA may also require a risk evaluation and mitigationstrategies, or REMS, program as a condition of approval of our product candidates, which could entail requirements for long-termpatient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricteddistribution methods, patient registries and other risk minimization tools. In addition, if the FDA, EMA or a comparable foreignregulatory authority approves our product candidates, we will have to comply with requirements including submissions of safetyand other post-marketing information and reports and registration.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheFDA may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintainedor if problems occur after the product reaches the market. Later discovery of previously unknown problems with our product candidates,including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes,or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information,imposition of post-market studies or clinical trials to assess new safety risks or imposition of distribution restrictions orother restrictions under a REMS program. Other potential consequences include, among other things:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           restrictions    on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product    recalls;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           fines,    warning letters or holds on clinical trials;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           refusal    by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation    of license approvals;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           product    seizure or detention or refusal to permit the import or export of our product candidates; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           injunctions    or the imposition of civil or criminal penalties.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 38; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           38           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheFDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Products maybe promoted only for the approved indications and in accordance with the provisions of the approved label. The policies of theFDA, EMA and comparable foreign regulatory authorities may change and additional government regulations may be enacted that couldprevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of governmentregulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slowor unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not ableto maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustainprofitability.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Coverageand reimbursement may be limited or unavailable in certain market segments for our product candidates, if approved, which couldmake it difficult for us to sell any product candidates profitably.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thesuccess of our product candidates, if approved, depends on the availability of coverage and adequate reimbursement from third-partypayors. We cannot be sure that coverage and reimbursement will be available for, or accurately estimate the potential revenuefrom, our product candidates or assure that coverage and reimbursement will be available for any product that we may develop.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Patientswho are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costsassociated with their treatment. Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare andMedicaid, and commercial payors is critical to new product acceptance.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Governmentauthorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which drugsand treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upona number of factors, including the third-party payor’s determination that use of a product is:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           a    covered benefit under its health plan;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           safe,    effective and medically necessary;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           appropriate    for the specific patient;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           cost-effective;    and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           neither    experimental nor investigational.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inthe United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. As a result,obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming andcostly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data forthe use of our products on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained.Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieveor sustain profitability or may require co-payments that patients find unacceptably high. Additionally, third-party payors maynot cover, or provide adequate reimbursement for, long-term follow-up evaluations required following the use of product candidates,once approved. Patients are unlikely to use our product candidates, once approved, unless coverage is provided and reimbursementis adequate       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ongoinghealthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Changesin regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, forexample: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recallor discontinuation of our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, theycould adversely affect the operation of our business.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inthe United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example,in March 2010, the ACA was passed, which substantially changed the way healthcare is financed by both governmental and privateinsurers, and significantly impacted the U.S. biopharmaceutical industry. The ACA, among other things, addressed a new methodologyby which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused,instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug RebateProgram and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual feesand taxes on manufacturers of certain branded prescription drugs and created a new Medicare Part D coverage gap discount program,in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligiblebeneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered underMedicare Part D.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 39; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           39           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Someof the provisions of the ACA have yet to be fully implemented, while certain provisions have been subject to judicial and Congressionalchallenges, as well as efforts by the Trump administration to repeal or replace certain aspects of the ACA. For example, Congresshas considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed repeallegislation, the Tax Reform Act includes a provision that repealed, effective January 1, 2019, the tax-based shared responsibilitypayment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year thatis commonly referred to as the “individual mandate.” As a result of the individual mandate repeal, subsequent litigationchallenged the validity of the ACA. On December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruledthat the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandatewas repealed as part of the Tax Cuts and Jobs Act, or TCJA, the remaining provisions of the ACA are invalid as well. The Trumpadministration and CMS have both stated that the ruling will have no immediate effect, and on December 30, 2018 the same judgeissued an order staying the judgment pending appeal. A Fifth Circuit U.S. Court of Appeals hearing to determine whether certainstates and the House of Representatives have standing to appeal the lower court decision was held on July 9, 2019, but it is unclearwhen the court will render its decision on this hearing, and what effect it will have on the status of the ACA. Litigation andlegislation over the ACA are likely to continue, with unpredictable and uncertain results. We will continue to evaluate the effectthat the ACA and its possible repeal and replacement has on our business.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        SinceJanuary 2017, President Trump has signed two Executive Orders designed to delay the implementation of certain provisions of theACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Further, the Trump administrationhas concluded that cost-sharing reduction, or CSR, payments to insurance companies required under the ACA have not received necessaryappropriations from Congress and announced that it will discontinue these payments immediately until those appropriations aremade. The loss of the CSR payments is expected to increase premiums on certain policies issued by qualified health plans underthe ACA. Bipartisan bills to appropriate funds for CSR payments were proposed in 2017 and 2018, but the proposals have not beenenacted into law. Multiple state Attorneys General filed suit to stop the administration from terminating the subsidies, but theircase was dismissed by a federal judge in California on July 18, 2018. Furthermore, on June 14, 2018, the U.S. Court of Appealsfor the Federal Circuit ruled that the federal government was not required to pay more than $12 billion in ACA risk corridor paymentsto third-party payors who argued were owed to them. The effects of this gap in reimbursement on third-party payors, the viabilityof the ACA marketplace and providers, and the potential effect on our business, are not yet known.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Inadequatefunding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel,prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agenciesfrom performing normal business functions on which the operation of our business may rely, which could negatively impact our business.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theability of the FDA to review and approve new products can be affected by a variety of factors, including government budget andfunding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policychanges. Average review times at the agency have fluctuated in recent years as a result.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Disruptionsat the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary governmentagencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut downseveral times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities.If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process ourregulatory submissions, which could have a material adverse effect on our business. Further, upon completion of this offeringand in our operations as a public company, future government shutdowns could impact our ability to access the public markets andobtain necessary capital in order to properly capitalize and continue our operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Approvalof our product candidates does not ensure successful commercialization and reimbursement.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weare not currently marketing our product candidates, nor can we until they are approved; however, we are seeking partnering andcommercial opportunities for our products. We cannot assure you that we will be able to commercialize any of our product candidatesourselves or find a commercialization partner or that we will be able to agree to acceptable terms with any partner to launchand commercialize our products.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thecommercial success of our product candidates is subject to risks in both the United States and European countries. In addition,in European countries, pricing and payment of prescription pharmaceuticals is subject to more extensive governmental control thanin the United States. Pricing negotiations with European governmental authorities can take six to 12 months or longer after thereceipt of regulatory approval and product launch. If reimbursement is unavailable in any country in which reimbursement is sought,limited in scope or amount, or if pricing is set at or reduced to unsatisfactory levels, our ability or any potential partner’sability to successfully commercialize in such a country would be impacted negatively. Furthermore, if these measures prevent usor any potential partner from selling on a profitable basis in a particular country, they could prevent the commercial launchor continued sale in that country and could adversely impact the commercialization market opportunity in other countries.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 40; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           40           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Moreover,as a condition of approval, the regulatory authorities may require that we conduct post-approval studies. Those studies may revealnew safety or efficacy findings regarding our drug that could adversely impact the continued commercialization or future marketopportunity in other countries.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, we predominantly rely on a network of suppliers and vendors to manufacture our products. Should a regulatory authoritymake any significant findings on an inspection of our own operations or the operations of those companies, the ability for usto continue producing our products could be adversely impacted and further production could cease. Regulatory GMP requirementsare extensive and can present a risk of injury or recall, among other risks, if not manufactured or labeled properly under GMPs.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourpotential revenues from the commercialization of our product candidates are subject to these and other factors, and thereforewe may never reach or maintain profitability.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Evenif we are successful in obtaining market approval, commercial success of any of our product candidates will also depend in largepart on the availability of coverage and adequate reimbursement from third-party payers, including government payers such as theMedicare and Medicaid programs and managed care organizations, which may be affected by existing and future health care reformmeasures designed to reduce the cost of health care. Third-party payers could require us to conduct additional studies, includingpost-marketing studies related to the cost effectiveness of a product, to qualify for reimbursement, which could be costly anddivert our resources. If government and other health care payers were not to provide adequate coverage and reimbursement levelsfor one any of our products once approved, market acceptance and commercial success would be reduced.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, if one of our products is approved for marketing, we will be subject to significant regulatory obligations regardingproduct promotion, the submission of safety and other post-marketing information and reports and registration, and will need tocontinue to comply (or ensure that our third party providers comply) with cGMPs, and Good Clinical Practices, or GCPs, for anyclinical trials that we conduct post-approval. In addition, there is always the risk that we or a regulatory authority might identifypreviously unknown problems with a product post-approval, such as adverse events of unanticipated severity or frequency. Compliancewith these requirements is costly, and any failure to comply or other issues with our product candidates’ post-market approvalcould have a material adverse effect on our business, financial condition and results of operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         RisksRelated to our Intellectual Property        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Werely upon patents to protect our technology. We may be unable to protect our intellectual property rights and we may be liablefor infringing the intellectual property rights of others.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourability to compete effectively will depend on our ability to maintain the proprietary nature of our technologies, including the        <i>         Lm        </i>        -LLO based immunotherapy platform technology, and the proprietary technology of others with whom we have entered intocollaboration and licensing agreements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Currently,we own or have rights to several hundred patents and applications, which are owned, licensed from, or co-owned with Penn and Merck.We have obtained the rights to all future patent applications in this field originating in the laboratories of Dr. Yvonne Patersonand Dr. Fred Frankel, at the University of Pennsylvania.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weown or hold licenses to a number of issued patents and U.S. pending patent applications, as well as foreign patents and foreigncounterparts. Our success depends in part on our ability to obtain patent protection both in the United States and in other countriesfor our product candidates, as well as the methods for treating patients in the product indications using these product candidates.Such patent protection is costly to obtain and maintain, and we cannot guarantee that sufficient funds will be available. Ourability to protect our product candidates from unauthorized or infringing use by third parties depends in substantial part onour ability to obtain and maintain valid and enforceable patents. Due to evolving legal standards relating to the patentability,validity and enforceability of patents covering pharmaceutical inventions and the scope of claims made under these patents, ourability to obtain, maintain and enforce patents is uncertain and involves complex legal and factual questions. Even if our productcandidates, as well as methods for treating patients for prescribed indications using these product candidates are covered byvalid and enforceable patents and have claims with sufficient scope, disclosure and support in the specification, the patentswill provide protection only for a limited amount of time. Accordingly, rights under any issued patents may not provide us withsufficient protection for our product candidates or provide sufficient protection to afford us a commercial advantage againstcompetitive products or processes.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, we cannot guarantee that any patents will issue from any pending or future patent applications owned by or licensedto us. Even if patents have issued or will issue, we cannot guarantee that the claims of these patents are or will be valid orenforceable or will provide us with any significant protection against competitive products or otherwise be commercially valuableto us. The laws of some foreign jurisdictions do not protect intellectual property rights to the same extent as in the UnitedStates and many companies have encountered significant difficulties in protecting and defending such rights in foreign jurisdictions.Furthermore, different countries have different procedures for obtaining patents, and patents issued in different countries offerdifferent degrees of protection against use of the patented invention by others. If we encounter such difficulties in protectingor are otherwise precluded from effectively protecting our intellectual property rights in foreign jurisdictions, our businessprospects could be substantially harmed.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 41; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           41           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thepatent positions of biotechnology and pharmaceutical companies, including our patent position, involve complex legal and factualquestions, and, therefore, validity and enforceability cannot be predicted with certainty. Patents may be challenged, deemed unenforceable,invalidated, or circumvented as a result of laws, rules and guidelines that are changed due to legislative, judicial or administrativeactions, or review, which render our patents unenforceable or invalid. Our patents can be challenged by our competitors who canargue that our patents are invalid, unenforceable, lack utility, sufficient written description or enablement, or that the claimsof the issued patents should be limited or narrowly construed. Patents also will not protect our product candidates if competitorsdevise ways of making or using these product candidates without infringing our patents.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wewill be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our technologies,methods of treatment, product candidates, and any future products are covered by valid and enforceable patents or are effectivelymaintained as trade secrets and we have the funds to enforce our rights, if necessary.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theexpiration of our owned or licensed patents before completing the research and development of our product candidates and receivingall required approvals in order to sell and distribute the products on a commercial scale can adversely affect our business andresults of operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Litigationregarding patents, patent applications and other proprietary rights may be expensive and time consuming. If we are involved insuch litigation, it could cause delays in bringing product candidates to market and harm our ability to operate.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Oursuccess will depend in part on our ability to operate without infringing the proprietary rights of third parties. The pharmaceuticalindustry is characterized by extensive litigation regarding patents and other intellectual property rights. Other parties mayobtain patents in the future and allege that the products or use of our technologies infringe these patent claims or that we areemploying their proprietary technology without authorization.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, third parties may challenge or infringe upon our existing or future patents. Proceedings involving our patents or patentapplications or those of others could result in adverse decisions regarding:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    patentability of our inventions relating to our product candidates; and/or          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    enforceability, validity or scope of protection offered by our patents relating to our product candidates.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Evenif we are successful in these proceedings, we may incur substantial costs and divert management time and attention in pursuingthese proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights ofothers, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court.Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion.In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement actionsuccessfully or have infringed patents declared valid, we may:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           incur    substantial monetary damages;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           encounter    significant delays in bringing our product candidates to market; and/or          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           be    precluded from participating in the manufacture, use or sale of our product candidates or methods of treatment requiring licenses.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wemay be unable to adequately prevent disclosure of trade secrets and other proprietary information.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wealso rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriateor obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees,consultants, outside scientific collaborators, sponsored researchers, and other advisors to protect our trade secrets and otherproprietary information. These agreements may not effectively prevent disclosure of confidential information and may not providean adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independentlydiscover our trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce anddetermine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affectour competitive business position.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 42; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           42           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Someof our products are dependent upon our license agreement with Penn; if we breach the license agreement and/or fail to make paymentsdue and owing to Penn under our license agreement, our business may be materially and adversely affected.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Pursuantto the terms of our license agreement with Penn, which has been amended from time to time, we have acquired exclusive worldwidelicenses for patents and patent applications related to our proprietary Listeria vaccine technology. The license provides us withthe exclusive commercial rights to the patent portfolio developed at Penn as of the effective date of the license, in connectionwith Dr. Paterson and requires us to pay various milestone, legal, filing and licensing payments to commercialize the technology.As of October 31, 2019, we did not have outstanding payables to Penn. We can provide no assurance that we will be able to makeall future payments due and owing thereunder, that such licenses will not be terminated or expire during critical periods, thatwe will be able to obtain licenses from Penn for other rights that may be important to us, or, if obtained, that such licenseswill be obtained on commercially reasonable terms. The loss of any current or future licenses from Penn or the exclusivity rightsprovided therein could materially harm our business, financial condition and operating results.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ifwe are unable to obtain licenses needed for the development of our product candidates, or if we breach any of the agreements underwhich we license rights to patents or other intellectual property from third parties, we could lose license rights that are importantto our business.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifwe are unable to maintain and/or obtain licenses needed for the development of our product candidates in the future, we may haveto develop alternatives to avoid infringing on the patents of others, potentially causing increased costs and delays in drug developmentand introduction or precluding the development, manufacture, or sale of planned products. Some of our licenses provide for limitedperiods of exclusivity that require minimum license fees and payments and/or may be extended only with the consent of the licensor.We can provide no assurance that we will be able to meet these minimum license fees in the future or that these third partieswill grant extensions on any or all such licenses. This same restriction may be contained in licenses obtained in the future.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Additionally,we can provide no assurance that the patents underlying any licenses will be valid and enforceable. To the extent any productsdeveloped by us are based on licensed technology, royalty payments on the licenses will reduce our gross profit from such productsales and may render the sales of such products uneconomical. In addition, the loss of any current or future licenses or the exclusivityrights provided therein could materially harm our business, financial condition and our operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         RisksRelated to Ownership of our Securities        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Salesof additional equity securities may adversely affect the market price of our common stock and your rights may be reduced.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weexpect to continue to incur drug development and selling, general and administrative costs, and to satisfy our funding requirements,we will need to sell additional equity securities, which may be subject to registration rights and warrants with anti-dilutiveprotective provisions. The sale or the proposed sale of substantial amounts of our common stock or other equity securities inthe public markets may adversely affect the market price of our common stock and our stock price may decline substantially. Ourshareholders may experience substantial dilution and a reduction in the price that they are able to obtain upon sale of theirshares. Also, new equity securities issued may have greater rights, preferences or privileges than our existing common stock.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Theprice of our common stock and warrants may be volatile.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thetrading price of our common stock and warrants may fluctuate substantially. The price of our common stock and warrants that willprevail in the market may be higher or lower than the price you have paid, depending on many factors, some of which are beyondour control and may not be related to our operating performance. These fluctuations could cause you to lose part or all of yourinvestment in our common stock and warrants. Those factors that could cause fluctuations include, but are not limited to, thefollowing:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           price    and volume fluctuations in the overall stock market from time to time;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           fluctuations    in stock market prices and trading volumes of similar companies;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           actual    or anticipated changes in our net loss or fluctuations in our operating results or in the expectations of securities analysts;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    issuance of new equity securities pursuant to a future offering, including issuances of preferred stock;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           general    economic conditions and trends;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           positive    and negative events relating to healthcare and the overall pharmaceutical and biotech sector;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           major    catastrophic events;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           sales    of large blocks of our stock;          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 43; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           43           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           significant    dilution caused by the anti-dilutive clauses in our financial agreements;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           departures    of key personnel;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           changes    in the regulatory status of our immunotherapies, including results of our clinical trials;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           events    affecting Penn or any current or future collaborators;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           announcements    of new products or technologies, commercial relationships or other events by us or our competitors;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           regulatory    developments in the United States and other countries;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           failure    of our common stock or warrants to be listed or quoted on The Nasdaq Stock Market, NYSE Amex Equities or other national market    system;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           changes    in accounting principles; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           discussion    of us or our stock price by the financial and scientific press and in online investor communities.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inthe past, following periods of volatility in the market price of a company’s securities, securities class action litigationhas often been brought against that company. Due to the potential volatility of our stock price, we may therefore be the targetof securities litigation in the future. Securities litigation could result in substantial costs and divert management’sattention and resources from our business.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Alimited public trading market may cause volatility in the price of our common stock.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thequotation of our common stock on the Nasdaq does not assure that a meaningful, consistent and liquid trading market currentlyexists, and in recent years such market has experienced extreme price and volume fluctuations that have particularly affectedthe market prices of many smaller companies like us. Our common stock is thus subject to this volatility. Sales of substantialamounts of common stock, or the perception that such sales might occur, could adversely affect prevailing market prices of ourcommon stock and our stock price may decline substantially in a short time and our shareholders could suffer losses or be unableto liquidate their holdings.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Themarket prices for our common stock may be adversely impacted by future events.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourcommon stock began trading on the over-the-counter-markets on July 28, 2005 and is currently quoted on the Nasdaq Capital Marketunder the symbol ADXS. Market prices for our common stock and warrants will be influenced by a number of factors, including:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    issuance of new equity securities pursuant to a future offering, including issuances of preferred stock;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           changes    in interest rates;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           significant    dilution caused by the anti-dilutive clauses in our financial agreements;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           competitive    developments, including announcements by competitors of new products or services or significant contracts, acquisitions, strategic    partnerships, joint ventures or capital commitments;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           variations    in quarterly operating results;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           change    in financial estimates by securities analysts;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    depth and liquidity of the market for our common stock and warrants;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           investor    perceptions of our company and the pharmaceutical and biotech industries generally; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           general    economic and other national conditions.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 44; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           44           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Weare not currently in compliance with the continued listing requirements for Nasdaq. If the price of our common stock continuesto trade below $1.00 per share for a sustained period or we do not meet other continued listing requirements, our common stockmay be delisted from the Nasdaq Capital Market, which could affect the market price and liquidity for our common stock and reduceour ability to raise additional capital.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inorder to maintain listing on the Nasdaq Capital Market, we must satisfy minimum financial and other requirements including, withoutlimitation, a requirement that our closing bid price be at least $1.00 per share. On April 8, 2020, the Company received writtennotice from Nasdaq indicating that the Company was not in compliance with this minimum bid price requirement because the Company’scommon stock had closed below $1.00 per share for the previous 30 consecutive business days. On April 17, 2020, the Company receivedan additional notice from Nasdaq indicating that, due to extraordinary market conditions, Nasdaq had tolled the compliance periodfor the bid-price requirement through June 30, 2020 (the “tolling period”) and that on April 16, 2020, Nasdaq filedan immediately effective rule change with the SEC to implement the tolling period. In accordance with the April 17, 2020 noticefrom Nasdaq, the Company had until December 21, 2020 to regain compliance with the minimum bid price requirement.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof December 21, 2020, the Company was yet to be in compliance with the minimum bid requirement as discussed above. On December22, 2020, the Company received notification from the Nasdaq that the Company’s application to transfer the listing of itscommon stock from the Nasdaq Global Select Market to the Nasdaq Capital Market had been approved. The Company’s securitieswere transferred to the Nasdaq Capital Market at the opening of business on December 24, 2020 and the Company will have an additional180 days, or until June 21, 2021, to regain compliance with the minimum bid price per share requirement.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifcompliance cannot be demonstrated by June 21, 2021 or the Company does not comply with the terms of this extension, Nasdaq willprovide written notification that the Company’s securities will be delisted which could adversely affect the market priceand liquidity of our common stock and reduce our ability to raise additional capital.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Unlessour common stock continues to be listed on a national securities exchange it will become subject to the so-called “pennystock” rules that impose restrictive sales practice requirements.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifwe are unable to maintain the listing of our common stock on The Nasdaq Capital Market or another national securities exchange,our common stock could become subject to the so-called “penny stock” rules if the shares have a market value of lessthan $5.00 per share. The SEC has adopted regulations that define a penny stock to include any stock that has a market price ofless than $5.00 per share, subject to certain exceptions, including an exception for stock traded on a national securities exchange.The SEC regulations impose restrictive sales practice requirements on broker-dealers who sell penny stocks to persons other thanestablished customers and accredited investors. An accredited investor generally is a person whose individual annual income exceeded$200,000, or whose joint annual income with a spouse exceeded $300,000 during the past two years and who expects their annualincome to exceed the applicable level during the current year, or a person with net worth in excess of $1.0 million, not includingthe value of the investor’s principal residence and excluding mortgage debt secured by the investor’s principal residenceup to the estimated fair market value of the home, except that any mortgage debt incurred by the investor within 60 days priorto the date of the transaction shall not be excluded from the determination of the investor’s net worth unless the mortgagedebt was incurred to acquire the residence. For transactions covered by this rule, the broker-dealer must make a special suitabilitydetermination for the purchaser and must have received the purchaser’s written consent to the transaction prior to sale.This means that if we are unable maintain the listing of our common stock on a national securities exchange, the ability of stockholdersto sell their common stock in the secondary market could be adversely affected.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifa transaction involving a penny stock is not exempt from the SEC’s rule, a broker-dealer must deliver a disclosure schedulerelating to the penny stock market to each investor prior to a transaction. The broker-dealer also must disclose the commissionspayable to both the broker-dealer and its registered representative, current quotations for the penny stock, and, if the broker-dealeris the sole market-maker, the broker-dealer must disclose this fact and the broker-dealer’s presumed control over the market.Finally, monthly statements must be sent disclosing recent price information for the penny stock held in the customer’saccount and information on the limited market in penny stocks.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ifwe fail to remain current with our listing requirements, we could be removed from the Nasdaq Capital Market, which would limitthe ability of broker-dealers to sell our securities and the ability of shareholders to sell their securities in the secondarymarket.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Companiestrading on the Nasdaq Marketplace, such as our Company, must be reporting issuers under Section 12 of the Exchange Act, as amended,and must meet the listing requirements in order to maintain the listing of our common stock on the Nasdaq Capital Market. If wedo not meet these requirements, the market liquidity for our securities could be severely adversely affected by limiting the abilityof broker-dealers to sell our securities and the ability of shareholders to sell their securities in the secondary market.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wemay be at an increased risk of securities litigation, which is expensive and could divert management attention.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Themarket price of our common stock may be volatile, and in the past companies that have experienced volatility in the market priceof their stock have been subject to securities class action litigation. We may be the target of this type of litigation in thefuture. Securities litigation against us could result in substantial costs and divert our management’s attention from otherbusiness concerns, which could seriously harm our business.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <!-- Field: Page; Sequence: 45; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           45           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Wedo not intend to pay cash dividends.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave not declared or paid any cash dividends on our common stock, and we do not anticipate declaring or paying cash dividendsfor the foreseeable future. Any future determination as to the payment of cash dividends on our common stock will be at our Boardof Directors’ discretion and will depend on our financial condition, operating results, capital requirements and other factorsthat our Board of Directors considers to be relevant.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          Ourcertificate of incorporation, bylaws and Delaware law have anti-takeover provisions that could discourage, delay or prevent achange in control, which may cause our stock price to decline.         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourcertificate of incorporation, Bylaws and Delaware law contain provisions which could make it more difficult for a third partyto acquire us, even if closing such a transaction would be beneficial to our shareholders. To date, we have not issued sharesof preferred stock, however, we are authorized to issue up to 5,000,000 shares of preferred stock. This preferred stock may beissued in one or more series, the terms of which may be determined at the time of issuance by our Board of Directors without furtheraction by shareholders. The terms of any series of preferred stock may include voting rights (including the right to vote as aseries on particular matters), preferences as to dividend, liquidation, conversion and redemption rights and sinking fund provisions.The issuance of any preferred stock could materially adversely affect the rights of the holders of our common stock, and therefore,reduce the value of our common stock. In particular, specific rights granted to future holders of preferred stock could be usedto restrict our ability to merge with, or sell our assets to, a third party and thereby preserve control by the present management.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Provisionsof our certificate of incorporation, Bylaws and Delaware law also could have the effect of discouraging potential acquisitionproposals or making a tender offer or delaying or preventing a change in control, including changes a shareholder might considerfavorable. Such provisions may also prevent or frustrate attempts by our shareholders to replace or remove our management. Inparticular, the certificate of incorporation, Bylaws and Delaware law, as applicable, among other things; provide the Board ofDirectors with the ability to alter the Bylaws without shareholder approval and provide that vacancies on the Board of Directorsmay be filled by a majority of directors in office, and less than a quorum.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inaddition, our Board of Directors recently adopted a short-term stockholder rights agreement with an expiration date of September28, 2021 and an ownership trigger threshold of 10%. This stockholder rights agreement could render more difficult, or discouragea merger, tender offer, or assumption of control of the Company that is not approved by our Board of Directors. The rights agreement,however, should not interfere with any merger, tender or exchange offer or other business combination approved by our Board ofDirectors. In addition, the rights agreement does not prevent our Board of Directors from considering any offer that it considersto be in the best interest of the Company’s stockholders.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weare also subject to Section 203 of the Delaware General Corporation Law, which, subject to certain exceptions, prohibits “businesscombinations” between a publicly-held Delaware corporation and an “interested shareholder,” which is generallydefined as a shareholder who becomes a beneficial owner of 15% or more of a Delaware corporation’s voting stock for a three-yearperiod following the date that such shareholder became an interested shareholder.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theseprovisions are expected to discourage certain types of coercive takeover practices and inadequate takeover bids and to encouragepersons seeking to acquire control of our company to first negotiate with its board. These provisions may delay or prevent someonefrom acquiring or merging with us, which may cause the market price of our common stock to decline.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_019">         </a>         Item1B: Unresolved Staff Comments.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        None.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_020">         </a>         Item2. Properties.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourcorporate offices and manufacturing facility are located in approximately 48,500 square feet of office space at 305 College RoadEast, Princeton, New Jersey 08540 which is occupied pursuant to a lease which expires on November 30, 2025.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_021">         </a>         Item3. Legal Proceedings.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Stendhal        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnSeptember 19, 2018, Stendhal filed a Demand for Arbitration before the International Centre for Dispute Resolution (Case No. 01-18-0003-5013)relating to the Co-development and Commercialization Agreement with Especificos Stendhal SA de CV (the “Stendhal Agreement”).In the demand, Stendhal alleged that (i) the Company breached the Stendhal Agreement when it made certain statements regardingits AIM2CERV program, (ii) that Stendhal was subsequently entitled to terminate the Agreement for cause, which it did so at thetime and (iii) that the Company owes Stendhal damages pursuant to the terms of the Stendhal Agreement. Stendhal is seeking torecover $3 million paid to the Company in 2017 as support payments for the AIM2CERV clinical trial along with approximately $0.3million in expenses incurred. Stendhal is also seeking fees associated with the arbitration and interest. The Company has answeredStendhal’s Demand for Arbitration and denied that it breached the Stendhal Agreement. The Company also alleges that Stendhalbreached its obligations to the Company by, among other things, failing to make support payments that became due in 2018 and thatStendhal therefore owes the Company $3 million. Advaxis is also seeking fees associated with the arbitration and interest.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        FromOctober 21-23, 2019, an evidentiary hearing for the arbitration was conducted. On April 1, 2020, the Arbitrator issued a finalaward denying Stendhal’s claim in full. The Arbitrator found that the Company had not repudiated the Agreement and did notowe Stendhal damages, fees, or interest associated with the arbitration. The Arbitrator also denied the Company’s claimthat Stendhal breached its obligations to the Company. The parties were ordered to bear their own attorneys’ fees and evenlysplit administrative fees and expenses for the arbitration.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_022">         </a>         Item4. Mine Safety Disclosures.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        None.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 46; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           46           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_023">         </a>         PARTII        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_024">         </a>         Item5. Market for Our Common stock and Related Shareholder Matters.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourcommon stock is listed on the Nasdaq Capital Market under the symbol “ADXS”.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof January 15, 2021 there were approximately 23,176 holders of our common stock.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave not declared or paid any cash dividends on our common stock, and we do not anticipate declaring or paying cash dividendsfor the foreseeable future.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         RecentSales of Unregistered Securities        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnJanuary 21, 2020, the Company completed a private placement of warrants to purchase the Company’s common stock with purchaserswho purchased common stock in a concurrent registered offering. The warrants became exercisable for an aggregate of 5,000,000shares of common stock beginning on the six-month anniversary of their issuance. The warrants have an exercise price of $1.25per share and will expire on the fifth anniversary from the date on which they became exercisable. The description of the warrantsabove is qualified in its entirety be reference to the full and complete terms of the warrant, the form of which is filed as Exhibit4.9 to this Annual Report on Form 10-K.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Additionally,on October 16, 2020, we entered into private exchange agreements with Anson Investments Master Fund LP and CVI Investments, Inc.(the “Investors”) of warrants issued in connection with our January 2020 public offering of common stock and concurrentprivate placement of warrants (the “Warrants”). The Warrants exchanged provided for the purchase of up to an aggregateof 5,000,000 shares of our common stock at an exercise price of $1.25 per share. The warrants became exercisable on July 21, 2020and had an expiration date of July 21, 2025. Pursuant to such exchange agreements, we agreed to issue 3,000,000 shares of commonstock to the Investors in exchange for such Warrants on a 1:0.6 basis. The exchanges were consummated to ensure that we are well-positionedto take advantage of any strategic, collaboration, financing or other potential transactions in the near future. Except as otherwisedisclosed above, no additional shares of common stock have been issued in connection with the exchanges on a fully diluted basis.The exchange of the warrants for the shares of common stock was exempt from registration under Section 3(a)(9) of the SecuritiesAct of 1933. The description of the exchange agreements above is qualified in its entirety by reference to the full andcomplete terms of such agreements, the form of which is filed as Exhibit 4.9 to this Annual Report on Form 10-K.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <a name="pri_025">        </a>        <b>         ITEM6. Selected Financial Data        </b>        .       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Notapplicable.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_026">         </a>         ITEM7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         ThisManagement’s Discussion and Analysis of Financial Conditions and Results of Operations and other portions of this reportcontain forward-looking information that involves risks and uncertainties. Our actual results could differ materially from thoseanticipated by the forward-looking information. Factors that may cause such differences include, but are not limited to, availabilityand cost of financial resources, product demand, market acceptance and other factors discussed in this report under the heading“Risk Factors”. This Management’s Discussion and Analysis of Financial Conditions and Results of Operationsshould be read in conjunction with our financial statements and the related notes included elsewhere in this report.        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Overview        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Advaxis,Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the developmentand commercialization of proprietary        <i>         Lm        </i>        Technology antigen delivery products based on a platform technology that utilizeslive attenuated        <i>         Listeria monocytogenes        </i>        , or        <i>         Lm        </i>        , bioengineered to secrete antigen/adjuvant fusion proteins. These        <i>         Lm        </i>        -based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions intoa single immunotherapy by accessing and directing antigen presenting cells to stimulate anti-tumor T cell immunity, stimulateand activate the innate immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection inthe Tumor Microenvironment, or TME, to enable the T cells to attack tumor cells.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany believes that        <i>         Lm        </i>        Technology immunotherapies can complement and address significant unmet needs in the current oncologytreatment landscape. Specifically, our product candidates (i.e., ADXS-PSA and ADXS-503) have the potential to optimize checkpointperformance, while having a generally well-tolerated safety profile, and most of our product candidates have an expected low costof goods. A new Investigator-Sponsored-Study with our FDA-approved IND is expected to start with ADXS-504-HOT construct in biochemicallyrecurrent prostate cancer patients at a leading US Medical Institution in the first quarter of 2021.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 47; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           47           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Advaxisis currently winding down clinical studies of        <i>         Lm        </i>        Technology immunotherapies in three program areas:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Human    Papilloma Virus (“HPV”)-associated cancers          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Personalized    neoantigen-directed therapies          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Human    epidermal growth factor receptor-2 (HER-2) associated cancers          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Allthese clinical program areas are anchored in the Company’s        <i>         Lm        </i>        Technology        <sup>         TM        </sup>        , a unique platform designedfor its ability to safely and effectively target various cancers in multiple ways. While we are currently winding down clinicalstudies of        <i>         Lm        </i>        Technology immunotherapies in these three program areas, our license agreements continue with OS Therapies,LLC for ADXS-HER2 and with Global BioPharma, or GBP, for the exclusive license for the development and commercialization of AXALin Asia, Africa, and the former USSR territory, exclusive of India and certain other countries.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Resultsof Operations for the Fiscal Year Ended October 31, 2020 Compared to the Fiscal Year Ended October 31, 2019        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Revenue        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Revenuedecreased $20.6 million to $0.3 million for the fiscal year ended October 31, 2020 compared to $20.9 million for the fiscal yearended October 31, 2019. The decrease was due to the fact that the Company did not have another large collaboration in currentyear after the Amgen agreement was terminated. On December 10, 2018, we received a written notice of termination from Amgen withrespect to the global agreement with Amgen (the “Amgen Agreement”). The termination was effective as of February 8,2019. As of the notification date, we adjusted revenue on a cumulative catch-up basis considering the revised measure of progressfor the combined performance obligation based on the modified service period up to and through the contract termination date ofFebruary 8, 2019 resulting in total revenue of $18.7 million in the prior period. In addition, the reimbursement of research anddevelopment costs of approximately $2.0 million by Amgen was included in revenue in the prior period.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Researchand Development Expenses        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weinvest in research and development to advance our        <i>         Lm        </i>        technology through our preclinical and clinical development programs.Research and development expenses for the years ended October 31, 2020 and 2019 were categorized as follows (in thousands):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Fiscal Years Ended          <br/>          October 31,         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Increase          <br/>          (Decrease)         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          $         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          %         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 40%; text-align: left">          Hotspot/Off-the-Shelf therapies         </td>         <td style="width: 1%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          3,515         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 1%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          3,221         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 1%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          294         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 1%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 12%; text-align: right">          9         </td>         <td style="width: 1%; text-align: left">          %         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Prostate cancer         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          948         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          863         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          85         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          10         </td>         <td style="text-align: left">          %         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          HPV-associated cancers         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          3,667         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          8,139         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (4,472         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (55         </td>         <td style="text-align: left">          )%         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Personalized neoantigen-directed therapy         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,266         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2,932         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (1,666         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (57         </td>         <td style="text-align: left">          )%         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Other expenses         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          6,216         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          11,522         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (5,306         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (46         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )%         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Total research &amp; development expense         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          15,612         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          26,677         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          (11,065         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (41         </td>         <td style="text-align: left">          )%         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Stock-based compensation expense included in research and development expense         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          308         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          1,036         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          (728         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (70         </td>         <td style="text-align: left">          )%         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 48; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           48           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Hotspot/Off-the-ShelfTherapies (ADXS-HOT)        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Researchand development costs associated with our hotspot mutation-based therapy for the fiscal year ended October 31, 2020 increasedapproximately 9% to $3.5 million compared to the same period in 2019. The increase is attributable to the costs associated withthe Part B and Part C expansion of the study.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         ProstateCancer Therapy (ADXS-PSA)        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Researchand development costs associated with our prostate cancer therapy for the fiscal year ended October 31, 2020 increased approximately$0.1 million, or 10%, compared to the same period in 2019. The increase is attributable to a change order from the contract researchorganization during the current period. The Phase 1/2 study of our ADXS-PSA compound is in combination with KEYTRUDA® (pembrolizumab),Merck’s humanized monoclonal antibody. During 2020, we presented updated data from this study which demonstrated an increasein the median overall survival, or mOS, to 33.7 months for patients in the combination arm of this study and mOS of 16.4 for patientswith visceral metasteses (n=11). We are in currently seeking potential partners on next steps for this therapy.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         HPV-AssociatedCancers (AXAL)        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Themajority of the HPV-associated research and development costs include clinical trial and other related costs associated with ourAXAL programs in cervical and head and neck cancers. HPV-associated costs for the fiscal year ended October 31, 2020 decreasedapproximately $4.5 million, or 55%, compared to the same period in 2019. The decrease resulted from the announcement made in June2019 regarding the closing of our Phase 3 AIM2CERV study in high-risk locally advanced cervical cancer. We anticipate that wewill continue to incur costs associated with the wind down of the study. Additionally, a winding down of several studies, includingour Fawcett study in anal cancer and our MEDI4736 study in combination with MedImmune’s investigational anti-PD-L1 immunecheckpoint inhibitor, durvalumab, drove further reduction in costs as compared to the prior period. We anticipate that our costssurrounding HPV-associated studies will continue to decline as we wrap up the remaining clinical and regulatory obligations ofthe program. We currently do not anticipate funding any new AXAL studies.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         PersonalizedNeoantigen-Directed Therapies (ADXS-NEO)        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Researchand development costs associated with personalized neoantigen-directed therapies for the fiscal year ended October 31, 2020 decreasedapproximately $1.7 million, or 57%, compared to the same period in 2019. In October 2019, we announced that we enrolled our lastpatient in the ADXS-NEO program in monotherapy and will not continue into Part B of this study. As a result, the costs incurredfor ADXS-NEO during the fiscal year ended October 31, 2020 consisted of wind down costs associated with terminating the study.We anticipate that we will incur wind down costs for this study and we plan to close our ADXS-NEO program IND as a next step.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         OtherExpenses        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Otherexpenses include salary and benefit costs, stock-based compensation expense, professional fees, laboratory costs and other internaland external costs associated with our research &amp; development activities. Other expenses for the fiscal year ended October31, 2020 decreased approximately $5.3 million, or 46%, compared to the same period in 2019. The decrease was primarily attributableto a decrease in salary related expenses, including stock compensation, and travel expenses resulting from cost control measuresput in place beginning in June 2018. In addition, there were decreases in laboratory and manufacturing costs, as we are focusedon the clinical development of our HOT program and less on early research programs. Additionally, we announced in October 2019that we are winding down ADXS-NEO and therefore no longer incurring costs to manufacture ADXS-NEO.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 49; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           49           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Generaland Administrative Expenses        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Generaland administrative expenses primarily include salary and benefit costs and stock-based compensation expense for employees includedin our finance, legal and administrative organizations, outside legal and professional services, and facilities costs. Generaland administrative expenses for the years ended October 31, 2020 and 2019 were as follows (in thousands):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Years Ended          <br/>          October 31,         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          Increase          <br/>          (Decrease)         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          $         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>         <td style="font-weight: bold; padding-bottom: 1.5pt">         </td>         <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">          %         </td>         <td style="padding-bottom: 1.5pt; font-weight: bold">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 40%; text-align: left">          General and administrative expense         </td>         <td style="width: 1%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          11,090         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 1%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          12,179         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 1%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          (1,089         </td>         <td style="width: 1%; text-align: left">          )         </td>         <td style="width: 1%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 12%; text-align: right">          (9         </td>         <td style="width: 1%; text-align: left">          )%         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Stock-based compensation expense included in general and administrative expense         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          583         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          966         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          (383         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (40         </td>         <td style="text-align: left">          )%         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Generaland administrative expenses for the fiscal year ended October 31, 2020 decreased approximately $1.1 million, or 9%, compared tothe same period in 2019. The decrease is attributable to lower legal fees and business development costs partially offset by increasedabandonment of certain non-strategic intellectual property.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Changesin Fair Values        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Forthe fiscal year ended October 31, 2020, we recorded non-cash expense from changes in the fair value of the warrant liability of$0.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Forthe fiscal year ended October 31, 2019, we recorded non-cash income from changes in the fair value of the warrant liability ofapproximately $2.6 million. The decrease in the fair value of liability warrants resulted from a decrease in our share price from$0.56 at October 31, 2018 to $0.32 at October 31, 2019, as well as a decrease in the number of liability warrants as a resultof the warrant exchange (see        <i>         Loss on shares issued in settlement of warrants        </i>        below        <i>         ).        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Losson shares issued in settlement of warrants        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">       OnOctober 16, 2020, the Company entered into private exchange agreements with certain holders of warrants issued in connection withthe Company’s January 2020 public offering of common stock and warrants. The warrants being exchanged provide for the purchaseof up to an aggregate of 5,000,000 shares of our common stock at an exercise price of $1.25 per share. The warrants became exercisableon July 21, 2020 and have an expiration date of July 21, 2025. Pursuant to such exchange agreements, the Company agreed to issue3,000,000 shares of common stock to the investors in exchange for the warrants.  In connection with the exchange of warrants forcommon stock, the Company recorded a loss of approximately $77 thousand as the fair value of the shares issued exceeded the fairvalue of warrants exchanged.      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnMarch 14, 2019, we entered into private exchange agreements with certain holders of warrants issued in connection with our September2018 public offering of common stock and warrants. Pursuant to the exchange agreements, we issued 856,865 shares of common stockto the investors in exchange for warrants on a 1:1 basis. In connection with the warrant exchange, we recorded a loss of approximately$1.6 million for the fiscal year ended October 31, 2019.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Liquidityand Capital Resources        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Management’sPlans        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Similarto other development stage biotechnology companies, our products that are being developed have not generated significant revenue.As a result, we have suffered recurring losses and we require significant cash resources to execute our business plans. Theselosses are expected to continue for the foreseeable future.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Historically,our major sources of cash have comprised proceeds from various public and private offerings of our securities (including our commonstock), debt financings, clinical collaborations, option and warrant exercises, income earned on investments and grants, and interestincome. From October 2013 through October 31, 2020, we raised approximately $309.4 million in gross proceeds ($17.2 million infiscal year 2020) from various public and private offerings of our common stock. We have sustained losses from operations in eachfiscal year since our inception, and we expect losses to continue for the indefinite future. As of October 31, 2020 and 2019,we had an accumulated deficit of approximately $410.7 million and $384.3 million, respectively, and stockholders’ equityof approximately $30.2 million and $39.5 million, respectively.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCOVID-19 pandemic has negatively affected the global economy and created significant volatility and disruption of financial markets.An extended period of economic disruption could negatively affect our business, financial condition, and access to sources ofliquidity. As of October 31, 2020, we had approximately $25.2 million in cash and cash equivalents. The actual amount of cashthat we will need to continue operating is subject to many factors. We have based this estimate on assumptions that may proveto be wrong, and we could use available capital resources sooner than currently expected.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 50; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           50           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany has reduced its operating expenses to $26.7 million for the fiscal year ended October 31, 2020 as compared to $38.9 millionduring the comparable prior period. Based on this, we expect to have sufficient capital to fund our obligations as they becomedue in the ordinary course of business until at least January 2022. In addition, we expect to adjust spending accordingly basedon the budgeted cash flow requirements developed and the excess cash on hand.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Werecognize that we will need to raise additional capital in order to continue to execute our business plan in the future. Thereis no assurance that additional financing will be available when needed or that we will be able to obtain financing on terms acceptableto us or whether we will become profitable and generate positive operating cash flow. If we are unable to raise sufficient additionalfunds, we will have to further scale back our operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnMay 8, 2020, the Company entered into a sales agreement related to an at-the-market equity offering program pursuant to whichthe Company may sell, from time to time, common stock with an aggregate offering price of up to $40 million through A.G.P./AllianceGlobal Partners, as sales agent, for general corporate purposes.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnJuly 30, 2020, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”).Over the 36-month term of the purchase agreement, the Company has the right, but not the obligation, from time to time, in itssole discretion and subject to certain conditions, to direct Lincoln Park to purchase up to an aggregate amount of $20,000,000of its common stock, subject to certain limitations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Dueto the current state of the Company’s stock price and general market conditions, these programs have not been utilized totheir fullest extent, thereby resulting in lower capital availability than anticipated. Management’s plans to mitigate anexpected shortfall of capital and to support future operations include obtaining additional funds through partnerships or strategicor financing investors.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <i>          CashFlows         </i>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         OperatingActivities        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Netcash used in operating activities was approximately $21.9 million for the fiscal year ended October 31, 2020 compared to $36.1million for the fiscal year ended October 31, 2019. Net cash used in operating activities includes reduced spending associatedwith our clinical trial programs and general and administrative activities. The decrease was due to measures to control costsfor non-essential items in areas that did not support our strategic direction, and as a result, we have continued to reduce non-strategicoperating expenditures over the past several quarters.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         InvestingActivities        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Netcash used in investing activities was approximately $0.7 million for the fiscal year ended October 31, 2020 compared to $1.2 millionfor the nine months ended July 31, 2019. The reduction is a result of the abandonment of certain non-strategic intellectual property.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         FinancingActivities        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Netcash provided by financing activities was approximately $15.5 million for the fiscal year ended October 31, 2020 as compared to$24.6 million for the fiscal year ended October 31, 2019. In January 2020, we completed a public offering of 10,000,000 sharesof our common stock, which resulted in net proceeds of approximately $9.7 million. Additionally, during the year end October 31,2020, we sold 2,489,104 shares under the ATM program for net proceeds of $1.531 million, and we sold 11,242,048 shares of commonstock under the Lincoln Park Purchase Agreement for net proceeds of approximately $5.1 million. In fiscal year 2019, we receivednet proceeds of approximately $24.5 million from the sales of 13,150,000 shares of our common stock and 13,656,000 pre-fundedwarrants in public offerings.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font: 10pt Times New Roman, Times, Serif">        OnNovember 27, 2020, the Company completed an underwritten public offering of 26,666,666 shares of common stock and common stockwarrants to purchase up to 13,333,333 shares of common stock (the “November 2020 Offering”). On November 24, 2020,the underwriters notified us that they had exercised their option to purchase an additional 3,999,999 shares of common stock and1,999,999 warrants in full. After giving effect to the full exercise of the underwriters’ option, we issued and sold anaggregate 30,666,665 shares of common stock and warrants to purchase up to 15,333,332 shares of common stock pursuant to our existingshelf registration statement on Form S-3 (File No. 333-226988). We received gross proceeds of approximately $9.2 million, beforededucting the underwriting discounts and commissions and fees and expenses payable by us in connection with the November 2020Offering.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <!-- Field: Page; Sequence: 51; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           51           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Off-BalanceSheet Arrangements        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof October 31, 2020, we had no off-balance sheet arrangements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         CriticalAccounting Policies        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         RevenueRecognition        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        EffectiveNovember 1, 2018, the Company adopted ASC Topic 606,        <i>         Revenue form Contracts with Customers        </i>        (ASC 606), using the modifiedretrospective transition method. Under this method, results for reporting periods beginning on November 1, 2018 are presentedunder ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with ASC Topic 605,        <i>         RevenueRecognition        </i>        (ASC 605). The Company only applied the modified retrospective transition method to contracts that were not completedas of November 1, 2018, the effective date of adoption for ASC 606. This standard applies to all contracts with customers, exceptfor contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtainscontrol of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchangefor those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scopeof ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performanceobligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligationsin the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only appliesthe five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchangefor the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within thescope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performanceobligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amountof the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation issatisfied.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany enters into licensing agreements that are within the scope of ASC 606, under which it may exclusively license rights toresearch, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typicallyinclude payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certaincosts; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales oflicensed products.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indetermining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Companyperforms the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whetherthe promised goods or services are performance obligations including whether they are distinct in the context of the contract;(iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transactionprice to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.As part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the number of performanceobligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; and (c) the stand-aloneselling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv)above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, shouldbe included in the transaction price as described further below. The transaction price is allocated to each performance obligationon a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligationsunder the contract are satisfied.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 52; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           52           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Amountsreceived prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying balance sheets.Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferredrevenue, net of current portion.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         ExclusiveLicenses.        </i>        If the license to the Company’s intellectual property is determined to be distinct from the other performanceobligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the licensewhen the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whethera performance obligation is distinct from the other performance obligations, the Company considers factors such as the research,development, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associatedexpertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from aperformance obligation for its intended purpose without the receipt of the remaining performance obligation, whether the valueof the performance obligation is dependent on the unsatisfied performance obligation, whether there are other vendors that couldprovide the remaining performance obligation, and whether it is separately identifiable from the remaining performance obligation.For licenses that are combined with other performance obligation, the Company utilizes judgment to assess the nature of the combinedperformance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and,if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measureof progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measureof progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may changeover the course of the research and development and licensing agreement. Such a change could have a material impact on the amountof revenue the Company records in future periods.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Researchand Development Services.        </i>        The performance obligations under the Company’s collaboration agreements may include researchand development services to be performed by the Company on behalf of the partner. Payments or reimbursements resulting from theCompany’s research and development efforts are recognized as the services are performed and presented on a gross basis becausethe Company is the principal for such efforts.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         MilestonePayments.        </i>        At the inception of each arrangement that includes research or development milestone payments, the Company evaluateswhether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction priceusing the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestonevalue is included in the transaction price. An output method is generally used to measure progress toward complete satisfactionof a milestone. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals,are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific,clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment.There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur.At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subjectto constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on acumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Royalties.        </i>        For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are theresult of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royaltiesrelate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligationto which some or all of the royalty has been allocated has been satisfied or partially satisfied.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         StockBased Compensation        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixednumber of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the costof services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of theaward is measured on the grant date and is then recognized over the requisite service period, usually the vesting period, in bothresearch and development expenses and general and administrative expenses on the statement of operations, depending on the natureof the services provided by the employees or consultants.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 53; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           53           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theprocess of estimating the fair value of stock-based compensation awards and recognizing stock-based compensation cost over theirrequisite service period involves significant assumptions and judgments. The Company estimates the fair value of stock optionawards on the date of grant using the Black Scholes Model (“BSM”) for the remaining awards, which requires that theCompany makes certain assumptions regarding: (i) the expected volatility in the market price of its common stock; (ii) dividendyield; (iii) risk-free interest rates; and (iv) the period of time employees are expected to hold the award prior to exercise(referred to as the expected holding period). As a result, if the Company revises its assumptions and estimates, stock-based compensationexpense could change materially for future grants.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany accounts for stock-based compensation using fair value recognition and records forfeitures as they occur. As such, theCompany recognizes stock-based compensation cost only for those stock-based awards that vest over their requisite service period,based on the vesting provisions of the individual grants.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         DerivativeFinancial Instruments        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluatesall of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embeddedderivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initiallyrecorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statementsof operations. For stock-based derivative financial instruments, the Company used the Monte Carlo simulation model to value thederivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, includingwhether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivativeliabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the instrumentcould be required within 12 months of the balance sheet date.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         IntangibleAssets        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Intangibleassets primarily consist of legal and filing costs associated with obtaining patents and licenses and are amortized on a straight-linebasis over their remaining useful lives which are estimated to be twenty years from the effective dates of the University of Pennsylvania(Penn) License Agreements, beginning in July 1, 2002. These legal and filing costs are invoiced to the Company through Penn andits patent attorneys.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Managementhas reviewed its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an assetmight not be recoverable and its carrying amount exceeds its fair value, which is based upon estimated undiscounted future cashflows. Net assets are recorded on the balance sheet for patents and licenses related to AXAL, ADXS-NEO, ADXS-HOT, ADXS-PSA andADXS-HER2 and other products that are in development. However, if a competitor were to gain FDA approval for a treatment beforeus or if future clinical trials fail to meet the targeted endpoints, the Company would likely record an impairment related tothese assets. In addition, if an application is rejected or fails to be issued, the Company would record an impairment of itsestimated book value.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         IncomeTaxes        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.”Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and(ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’sfinancial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to applyto taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferredtax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes theenactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the availablepositive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 54; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           54           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        ASCTopic 740-10-30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statementsand prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of atax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition, classification,interest and penalties, accounting in interim periods, disclosure, and transition. The Company will classify as income tax expenseany interest and penalties. The Company has no material uncertain tax positions for any of the reporting periods presented. TheCompany files tax returns in U.S. federal and state jurisdictions, including New Jersey, and is subject to audit by tax authoritiesbeginning with the fiscal year ended October 31, 2017.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Leases        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        EffectiveNovember 1, 2019, the Company adopted ASC Topic 842,        <i>         Leases        </i>        (“ASC 842”) using the modified retrospective transitionapproach by applying the new standard to all leases existing as of the date of initial application. Results and disclosure requirementsfor reporting periods beginning after November 1, 2019 are presented under ASC 842, while prior period amounts have not been adjustedand continue to be reported in accordance with the previous guidance in ASC 840,        <i>         Leases        </i>        .       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Atthe inception of an arrangement, the Company determines whether an arrangement is or contains a lease based on the facts and circumstancespresent in the arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of anidentified asset for a period of time in exchange for consideration. Most leases with a term greater than one year are recognizedon the balance sheet as operating lease right-of-use assets and current and long-term operating lease liabilities, as applicable.The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically onlyincludes the initial lease term in its assessment of a lease arrangement. Options to extend a lease are not included in the Company’sassessment unless there is reasonable certainty that the Company will renew.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Operatinglease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over theexpected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as prepaid or accruedrent. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Companyutilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basisthe amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition toASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NewAccounting Standards        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        SeeNote 2 to our financial statements that discusses new accounting standards.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_027">         </a>         Item7A. Quantitative and Qualitative Disclosures About Market Risk.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Notapplicable.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_028">         </a>         Item8. Financial Statements and Supplementary Data.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theinformation required by this Item 8 is incorporated by reference to our financial statements and the related notes and the reportof our independent registered public accounting firm beginning at page F-1 of this report.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_029">         </a>         Item9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        None.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 55; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           55           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_030">         </a>         Item9A: Controls and Procedures.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Evaluationof Disclosure Controls and Procedures        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wemaintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our ExchangeAct reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms,and that such information is accumulated and communicated to our management, including our Chief Executive Officer and interimChief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluatingthe disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed andoperated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosurecontrols and procedures reflects the fact that there are resource constraints and that management is required to apply its judgmentin evaluating the benefits of possible controls and procedures relative to their costs.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asrequired by Rule 13a-15(b) under the Exchange Act, our management, under the supervision and with the participation of our ChiefExecutive Officer and interim Chief Financial Officer, conducted an evaluation of the effectiveness of our disclosure controlsand procedures as of October 31, 2020. Based on such evaluation, our Chief Executive Officer and interim Chief Financial Officerconcluded that, as of October 31, 2020, our disclosure controls and procedures were effective.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Management’sAnnual Report on Internal Control over Financial Reporting        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ourmanagement is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule13a-15(f) under the Exchange Act. With the participation of our Chief Executive Officer and interim Chief Financial Officer, ourmanagement conducted an evaluation of the effectiveness of our internal control over financial reporting as of October 31, 2020.In conducting such evaluation, management used the criteria set forth in the report entitled “        <i>         Internal Control —Integrated Framework        </i>        ” published by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework)to evaluate the effectiveness of our internal control over financial reporting. Based on this evaluation, management has concludedthat our internal control over financial reporting was effective as of October 31, 2020, based on those criteria.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thisreport does not include an attestation report of our independent registered public accounting firm regarding our internal controlover financial reporting, in accordance with applicable SEC rules that permit us to provide only management’s report inthis report.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Changesin Internal Control Over Financial Reporting        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Therewas no change in our internal control over financial reporting during the fiscal year ended October 31, 2020, that has materiallyaffected, or is reasonably likely to materially affect, our internal control over financial reporting.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Internalcontrol over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reportingand the preparation of financial statements prepared for external purposes in accordance with generally accepted accounting principles.Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate becauseof changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_031">         </a>         Item9B. Other Information.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        None.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 56; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           56           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_007">         </a>         PARTIII        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_008">         </a>         Item10. Directors, Executive Officers and Corporate Governance.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theinformation required by this Item is incorporated herein by reference from our Proxy Statement for our 2021 Annual Meeting ofStockholders.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_009">         </a>         Item11. Executive Compensation.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theinformation required by this Item is incorporated herein by reference from our Proxy Statement for our 2020 Annual Meeting ofStockholders.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_010">         </a>         Item12. Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theinformation required by this Item is incorporated herein by reference from our Proxy Statement for our 2021 Annual Meeting ofStockholders.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_011">         </a>         Item13. Certain Relationships and Related Transactions, and Director Independence.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theinformation required by this Item is incorporated herein by reference from our Proxy Statement for our 2021 Annual Meeting ofStockholders.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_012">         </a>         Item14. Principal Accountant Fees and Services.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theinformation required by this Item is incorporated herein by reference from our Proxy Statement for our 2021 Annual Meeting ofStockholders.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_013">         </a>         PARTIV        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_014">         </a>         Item15. Exhibits and Financial Statements Schedules.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (a)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            1.    Financial Statements.           </b>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.3pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.3pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Fora list of the financial statements included herein, see Index to the Financial Statements on page F-1 of this Form 10-K.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            2.    Financial Statement Schedules.           </b>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.3pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.3pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Nofinancial statement schedules have been submitted because they are not required or are not applicable or because the informationrequired is included in the financial statements or the notes thereto.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.3pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            3.    List of Exhibits.           </b>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.3pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.3pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Seethe Exhibit Index in Item 15(b) below.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 29.3pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.6in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Exhibit    Number           </b>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Description    of Exhibits           </b>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.1          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420406020255/v042657def14a.htm" style="-sec-extract: exhibit">            Amended and Restated Certificate of Incorporation. Incorporated by reference to Annex C to DEF 14A Proxy Statement filed with the SEC on May 15, 2006.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.2          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420409050029/v161315_ex4-1.htm" style="-sec-extract: exhibit">            Certificate of Designations of Preferences, Rights and Limitations of Series A Preferred Stock of the registrant, dated September 24, 2009. Incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K filed with the SEC on September 25, 2009.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.3          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420410038581/v190951_ex4-1.htm" style="-sec-extract: exhibit">            Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the registrant, dated July 19, 2010. Incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K filed with the SEC on July 20, 2010.           </a>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 57; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           57           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.6in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.4          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420412046790/v321794_ex3-1.htm" style="-sec-extract: exhibit">            Certificate of Amendment to Amended and Restated Certificate of Incorporation filed with the Delaware Secretary of State on August 16, 2012. Incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed with the SEC on August 17, 2012.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.5          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420413039531/v350002_ex3-1.htm" style="-sec-extract: exhibit">            Certificate of Amendment to Amended and Restated Certificate of Incorporation filed with the Delaware Secretary of State on July 11, 2013 (reverse stock split). Incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed with the SEC on July 15, 2013.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.6          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420413039531/v350002_ex3-2.htm" style="-sec-extract: exhibit">            Certificate of Amendment to Amended and Restated Certificate of Incorporation filed with the Delaware Secretary of State on July 12, 2013 (reverse stock split). Incorporated by reference to Exhibit 3.2 to Current Report on Form 8-K filed with the SEC on July 15, 2013.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.7          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315214002124/ex3-1.htm" style="-sec-extract: exhibit">            Certificate of Amendment to Amended and Restated Certificate of Incorporation filed with the Delaware Secretary of State on July 9, 2014. Incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed with the SEC on July 10, 2014.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.8          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315216007989/ex3-1.htm" style="-sec-extract: exhibit">            Certificate of Amendment to Amended and Restated Certificate of Incorporation filed with the Delaware Secretary of State on March 10, 2016. Incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed with the SEC on March 11, 2016.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.9          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315218003707/ex3-1.htm" style="-sec-extract: exhibit">            Certificate of Amendment to Amended and Restated Certificate of Incorporation filed with the Delaware Secretary of State on March 21, 2018. Incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed with the SEC on March 21, 2018.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.10          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315220018509/ex3-1.htm" style="-sec-extract: exhibit">            Certificate of Designation of Series C Junior Participating Preferred Stock of Advaxis, Inc. Incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on September 29, 2020.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.11          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315220018509/ex3-2.htm" style="-sec-extract: exhibit">            Amended and Restated Bylaws. Incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed with the SEC on September 29, 2020.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.1          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420407055882/v091077_ex4-1.htm" style="-sec-extract: exhibit">            Form of Common Stock certificate. Incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K filed with the SEC on October 23, 2007.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.2          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420411050832/v233956_ex4-1.htm" style="-sec-extract: exhibit">            Form of Common stock Purchase Warrant. Incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K filed with the SEC on August 31, 2011.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.3          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420413052899/v350836_ex4-19.htm" style="-sec-extract: exhibit">            Form of Representative’s Warrant. Incorporated by reference to Exhibit 4.19 to Registration Statement on Form S-1/A (File No. 333-188637) filed with the SEC on September 27, 2013.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.4          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315214001851/ex4-2.htm" style="-sec-extract: exhibit">            Form of Representative’s Warrant related to the Underwriting Agreement, dated as of March 31, 2014, by and between Advaxis, Inc. and Aegis Capital Group. Incorporated by reference to Exhibit 4.2 to Quarterly Report on Form 10-Q filed with the SEC on June 10, 2014.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.5          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315218013098/ex4-1.htm" style="-sec-extract: exhibit">            Form of Warrant Agency Agreement, dated as of September 11, 2018 between Advaxis, Inc. and Continental Stock Transfer and Trust Company (and Form of Warrant contained therein), Incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K filed with the SEC on September 11, 2018.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.6          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315218013098/ex4-1.htm" style="-sec-extract: exhibit">            Form of Common Stock Warrant dated September 11, 2018 (included in Exhibit 4.5)           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.7          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315220000983/ex4-1.htm" style="-sec-extract: exhibit">            Form of Common Stock Warrant dated January 21, 2020. Incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on January 23, 2020.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.8          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315220022626/ex4-1.htm" style="-sec-extract: exhibit">            Form of Common Stock Warrant dated November 27, 2020. Incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on November 27, 2020.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.9*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="ex4-9.htm">            Form of Warrant Exchange Agreement, dated October 16, 2020.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.10          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315220018509/ex4-1.htm" style="-sec-extract: exhibit">            Rights Agreement, dated as of September 29, 2020, by and between Advaxis, Inc. and Continental Stock Transfer and Trust Company, as rights agent. Incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on September 29, 2020.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.1          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420407007215/v063533_ex10-11.htm" style="-sec-extract: exhibit">            License Agreement, between the Trustees of the University of Pennsylvania and the registrant dated as of June 17, 2002, as Amended and Restated on February 13, 2007. Incorporated by reference to Exhibit 10.11 to Annual Report on Form 10-KSB filed with the SEC on February 13, 2007.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.2          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420410023174/v182596_def14a.htm" style="-sec-extract: exhibit">            Amended and Restated 2009 Stock Option Plan of the registrant. Incorporated by reference to Annex A to DEF 14A Proxy Statement filed with the SEC on April 30, 2010.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.3          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420410031668/v186982_ex10-1.htm" style="-sec-extract: exhibit">            Second Amendment to the Amended and Restated Patent License Agreement between the registrant and the Trustees of the University of Pennsylvania dated as of May 10, 2010. Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on June 3, 2010.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.4          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420411050244/v233187_def14a.htm" style="-sec-extract: exhibit">            2011 Omnibus Incentive Plan of registrant. Incorporated by reference to Annex A to DEF 14A Proxy Statement filed with the SEC on August 29, 2011.           </a>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 58; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           58           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.6in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.5          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420412034931/v314612_ex10-1.htm" style="-sec-extract: exhibit">            Amendment No. 1, dated as of March 26, 2007, to the License Agreement, between the Trustees of the University of Pennsylvania and Advaxis, Inc. dated as of June 17, 2002, as amended and restated on February 13, 2007. Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on June 14, 2012.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.6          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420412034931/v314612_ex10-5.htm" style="-sec-extract: exhibit">            Amendment No. 3, dated as of December 12, 2011, to the License Agreement, between the Trustees of the University of Pennsylvania and Advaxis, Inc. dated as of June 17, 2002, as amended and restated on February 13, 2007. Incorporated by reference to Exhibit 10.5 to Quarterly Report on Form 10-Q filed with the SEC on June 14, 2012.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.7          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420412040204/v318209_def14a.htm" style="-sec-extract: exhibit">            Amendment No. 1 to 2011 Omnibus Incentive Plan of registrant. Incorporated by reference to Annex B to DEF 14A Proxy Statement filed with the SEC on July 19, 2012.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.8          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420413047147/v353414_ex10-3.htm" style="-sec-extract: exhibit">            Indemnification Agreement. Incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed with the SEC on August 20, 2013.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.9    ‡          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420413052899/v350836_ex10-70.htm" style="-sec-extract: exhibit">            Employment Agreement between Advaxis, Inc. and Robert Petit, dated September 26, 2013. Incorporated by reference to Exhibit 10.70 to Registration Statement on Form S-1/A (File No. 333-188637) filed with the SEC on September 27, 2013.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.10          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420414006607/v367396_ex10-79.htm" style="-sec-extract: exhibit">            Exclusive License and Technology Transfer Agreement by and between Advaxis, Inc. and Global BioPharma, Inc., dated December 9, 2013. Incorporated by reference to Exhibit 10.79 to Annual Report on Form 10-K/A filed with the SEC on February 6, 2014.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.11‡          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420414006607/v367396_ex10-82.htm" style="-sec-extract: exhibit">            Amendment No. 1, dated as of December 19, 2013, to the Employment Agreement by and between Advaxis, Inc. and Robert G. Petit. Incorporated by reference to Exhibit 10.82 to Annual Report on Form 10-K/A filed with the SEC on February 6, 2014.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.12          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420414016138/v371064_ex10-7.htm" style="-sec-extract: exhibit">            Distribution and Supply Agreement, dated as of January 20, 2014, by and between Advaxis, Inc. and Biocon, Limited. Incorporated by reference to Exhibit 10.7 to Quarterly Report on Form 10-Q filed with the SEC on March 17, 2014.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.13          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315214001851/ex10-1.htm" style="-sec-extract: exhibit">            Exclusive License Agreement, dated March 19, 2014, by and between Advaxis, Inc. and Aratana Therapeutics, Inc. Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on June 10, 2014.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.14‡          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315214001851/ex10-6.htm" style="-sec-extract: exhibit">            Amendment No. 2, dated as of June 5, 2014, to the Employment Agreement by and between Advaxis, Inc. and Robert G. Petit. Incorporated by reference to Exhibit 10.6 to Quarterly Report on Form 10-Q filed with the SEC on June 10, 2014.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.15          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315214002907/ex10-1.htm" style="-sec-extract: exhibit">            Clinical Trial Collaboration Agreement, dated July 21, 2014, by and between Advaxis, Inc. and MedImmune, LLC. Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on September 9, 2014.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.16          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315214002907/ex10-2.htm" style="-sec-extract: exhibit">            5            <sup>             th            </sup>            Amendment to the Amended &amp; Restated License Agreement, dated July 25, 2014, by and between Advaxis, Inc. and University of Pennsylvania. Incorporated by reference to Exhibit 10.2 to Quarterly Report on Form 10-Q filed with the SEC on September 9, 2014.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.17          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315214001629/defr14a.htm#a_005" style="-sec-extract: exhibit">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Amendment No. 2 to the Advaxis, Inc. 2011 Omnibus Incentive Plan, effective July 9, 2014. Incorporated by reference to Annex A to Current Report on Schedule 14A filed with the SEC on May 20, 2014.           </font>          </a>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.18          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315214002907/ex10-4.htm" style="-sec-extract: exhibit">            Amended and Restated 2011 Omnibus Incentive Plan, dated September 8, 2014. Incorporated by reference to Exhibit 10.4 to Quarterly Report on Form 10-Q filed with the SEC on September 9, 2014.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.19          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000114420414007594/v367877_ex10-1.htm" style="-sec-extract: exhibit">            Master Services Agreement for Technical Transfer and Clinical Supply, dated February 5, 2014, by and between Advaxis, Inc. and SynCo Bio Partners B.V. Incorporated by reference to Exhibit 10.1 to Current Report to Form 8-K filed with the SEC on February 11, 2014.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.20          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315215000050/ex10-101.htm" style="-sec-extract: exhibit">            Clinical Trial Collaboration and Supply Agreement by and between Advaxis, Inc. and Merck &amp; Co. dated August 22, 2014. Incorporated by reference to Exhibit 10.101 to Annual Report on Form 10-K filed with the SEC on January 6, 2015           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.21‡          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315215002480/ex10-6.htm" style="-sec-extract: exhibit">            Amendment No. 3, dated as of April 17, 2015, to the Employment Agreement by and between Advaxis, Inc. and Robert G. Petit. Incorporated by reference to Exhibit 10.6 to Quarterly Report on Form 10-Q filed with the SEC on June 15, 2015.           </a>          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 59; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           59           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.6in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.22          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315216007685/ex10-1.htm" style="-sec-extract: exhibit">            Co-Development and Commercialization Agreement between Advaxis, Inc. and Especificos Stendhal SA de CV dated February 3, 2016. Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on February 26, 2016.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.23‡          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315217007553/ex10-1.htm" style="-sec-extract: exhibit">            Separation Agreement and General Release, dated July 6, 2017, between Advaxis, Inc. and Daniel J. O’Connor. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on July 7, 2017.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.24          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315215001278/def14a.htm" style="-sec-extract: exhibit">            2015 Incentive Plan of registrant. Incorporated by reference to Annex A to DEF 14A Proxy Statement filed with the SEC on April 7, 2015.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.25          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315216007316/def14a.htm" style="-sec-extract: exhibit">             Amendment to the Advaxis, Inc. 2015 Incentive Plan. Incorporated by reference to Exhibit B to DEF 14A Proxy Statement filed with the SEC on February 11, 2016.            </a>           </font>          </p>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.26          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315217001334/def14a.htm" style="-sec-extract: exhibit">            Amendment to the Advaxis, Inc. 2015 Incentive Plan. Incorporated by reference to Exhibit A to DEF 14A Proxy Statement filed with the SEC on February 10, 2017.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.27          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315220004431/def14a.htm" style="-sec-extract: exhibit">            Amendment to the Advaxis, Inc. 2015 Incentive Plan. Incorporated by reference to Exhibit A to DEF 14A Proxy Statement filed with the SEC on March 20, 2020.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.28‡          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315218008256/ex10-1.htm" style="-sec-extract: exhibit">            Employment Agreement between Advaxis, Inc. and Molly Henderson, dated June 6, 2018. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on June 6, 2018.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.29          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315218001547/formdef14a.htm" style="-sec-extract: exhibit">            2018 Employee Stock Purchase Plan. Incorporated by reference Exhibit B to the DEF14A Proxy Statement filed with the SEC on February 6, 2018.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.30          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315220008067/ex1-1.htm" style="-sec-extract: exhibit">            Sales Agreement, dated May 8, 2020, by and between Advaxis, Inc. and A.G.P./Alliance Global Partners (incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 8, 2020)           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.31          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315220014443/ex10-1.htm" style="-sec-extract: exhibit">            Purchase Agreement, dated July 30, 2020, by and between Advaxis, Inc. and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on August 3, 2020)           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           14.1          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1100397/000149315214002124/ex14-1.htm" style="-sec-extract: exhibit">            Code of Business Conduct and Ethics dated July 9, 2014. Incorporated by reference to Exhibit 14.1 to Current Report on Form 8-K filed with the SEC on July 10, 2014.           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           23.1*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="ex23-1.htm">            Consent of Independent Registered Public Accounting Firm           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           31.1*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="ex31-1.htm">            Certification of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           31.2*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="ex31-2.htm">            Certification of interim Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           32.1*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="ex32-1.htm">            Certification of Chief Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           32.2*          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="ex32-2.htm">            Certification of interim Chief Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002           </a>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           101.INS**          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           XBRL    Instance Document          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           101.SCH**          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           XBRL    Taxonomy Extension Schema Document          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           101.CAL**          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           XBRL    Taxonomy Extension Calculation Linkbase Document          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           101.DEF**          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           XBRL    Taxonomy Extension Definitions Linkbase Document          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           101.LAB**          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           XBRL    Taxonomy Extension Label Linkbase Document          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           101.PRE**          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           XBRL    Taxonomy Extension Presentation Linkbase Document          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; padding-right: 0.8pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           *          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Filed    herewith.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           **          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Furnished    herewith.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ‡          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Denotes    management contract or compensatory plan or arrangement.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_015">         </a>         ITEM16. Form 10-K Summary        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.3pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.3pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        None.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.3pt">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 60; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           60           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_016">         </a>         SIGNATURE        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Pursuantto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed onits behalf by the undersigned, thereunto duly authorized, in Princeton, Mercer County, State of New Jersey, on this 22        <sup>         nd        </sup>        day of January 2021.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td colspan="2" style="text-align: left; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ADVAXIS,    INC.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 50%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 3%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 47%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           By:          </font>         </td>         <td style="text-align: left; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Kenneth Berlin           </i>          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           President    and Chief Executive Officer          </font>         </td>        </tr>       </tbody>      </table>      <p style="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        KNOWALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kenneth Berlin (with fullpower to act alone), as his true and lawful attorneys-in-fact and agents, with full powers of substitution and resubstitution,for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and ExchangeCommission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act andthing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he might or could doin person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, lawfullydo or cause to be done by virtue hereof.       </font>      </p>      <p style="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Pursuantto the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons onbehalf of the registrant and in the capacities and on the dates indicated:       </font>      </p>      <p style="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 24%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           SIGNATURE          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 54%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Title          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           DATE          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Kenneth Berlin           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Kenneth    Berlin          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           President,    Chief Executive Officer, Director and interim Chief Financial Officer          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           January    22, 2021          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           (Principal    Executive Officer, Principal Financial and Accounting Officer)          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    David Sidransky           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           David    Sidransky          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Chairman    of the Board          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           January    22, 2021          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    James Patton           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           James    Patton          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Vice    Chairman of the Board          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           January    22, 2021          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Richard Berman           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Richard    Berman          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Director          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           January    22, 2021          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Samir Khleif           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Samir    Khleif          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Director          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           January    22, 2021          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <i>            /s/    Roni Appel           </i>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Roni    Appel          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Director          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           January    22, 2021          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 61; Value: 2 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           61           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         ADVAXIS,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         FINANCIALSTATEMENTS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         INDEX        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Page          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_001">            Report of Independent Registered Public Accounting Firm           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           F-2          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_002">            Balance Sheets           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           F-3          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_003">            Statements of Operations           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           F-4          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_004">            Statements of Shareholders’ Equity           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           F-5          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_005">            Statements of Cash Flows           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           F-6          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <a href="#pri_006">            Notes to the Financial Statements           </a>          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           F-8          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 62; Options: NewSection -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           1           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_001">         </a>         REPORTOF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Tothe Shareholders and Board of Directors of       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Advaxis,Inc.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Opinionon the Financial Statements        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave audited the accompanying balance sheets of Advaxis, Inc. (the “Company”) as of October 31, 2020 and 2019,the related statements of operations, stockholders’ equity and cash flows for each of the two years in the periodended October 31, 2020, and the related notes (collectively referred to as the “financial statements”). In our opinion,the financial statements present fairly, in all material respects, the financial position of the Company as of October 31 2020and 2019, and the results of its operations and its cash flows for each of the two years in the period ended October 31, 2020,in conformity with accounting principles generally accepted in the United States of America.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Changein Accounting Principle        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asdiscussed in Note 2 to the financial statements, the Company has changed its method of accounting for leases in 2020 due to theadoption of the guidance in ASC Topic 842, Leases (“Topic 842”), as amended, effective November 1, 2019, using themodified retrospective transition approach.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         Basisfor Opinion        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thesefinancial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion onthe Company’s financial statements based on our audits. We are a public accounting firm registered with the Public CompanyAccounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Companyin accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commissionand the PCAOB.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Weconducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the auditsto obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to erroror fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financialreporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but notfor the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting.Accordingly, we express no such opinion.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ouraudits included performing procedures to assess the risks of material misstatement of the financial statements, whether due toerror or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidenceregarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principlesused and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.We believe that our audits provide a reasonable basis for our opinion.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         /s/Marcum         <font style="font-variant: small-caps">          llp         </font>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Marcum        <font style="font-variant: small-caps">         llp        </font>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Wehave served as the Company’s auditor since 2012.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        NewYork, NY       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        January22, 2021       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 63 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           2           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_002">         </a>         ADVAXIS,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         BALANCESHEETS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        (Inthousands, except share and per share data)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">          October 31,         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          ASSETS         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Current assets:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; width: 68%; text-align: left">          Cash and cash equivalents         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          25,178         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          32,363         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Deferred expenses         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,808         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2,353         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          Prepaid expenses and other current assets         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          865         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          1,433         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 20pt; text-align: left">          Total current assets         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          27,851         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          36,149         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Property and equipment (net of accumulated depreciation)         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2,393         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          4,350         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Intangible assets (net of accumulated amortization)         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          3,261         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          4,575         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Operating right-of-use asset (net of accumulated amortization)         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          4,839         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          Other assets         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          182         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          183         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 2.5pt">          Total assets         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          38,526         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          45,257         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          LIABILITIES AND STOCKHOLDERS’ EQUITY         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Current liabilities:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Accounts payable         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          410         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          976         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Accrued expenses         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,737         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          3,478         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Current portion of operating lease liability         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          962         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Deferred revenue         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          165         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Common stock warrant liability         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          17         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          19         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          Other current liabilities         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          -         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          48         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 20pt; text-align: left">          Total current liabilities         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          3,291         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          4,521         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Operating lease liability, net of current portion         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          5,055         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          Other liabilities         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          -         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          1,205         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Total liabilities         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          8,346         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          5,726         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Commitments and contingencies – Note 9         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Stockholders’ equity:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at October 31, 2020 and 2019. Liquidation preference of $0 at October 31, 2020 and 2019.         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Common stock - $0.001 par value; 170,000,000 shares authorized, 78,074,023 and 50,201,671 shares issued and outstanding at October 31, 2020 and 2019.         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          78         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          50         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Additional paid-in capital         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          440,840         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          423,750         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          Accumulated deficit         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (410,738         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (384,269         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          Total stockholders’ equity         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          30,180         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          39,531         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 2.5pt">          Total liabilities and stockholders’ equity         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          38,526         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          45,257         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theaccompanying notes should be read in conjunction with the financial statements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 64 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           3           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_003">         </a>         ADVAXIS,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         STATEMENTSOF OPERATIONS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        (Inthousands, except share and per share data)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">          Year Ended October 31,         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>         <td>         </td>         <td colspan="2">         </td>         <td>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 68%; padding-bottom: 1.5pt">          Revenue         </td>         <td style="width: 2%; padding-bottom: 1.5pt">         </td>         <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">          $         </td>         <td style="width: 12%; border-bottom: Black 1.5pt solid; text-align: right">          253         </td>         <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">         </td>         <td style="width: 2%; padding-bottom: 1.5pt">         </td>         <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">          $         </td>         <td style="width: 12%; border-bottom: Black 1.5pt solid; text-align: right">          20,884         </td>         <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Operating expenses:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Research and development expenses         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          15,612         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          26,677         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          General and administrative expenses         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          11,090         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          12,179         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">          Total operating expenses         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          26,702         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          38,856         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Loss from operations         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (26,449         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (17,972         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Other income (expense):         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Interest income         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          110         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          435         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Net changes in fair value of derivative liabilities         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2,589         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Loss on shares issued in settlement of warrants         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (77         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (1,607         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          Other expense         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (3         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (7         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Net loss before income tax benefit         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (26,419         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (16,562         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          Income tax expense         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          50         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          50         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 2.5pt">          Net loss         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          (26,469         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          (16,612         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 2.5pt">          Net loss per common share, basic and diluted         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          (0.43         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          (1.09         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Weighted average number of common shares outstanding, basic and diluted         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          61,003,839         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          15,207,637         </td>         <td style="text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theaccompanying notes should be read in conjunction with the financial statements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 65 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           4           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_004">         </a>         ADVAXIS,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         STATEMENTSOF STOCKHOLDERS’ EQUITY        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        (Inthousands, except share and per share data)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td>         </td>         <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">          Preferred Stock         </td>         <td>         </td>         <td>         </td>         <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">          Common Stock         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">          Additional          <br/>          Paid-In         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">          Accumulated         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">          Total          <br/>          Shareholders’         </td>         <td>         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td>         </td>         <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">          Shares         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">          Amount         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">          Shares         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">          Amount         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">          Capital         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">          Deficit         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">          Equity         </td>         <td>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 37%; padding-bottom: 1.5pt">          Balance at October 31, 2018         </td>         <td style="width: 1%; padding-bottom: 1.5pt">         </td>         <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="width: 6%; border-bottom: Black 1.5pt solid; text-align: right">          -         </td>         <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">         </td>         <td style="width: 1%; padding-bottom: 1.5pt">         </td>         <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">          $         </td>         <td style="width: 6%; border-bottom: Black 1.5pt solid; text-align: right">          -         </td>         <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">         </td>         <td style="width: 1%; padding-bottom: 1.5pt">         </td>         <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="width: 6%; border-bottom: Black 1.5pt solid; text-align: right">          4,634,189         </td>         <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">         </td>         <td style="width: 1%; padding-bottom: 1.5pt">         </td>         <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">          $         </td>         <td style="width: 6%; border-bottom: Black 1.5pt solid; text-align: right">          5         </td>         <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">         </td>         <td style="width: 1%; padding-bottom: 1.5pt">         </td>         <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">          $         </td>         <td style="width: 6%; border-bottom: Black 1.5pt solid; text-align: right">          391,703         </td>         <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">         </td>         <td style="width: 1%; padding-bottom: 1.5pt">         </td>         <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">          $         </td>         <td style="width: 6%; border-bottom: Black 1.5pt solid; text-align: right">          (367,657         </td>         <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="width: 1%; padding-bottom: 1.5pt">         </td>         <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">          $         </td>         <td style="width: 6%; border-bottom: Black 1.5pt solid; text-align: right">          24,051         </td>         <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Stock-based compensation         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          12,220         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2,002         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2,002         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Tax withholdings paid on equity awards         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (15         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (15         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Tax shares sold to pay for tax withholdings on equity awards         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          14         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          14         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Issuance of shares to employees under ESPP Plan         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          7,435         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          20         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          20         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          ESPP Expense         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Pre-funded warrant exercises         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          13,656,000         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          13         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          13         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Warrant exercises         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          17,884,962         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          18         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          104         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          122         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          <p style="margin: 0; font: 10pt Times New Roman, Times, Serif">           Shares issued in settlement                                 of warrants          </p>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          856,865         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          5,462         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          5,463         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Advaxis public offerings         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          13,150,000         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          13         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          24,458         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          24,471         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Net Loss         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          -         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          -         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          -         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          -         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (16,612         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (16,612         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          Balance at October 31, 2019         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          50,201,671         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          50         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          423,750         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          (384,269         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          39,531         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Stock-based compensation         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          8,870         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          891         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          891         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Tax withholdings paid on equity awards         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (1         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (1         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Tax shares sold to pay for tax withholdings on equity awards         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Issuance of shares to employees under ESPP Plan         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          14,148         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          7         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          7         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          ESPP Expense         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Warrant exercises         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          33,916         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          <p style="margin: 0; font: 10pt Times New Roman, Times, Serif">           Shares issued in settlement                                 of warrants          </p>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          3,000,000         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          3         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <p style="margin: 0; font: 10pt Times New Roman, Times, Serif">           74          </p>         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          77         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Advaxis public offerings         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          10,000,000         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          10         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          9,618         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          9,628         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          At-the-market shares issued         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2,489,104         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          3         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,435         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,438         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Commitment fee shares issued for equity line         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,084,266         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          643         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          644         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Shares issued under equity line         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          11,242,048         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          11         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          4,419         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          4,430         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          Net Loss         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          -         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          -         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          -         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          -         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          -         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (26,469         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (26,469         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 2.5pt">          Balance at October 31, 2020         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          -         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          -         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          78,074,023         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          78         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          440,840         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          (410,738         </td>         <td style="padding-bottom: 2.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          30,180         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theaccompanying notes should be read in conjunction with the financial statements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 66 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           5           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_005">         </a>         ADVAXIS,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         STATEMENTOF CASH FLOWS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        (Inthousands, except share and per share data)       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">          Year Ended October 31,         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          OPERATING ACTIVITIES         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="width: 68%; text-align: left">          Net loss         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          (26,469         </td>         <td style="width: 1%; text-align: left">          )         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          (16,612         </td>         <td style="width: 1%; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Adjustments to reconcile net loss to net cash used in operating activities:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Stock compensation         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          891         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2,002         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Employee stock purchase plan expense         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          3         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Gain on change in value of warrants         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (2,589         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Loss on shares issued in settlement of warrants         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          77         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,607         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Loss on disposal of property and equipment         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          344         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Loss on write-down of property and equipment         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,060         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          943         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Abandonment of intangible assets         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,725         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,104         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Depreciation expense         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          897         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,097         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Amortization of deferred offering costs         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          644         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Amortization expense of intangible assets         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          337         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          386         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left">          Amortization expense of right-of-use assets         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          744         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-decoration: underline; text-align: left">          Change in operating assets and liabilities:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 20pt; text-align: left">          Accounts receivable         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,664         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 20pt; text-align: left">          Prepaid expenses and other current assets         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,113         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (103         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 20pt; text-align: left">          Other assets         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          18         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 20pt; text-align: left">          Accounts payable and accrued expenses         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (2,307         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (7,377         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 20pt; text-align: left">          Deferred revenue         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          165         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (18,665         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 20pt; text-align: left">          Operating lease liabilities         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (819         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">          Other liabilities         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          -         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          50         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Net cash used in operating activities         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (21,940         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (36,128         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          INVESTING ACTIVITIES         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Purchase of property and equipment         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (54         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Proceeds from disposal of property and equipment         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          83         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          Cost of intangible assets         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (748         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (1,227         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Net cash used in investing activities         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (748         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (1,198         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          FINANCING ACTIVITIES         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Net proceeds from issuance of common stock and pre-funded warrants         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          15,496         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          24,471         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Warrant exercises         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          68         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Pre-funded warrant exercises         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          13         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Proceeds from employee stock purchase plan         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          7         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          20         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Employee tax withholdings paid on equity awards         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (1         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (15         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Tax shares sold to pay for employee tax withholdings on equity awards         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          1         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          14         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          Net cash provided by financing activities         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          15,503         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          24,571         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Net decrease in cash and cash equivalents         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (7,185         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (12,755         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Cash and cash equivalents at beginning of year         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          32,363         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          45,118         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 2.5pt">          Cash and cash equivalents at end of year         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          25,178         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          32,363         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theaccompanying notes should be read in conjunction with the financial statements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 67 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           6           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         SupplementalDisclosures of Cash Flow Information        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">          Year Ended October 31,         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 68%; text-align: left; padding-bottom: 2.5pt">          Cash paid for taxes         </td>         <td style="width: 2%; padding-bottom: 2.5pt">         </td>         <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="width: 12%; border-bottom: Black 2.5pt double; text-align: right">          50         </td>         <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">         </td>         <td style="width: 2%; padding-bottom: 2.5pt">         </td>         <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="width: 12%; border-bottom: Black 2.5pt double; text-align: right">          50         </td>         <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         SupplementalSchedule of Noncash Investing and Financing Activities        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">          Year Ended October 31,         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 68%; text-align: left">          Shares issued in settlement of warrants         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          77         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          5,463         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Warrant liability reclassified into equity         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          54         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Reclass of security deposit to property and equipment for delivered equipment         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          79         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Commitment fee shares issued for equity line         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          644         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          Cashless exercise of warrants         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          2         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theaccompanying notes should be read in conjunction with the financial statements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 68 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           7           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         <a name="pri_006">         </a>         ADVAXIS,INC.        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         NOTESTO FINANCIAL STATEMENTS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         1.NATURE OF OPERATIONS AND BASIS OF PRESENTATION        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Advaxis,Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the developmentand commercialization of proprietary        <i>         Listeria monocytogenes        </i>        (“        <i>         Lm        </i>        ”)-based antigen delivery products.The Company is using its        <i>         Lm        </i>        platform directed against tumor-specific targets in order to engage the patient’s immunesystem to destroy tumor cells. Through a license from the University of Pennsylvania, Advaxis has exclusive access to this proprietaryformulation of attenuated        <i>         Lm        </i>        called        <i>         Lm        </i>        Technology        <sup>         TM        </sup>        . Advaxis’ proprietary approach is designedto deploy a unique mechanism of action that redirects the immune system to attack cancer in three distinct ways:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Alerting    and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent    of multiple adjuvants;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Attacking    the tumor by generating a strong, cancer-specific T cell response; and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Breaking    down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields    the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Advaxis’proprietary        <i>         Lm        </i>        platform technology has demonstrated clinical activity in several of its programs and has been dosed inover 470 patients across multiple clinical trials and in various tumor types. The Company believes that        <i>         Lm        </i>        Technology immunotherapiescan complement and address significant unmet needs in the current oncology treatment landscape. Specifically, its product candidateshave the potential to work synergistically with other immunotherapies, including checkpoint inhibitors, while having a generallywell-tolerated safety profile.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Liquidityand        </i>       </font>       <font style="font: 10pt Times New Roman, Times, Serif">        <i>         Managements Plans        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany has not yet commercialized any human products and the products that are being developed have not generated significantrevenue. As a result, the Company has suffered recurring losses and requires significant cash resources to execute its businessplans. These losses are expected to continue for an extended period of time. The aforementioned factors raise substantial doubtabout the Company’s ability to continue as a going concern.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Historically,the Company’s major sources of cash have been comprised of proceeds from various public and private offerings of its commonstock, debt financings, clinical collaborations, option and warrant exercises, income earned on investments and grants and interestincome. From October 2013 through October 2020, the Company raised approximately $309.4 million in gross proceeds ($17.2 millionin fiscal year 2020) from various public and private offerings of its common stock.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       As of October 31, 2020,the Company had approximately $25.2 million in cash and cash equivalents. Although the Company expects to have sufficient capitalto fund its obligations, as they become due, in the ordinary course of business until at least January 2022, the actual amountof cash that it will need to operate is subject to many factors. Over the past several months, the Company has taken steps toobtain additional financing, including the at-the-market (“ATM”) program and the equity line with Lincoln Park Capital.Due to the current state of the Company’s stock price and general market conditions, these programs have not been utilizedto the fullest extent, thereby resulting in lower capital availability than anticipated. Management’s plans to mitigatean expected shortfall of capital and to support future operations include obtaining additional funds through partnerships or strategicor financing investors. The Company was able to raise additional funds subsequent to year end more fully described in the subsequentevents footnote (Note 15). The Company has reduced its operating expenses to $26.7 million for the fiscal year ended October31, 2020 as compared to $38.9 million during the comparable prior period. With these funds raised and a reduction in the operatingexpenses the Company believes that it has enough cash to fund its operations for one year from the date of filing. Therefore, such conditions of substantial doubt as of October 31, 2020 have subsequently been alleviated.      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. Thereis no assurance that additional financing will be available when needed or that management will be able to obtain financing onterms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If theCompany is unable to raise sufficient additional funds, it will have to further scale back its operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 69 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           8           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Estimates        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thepreparation of financial statements in conformity with accounting principles generally accepted in the United States of America(“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financialstatements and accompanying notes. Estimates are used when accounting for such items as the fair value and recoverability of thecarrying value of property and equipment and intangible assets (patents and licenses), determining the Incremental Borrowing Rate(“IBR”) for calculating Right-Of-Use (“ROU”) assets and lease liabilities, deferred expenses, deferredrevenue, the fair value of options, warrants and related disclosure of contingent assets and liabilities. The Company bases itsestimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, theresults of which form the basis for making judgments about the carrying values of assets and liabilities that are not readilyapparent from other sources. On an ongoing basis, the Company reviews its estimates to ensure that they appropriately reflectchanges in the business or as new information becomes available. Actual results may differ from these estimates.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         RevenueRecognition        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        UnderASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflectsthe consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognitionfor arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transactionprice; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (oras) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probablethat the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or servicespromised within each contract, determines those that are performance obligations and assesses whether each promised good or serviceis distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performanceobligation when (or as) the performance obligation is satisfied.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany enters into licensing agreements that are within the scope of ASC 606, under which it may exclusively license rights toresearch, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typicallyinclude payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certaincosts; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales oflicensed products.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Indetermining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Companyperforms the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whetherthe promised goods or services are performance obligations including whether they are distinct in the context of the contract;(iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transactionprice to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.As part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the number of performanceobligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; and (c) the stand-aloneselling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv)above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, shouldbe included in the transaction price as described further below. The transaction price is allocated to each performance obligationon a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligationsunder the contract are satisfied.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Amountsreceived prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying balance sheets.Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferredrevenue, net of current portion.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 70 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           9           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         ExclusiveLicenses.        </i>        If the license to the Company’s intellectual property is determined to be distinct from the other performanceobligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the licensewhen the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whethera performance obligation is distinct from the other performance obligations, the Company considers factors such as the research,development, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associatedexpertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from aperformance obligation for its intended purpose without the receipt of the remaining performance obligation, whether the valueof the performance obligation is dependent on the unsatisfied performance obligation, whether there are other vendors that couldprovide the remaining performance obligation, and whether it is separately identifiable from the remaining performance obligation.For licenses that are combined with other performance obligation, the Company utilizes judgment to assess the nature of the combinedperformance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and,if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measureof progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measureof progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may changeover the course of the research and development and licensing agreement. Such a change could have a material impact on the amountof revenue the Company records in future periods.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Researchand Development Services.        </i>        The performance obligations under the Company’s collaboration agreements may include researchand development services to be performed by the Company on behalf of the partner. Payments or reimbursements resulting from theCompany’s research and development efforts are recognized as the services are performed and presented on a gross basis becausethe Company is the principal for such efforts.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         MilestonePayments.        </i>        At the inception of each arrangement that includes research or development milestone payments, the Company evaluateswhether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction priceusing the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestonevalue is included in the transaction price. An output method is generally used to measure progress toward complete satisfactionof a milestone. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals,are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific,clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment.There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur.At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subjectto constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on acumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Royalties.        </i>        For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are theresult of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royaltiesrelate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligationto which some or all of the royalty has been allocated has been satisfied or partially satisfied.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         CollaborativeArrangements        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performedby parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercialsuccess of such activities and therefore within the scope of ASC Topic 808,        <i>         Collaborative Arrangements        </i>        (ASC 808). Thisassessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in thearrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determineswhich elements of the collaboration are deemed to be within the scope of ASC 808 and which elements of the collaboration are morereflective of a vendor-customer relationship and therefore within the scope of ASC 606. For elements of collaboration arrangementsthat are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generallyby analogy to ASC 606. Amounts that are owed to collaboration partners are recognized as an offset to collaboration revenue assuch amounts are incurred by the collaboration partner. For those elements of the arrangement that are accounted for pursuantto ASC 606, the Company applies the five-step model described above under ASC 606.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 71 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           10           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Cashand Cash Equivalents        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany considers all highly liquid investments with an original maturity of three months or less from the date of purchase tobe cash equivalents.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Concentrationof Credit Risk        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       The Company maintains itscash in bank deposit accounts (checking) that at times exceed federally insured limits. Approximately $24.1 million is subjectto credit risk at October 31, 2020. The Company has not experienced any losses in such accounts.      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         DeferredExpenses        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Deferredexpenses consist of advanced payments made on research and development projects. Expense is recognized in the Statement of Operationsas the research and development activity is performed.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Propertyand Equipment        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Propertyand equipment is stated at cost. Additions and improvements that extend the lives of the assets are capitalized, while expendituresfor repairs and maintenance are expensed as incurred. Leasehold improvements are amortized on a straight-line basis over the shorterof the asset’s estimated useful life or the remaining lease term. Depreciation is calculated on a straight-line basis overthe estimated useful lives of the assets ranging from three to ten years.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Whendepreciable assets are retired or sold the cost and related accumulated depreciation are removed from the accounts and any resultinggain or loss is recognized in operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         IntangibleAssets        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Intangibleassets are recorded at cost and include patents and patent application costs, licenses and software. Intangible assets are amortizedon a straight-line basis over their estimated useful lives ranging from 3 to 20 years. Patent application costs are written-offif the application is rejected, withdrawn or abandoned.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Impairmentof Long-Lived Assets        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany periodically assesses the carrying value of intangible and other long-lived assets, and whenever events or changes incircumstances indicate that the carrying amount of an asset might not be recoverable. The assets are considered to be impairedif the Company determines that the carrying value may not be recoverable based upon its assessment, which includes considerationof the following events or changes in circumstances:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    asset’s ability to continue to generate income from operations and positive cash flow in future periods;          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           loss    of legal ownership or title to the asset(s);          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           significant    changes in the Company’s strategic business objectives and utilization of the asset(s); and          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           the    impact of significant negative industry or economic trends.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifthe assets are considered to be impaired, the impairment recognized is the amount by which the carrying value of the assets exceedsthe fair value of the assets. Fair value is determined by the application of discounted cash flow models to project cash flowsfrom the assets. In addition, the Company bases estimates of the useful lives and related amortization or depreciation expenseon its subjective estimate of the period the assets will generate revenue or otherwise be used by it. Assets to be disposed ofare reported at the lower of the carrying amount or fair value, less selling costs. The Company also periodically reviews thelives assigned to long-lived assets to ensure that the initial estimates do not exceed any revised estimated periods from whichthe Company expects to realize cash flows from its assets.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <!-- Field: Page; Sequence: 72 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           11           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Leases        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        EffectiveNovember 1, 2019, the Company adopted ASC Topic 842,        <i>         Leases        </i>        (“ASC 842”) using the modified retrospective transitionapproach by applying the new standard to all leases existing as of the date of initial application. Results and disclosure requirementsfor reporting periods beginning after November 1, 2019 are presented under ASC 842, while prior period amounts have not been adjustedand continue to be reported in accordance with the previous guidance in ASC 840,        <i>         Leases        </i>        .       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Atthe inception of an arrangement, the Company determines whether an arrangement is or contains a lease based on the facts and circumstancespresent in the arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of anidentified asset for a period of time in exchange for consideration. Most leases with a term greater than one year are recognizedon the balance sheet as operating lease right-of-use assets and current and long-term operating lease liabilities, as applicable.The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically onlyincludes the initial lease term in its assessment of a lease arrangement. Options to extend a lease are not included in the Company’sassessment unless there is reasonable certainty that the Company will renew.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Operatinglease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over theexpected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as prepaid or accruedrent. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Companyutilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basisthe amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition toASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         NetIncome (Loss) per Share        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Basicnet income or loss per common share is computed by dividing net income or loss available to common stockholders by the weightedaverage number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants,restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact ofthe potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computationof diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential commonstock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table setsforth the number of potential shares of common stock that have been excluded from diluted net loss per share (as of October 31,2020, 327,338 warrants are included in the basic earnings per share computation because the exercise price is $0, and as of October31, 2019, 13,079,000 pre-funded warrants are included in the basic earnings per share computation because the exercise price isnominal):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">          As of October 31,         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 68%">          Warrants         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 12%; text-align: right">          398,226         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 12%; text-align: right">          432,142         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Stock options         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,011,768         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          560,490         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Restricted stock units         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          5,556         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          14,706         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 2.5pt">          Total         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          1,415,550         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          1,007,338         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Researchand Development Expenses        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Researchand development costs are expensed as incurred and include but are not limited to clinical trial and related manufacturing costs,payroll and personnel expenses, lab expenses, and related overhead costs.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 73 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           12           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         StockBased Compensation        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixednumber of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the costof services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of theaward is measured on the grant date and is then recognized over the requisite service period, usually the vesting period, in bothresearch and development expenses and general and administrative expenses on the statement of operations, depending on the natureof the services provided by the employees or consultants.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theprocess of estimating the fair value of stock-based compensation awards and recognizing stock-based compensation cost over theirrequisite service period involves significant assumptions and judgments. The Company estimates the fair value of stock optionawards on the date of grant using the Black Scholes Model (“BSM”) for the remaining awards, which requires that theCompany makes certain assumptions regarding: (i) the expected volatility in the market price of its common stock; (ii) dividendyield; (iii) risk-free interest rates; and (iv) the period of time employees are expected to hold the award prior to exercise(referred to as the expected holding period). As a result, if the Company revises its assumptions and estimates, stock-based compensationexpense could change materially for future grants.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany accounts for stock-based compensation using fair value recognition and records forfeitures as they occur. As such, theCompany recognizes stock-based compensation cost only for those stock-based awards that vest over their requisite service period,based on the vesting provisions of the individual grants.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         FairValue of Financial Instruments        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thecarrying value of financial instruments, including cash and cash equivalents, restricted cash and accounts payable approximatedfair value as of the balance sheet date presented, due to their short maturities.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         DerivativeFinancial Instruments        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluatesall of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embeddedderivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initiallyrecorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statementsof operations. For stock-based derivative financial instruments, the Company used the Monte Carlo simulation model to value thederivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, includingwhether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivativeliabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the instrumentcould be required within 12 months of the balance sheet date.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         IncomeTaxes        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740,        <i>         “IncomeTaxes.”        </i>        Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for thecurrent year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in anentity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expectedto apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effecton deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period thatincludes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weightof the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets willnot be realized.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 74 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           13           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         RecentAccounting Standards        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InDecember 2019, the FASB issued authoritative guidance intended to simplify the accounting for income taxes (ASU 2019-12, “        <i>         IncomeTaxes (Topic 740): Simplifying the Accounting for Income Taxes        </i>        ”). This guidance eliminates certain exceptions to thegeneral approach to the        <i>         income        </i>        tax accounting model and adds new guidance to reduce the complexity in accounting for incometaxes. This guidance is effective for annual periods after December 15, 2020, including interim periods within those annual periods.The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         RecentlyAdopted Accounting Standards        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnNovember 1, 2019, the Company adopted Accounting Standards Update No. 2016-02,        <i>         Leases        </i>        (Topic 842) (ASU 2016-02), as amended,which establishes ASC 842 and supersedes the lease accounting guidance under ASC 840, and generally requires lessees to recognizeoperating and financing lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and to provide enhanceddisclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. We adopted the newguidance using the modified retrospective transition approach by applying the new standard to all leases existing at the dateof initial application and not restating comparative periods.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inadopting the new standard, the Company elected to utilize the available package of practical expedients permitted under the transitionguidance within the new standard, which does not require the reassessment of the following: (i) whether existing or expired arrangementsare or contain a lease, (ii) the lease classification of existing or expired leases, and (iii) whether previous initial directcosts would qualify for capitalization under the new lease standard. Additionally, the Company elected to combine lease and non-leasecomponents and to exclude leases with a term of 12 months or less.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof the November 1, 2019 effective date, the Company had identified one operating lease arrangement and one short-term lease inwhich it is a lessee. The adoption of ASC 842 resulted in the recognition of an operating lease liability and a right-of-use assetof approximately $6.8 million and $5.6 million, respectively, on the Company’s balance sheet relating to its leases, withthe difference relating to reclassifications of the current accrued rent liability and the current lease incentive obligationof approximately $0.9 million and $0.3 million, respectively, as reductions to the right-of-use-asset for its operating lease.The adoption of the standard did not have a material effect on the Company’s statements of operations or statements of cashflows.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Managementdoes not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a materialimpact on the accompanying financial statements.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         3.PROPERTY AND EQUIPMENT        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Propertyand equipment consists of the following (in thousands):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">          October 31,         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 68%; text-align: left">          Leasehold improvements         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          2,335         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          2,335         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Laboratory equipment         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,218         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          3,405         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Furniture and fixtures         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          744         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          744         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Computer equipment         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          409         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          409         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Construction in progress         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          19         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          83         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Total property and equipment         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          4,725         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          6,976         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Accumulated depreciation and amortization         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (2,332         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (2,626         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 2.5pt">          Net property and equipment         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          2,393         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          4,350         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Depreciationexpense for the years ended October 31, 2020 and 2019 was approximately $0.9 million and $1.1 million, respectively. Disposalsof laboratory equipment resulted in losses of approximately $0 and $0.3 million for the years ended October 31, 2020 and 2019,respectively, that was charged to research and development expenses in the statement of operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 75 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           14           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Managementhas reviewed its property and equipment for impairment whenever events and circumstances indicate that the carrying value of anasset might not be recoverable. During the years ended October 31, 2020 and 2019, the Company recorded impairment losses on idlelaboratory equipment of $1.1 million and $0.9 million, respectively, that was charged to research and development expenses inthe statement of operations. Fair value for the idle assets was determined by a quoted purchase price for the assets.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         4.INTANGIBLE ASSETS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Intangibleassets consist of the following (in thousands):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">          October 31,         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 68%">          Patents         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          4,479         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          5,833         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          License         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          777         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          777         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 1.5pt">          Software         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          117         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          117         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Total intangibles         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          5,373         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          6,727         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Accumulated amortization         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (2,112         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (2,152         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 2.5pt">          Net intangible assets         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          3,261         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          4,575         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theexpirations of the existing patents range from 2020 to 2040 but the expirations can be extended based on market approval if grantedand/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned withoutfuture value are charged to expense when the determination is made not to pursue the application. Patent applications having anet book value of approximately $1.7 million and $1.1 million were abandoned and were charged to general and administrative expensesin the statement of operations for the years ended October 31, 2020 and 2019, respectively. Intangible asset amortization expensethat was charged to general and administrative expense in the statement of operations was approximately $0.3 million and $0.4million for each of the years ended October 31, 2020 and 2019, respectively.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Managementhas reviewed its intangible assets for impairment whenever events and circumstances indicate that the carrying value of an assetmight not be recoverable. Net assets are recorded on the balance sheet for patents and licenses related to axalimogene filolisbac(AXAL), ADXS-HOT, ADXS-PSA ADXS-HER2 and other products that are in development or out-licensed. However, if a competitor wereto gain FDA approval for a treatment before us or if future clinical trials fail to meet the targeted endpoints, the Company wouldlikely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued, the Companywould record an impairment of its estimated book value. Lastly, if the Company is unable to raise enough capital to continue fundingour studies and developing its intellectual property, the Company would likely record an impairment to certain of these assets.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        AtOctober 31, 2020, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets isas follows (in thousands):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 82%; text-align: justify">          2021         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 14%; text-align: right">          289         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: justify">          2022         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          289         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: justify">          2023         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          289         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: justify">          2024         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          289         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: justify">          2025         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          289         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: justify; padding-bottom: 1.5pt">          Thereafter         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          1,816         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: justify; padding-bottom: 2.5pt">          Total         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          3,261         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 76 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           15           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         5.ACCRUED EXPENSES:        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefollowing table represents the major components of accrued expenses (in thousands):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">          October 31,         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 68%; text-align: left">          Salaries and other compensation         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          737         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          158         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          Vendors         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          671         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          3,194         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Professional fees         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          329         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          126         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 2.5pt">          Total accrued expenses         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          1,737         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          3,478         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         6.COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Warrants        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof October 31, 2020, there were outstanding warrants to purchase 398,226 shares of our common stock with exercise prices rangingfrom $0 to $281.25 per share. Information on the outstanding warrants is as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Exercise          <br/>          Price         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Number of Shares Underlying Warrants         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="text-align: center; border-bottom: Black 1.5pt solid">          Expiration Date         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="text-align: center; border-bottom: Black 1.5pt solid">          Summary of Warrants         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 18%; text-align: right">          -         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 18%; text-align: right">          327,338         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 24%">          July 2024         </td>         <td style="width: 2%">         </td>         <td style="width: 30%">          July 2019 Public Offering         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          $         </td>         <td style="text-align: right">          281.25         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          25         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td>          N/A         </td>         <td>         </td>         <td style="text-align: left">          Other Warrants         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 1.5pt; text-align: left">          $         </td>         <td style="padding-bottom: 1.5pt; text-align: right">          0.372         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          70,863         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">          September 2024         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">          September 2018 Public Offering         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Grand Total           </b>          </font>         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          398,226         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="padding-bottom: 2.5pt">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof October 31, 2019, there were outstanding warrants to purchase 432,142 shares of our common stock with exercise prices rangingfrom $0 to $281.25 per share. Information on the outstanding warrants is as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Exercise          <br/>          Price         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Number of Shares Underlying Warrants         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="text-align: center; border-bottom: Black 1.5pt solid">          Expiration Date         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="text-align: center; border-bottom: Black 1.5pt solid">          Summary of Warrants         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 18%; text-align: right">          -         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 18%; text-align: right">          359,838         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 24%">          July 2024         </td>         <td style="width: 2%">         </td>         <td style="width: 30%">          July 2019 Public Offering         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          $         </td>         <td style="text-align: right">          281.25         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          25         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td>          N/A         </td>         <td>         </td>         <td style="text-align: left">          Other Warrants         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 1.5pt; text-align: left">          $         </td>         <td style="padding-bottom: 1.5pt; text-align: right">          0.372         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          72,279         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">          September 2024         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">          September 2018 Public Offering         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           <b>            Grand Total           </b>          </font>         </td>         <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          432,142         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="padding-bottom: 2.5pt">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asummary of warrant activity was as follows (In thousands, except share and per share data):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Shares         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Weighted          <br/>          Average          <br/>          Exercise Price         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Weighted          <br/>          Average          <br/>          Remaining          <br/>          Contractual Life          <br/>          In Years         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Aggregate          <br/>          Intrinsic Value         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 44%; text-align: left">          Outstanding and exercisable warrants at October 31, 2018         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 10%; text-align: right">          944,635         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 10%; text-align: right">          22.50         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 10%; text-align: right">          5.87         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 10%; text-align: right">          -         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          Issued         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          31,885,500         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          Exercised *         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (31,540,962         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          Exchanged         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (856,865         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          0.37         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 1.5pt">          Expired         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (166         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          56.25         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Outstanding and exercisable warrants at October 31, 2019         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          432,142         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          0.08         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          4.76         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          114,069         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          Issued         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          5,000,000         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1.25         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          Exercised **         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (33,916         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          0.02         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 1.5pt">          Exchanged         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (5,000,000         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          1.25         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 2.5pt">          Outstanding and exercisable warrants at October 31, 2020         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          398,226         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          0.08         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          3.76         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          110,640         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        *Includes the cashless exercise of 17,869,662 warrants that resulted in the issuance of 17,869,662 shares of common stock.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        **Includes the cashless exercise of 32,500 warrants that resulted in the issuance of 32,500 shares of common stock.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">      </p>      <!-- Field: Page; Sequence: 77 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           16           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        AtOctober 31, 2020, the Company had 327,363 of its total 398,226 outstanding warrants classified as equity (equity warrants). AtOctober 31, 2019, the Company had 359,863 of its total 432,142 outstanding warrants classified as equity (equity warrants). Atissuance, equity warrants are recorded at their relative fair values, using the Relative Fair Value Method, in the shareholdersequity section of the balance sheet.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         SharesIssued in Settlement of Equity Warrants        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnOctober 16, 2020, the Company entered into private exchange agreements with certain holders of warrants issued in connection withthe Company’s January 2020 public offering of common stock and warrants. The warrants being exchanged provide for the purchaseof up to an aggregate of 5,000,000 shares of our common stock at an exercise price of $1.25 per share. The warrants became exercisableon July 21, 2020 and have an expiration date of July 21, 2025. Pursuant to such exchange agreements, the Company agreed to issue3,000,000 shares of common stock to the investors in exchange for the warrants.  The fair value of these warrants approximatedthe fair value of shares issued in the exchange for these warrants. The Company used the closing stock price to value the sharesand Black Scholes model to value these warrants on the date of the exchange. In determining the fair warrant of the warrants issuedon October 16, 2020, the Company used the following inputs in its Black-Sholes model: exercise price $1.25, stock price $0.406,expected term 4.76 years, volatility 101.18% and risk-free interest rate 0.32%. In connection with the exchange of warrants forcommon stock, the Company recorded a loss of approximately $77 thousand as the fair value of the shares issued exceeded the fairvalue of warrants exchanged.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         SharesIssued in Settlement of Liability Warrants        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnMarch 14, 2019, the Company entered into private exchange agreements with certain holders of warrants issued in connection withthe Company’s September 2018 public offering of common stock and warrants. The warrants being exchanged provided for thepurchase of up to an aggregate of 856,865 shares of the Company’s common stock at an exercise price of $22.50, with an expirationdate of September 11, 2024. Pursuant to such exchange agreements, the Company issued 856,865 shares of common stock to the investorsin exchange for such warrants on a 1:1 basis. The exchange of warrants for common stock caused the down round provision to betriggered for the first time and the exercise price of the warrants that were not exchanged were reduced from $22.50 to $4.50.The warrants were valued at approximately $3.9 million on the March 14, 2019 using the Monte Carlo simulation model. In determiningthe fair warrant of the warrants issued on March 14, 2019, the Company used the following inputs in its Monte Carlo simulationmodel: exercise price $22.50, stock price $6.45, expected term 5.50 years, volatility 96.37% and risk-free interest rate 2.44%.In connection with the exchange of warrants for common stock, the Company recorded a loss of approximately $1.6 million as thefair value of the shares issued exceeded the fair value of warrants exchanged.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         WarrantLiability        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        AtOctober 31, 2020, the Company had 70,863 of its total 398,226 outstanding warrants classified as liabilities (liability warrants).At October 31, 2019, the Company had 72,279 of its total 432,142 outstanding warrants classified as liabilities (liability warrants).These warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exerciseprice would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes inoption price or rate of conversion.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof October 31, 2020, the down round feature was triggered three times and the exercise price of the warrants were reduced from$22.50 to $0.372. The warrants require liability classification as the warrant agreement requires the Company to maintain an effectiveregistration statement and does not specify any circumstances under which settlement in other than cash would be permitted orrequired. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants,the Company utilized the Monte Carlo simulation model to calculate the fair value of these warrants at issuance and at each subsequentreporting date.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        AtOctober 31, 2020 and October 31, 2019, the fair value of the warrant liability was approximately $17,000 and $19,000, respectively.For the years ended October 31, 2020 and 2019, the Company reported income of approximately $0 and $2.6 million, respectively,due to changes in the fair value of the warrant liability.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 78 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           17           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inmeasuring the warrant liability, the Company used the following inputs in its Monte Carlo simulation model:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          October 31, 2020         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          October 31, 2019         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%">          Exercise Price         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          0.37         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          0.37         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          Stock Price         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          0.34         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          0.32         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Expected Term         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           3.87 years          </font>         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           4.87 years          </font>         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          Volatility %         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          105.58         </td>         <td style="text-align: left">          %         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          100.99         </td>         <td style="text-align: left">          %         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Risk Free Rate         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          0.29         </td>         <td style="text-align: left">          %         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1.51         </td>         <td style="text-align: left">          %         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         7.SHARE BASED COMPENSATION        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefollowing table summarizes share-based compensation expense included in the statement of operations by expense category for theyears ended October 31, 2020 and 2019 (in thousands):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">          Year Ended October 31,         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 68%; text-align: left">          Research and development         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          308         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          1,036         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          General and administrative         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          583         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          966         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 2.5pt">          Total         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          891         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          2,002         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Amendments        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheAdvaxis, Inc. 2015 Incentive Plan (the “2015 Plan”) was originally ratified and approved by the Company’s stockholderson May 27, 2015. Subject to proportionate adjustment in the event of stock splits and similar events, the aggregate number ofshares of common stock that may be issued under the 2015 Plan is 240,000 shares, plus a number of additional shares (not to exceed43,333) underlying awards outstanding as of the effective date of the 2015 Plan under the prior plan that thereafter terminateor expire unexercised, or are cancelled, forfeited or lapse for any reason.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Atthe Annual Meeting of Stockholders of the Company held on February 21, 2019, the Company’s stockholders voted to approvean amendment to increase the number of authorized shares of common stock from 95,000,000 to 170,000,000 and also voted to approvean amendment to allow the Company to execute a reverse stock split of common stock at the discretion of the Board of Directors.The amendment to increase the number of authorized shares of common stock became effective upon filing of the amendment with theSecretary of State of the State of Delaware on February 28, 2019. Additionally, on March 29, 2019, the Company executed a 1 for15 reverse stock split. On January 1, 2020, 166,667 shares were added to the 2015 Plan.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Atthe Annual Meeting of Stockholders of the Company held on May 4, 2020, the Company’s stockholders voted to approve an amendmentto increase the number of shares authorized for issuance under the 2015 Plan from 877,744 shares to 6,000,000 shares.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof October 31, 2020, there were 4,856,116 shares available for issuance under the 2015 Plan.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         RestrictedStock Units (RSUs)        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asummary of the Company’s RSU activity and related information for the fiscal year ended October 31, 2020 and 2019 is asfollows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Number of          <br/>          RSU’s         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Weighted-Average          <br/>          Grant Date Fair Value         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%">          Unvested as of October 31, 2018         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 16%; text-align: right">          32,614         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          70.41         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          Vested         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (12,257         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          78.41         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 1.5pt">          Cancelled         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (5,651         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          112.39         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          Unvested as of October 31, 2019         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          14,706         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          47.62         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          Vested         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (8,870         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          60.59         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 1.5pt">          Cancelled         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (280         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          98.80         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 2.5pt">          Unvested as of October 31, 2020         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          5,556         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          24.32         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 79 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           18           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefair value of the RSUs as of the respective vesting dates was approximately $5,000 and $51,000 for the years ended October 31,2020 and 2019, respectively.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof October 31, 2020, there was approximately $64,000 of unrecognized compensation cost related to non-vested RSUs, which is expectedto be recognized over a remaining weighted average vesting period of approximately 0.47 years.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof October 31, 2020, the aggregate intrinsic value of non-vested RSUs was approximately $2,000.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         EmployeeStock Awards        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Commonstock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchasesand employee excellence awards totaled 8,870 shares and 12,245 shares during the years ended October 31, 2020 and 2019, respectively.Total stock compensation expense associated with these awards for the years ended October 31, 2020 and 2019 was approximately$0.2 million and $0.8 million, respectively.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         StockOptions        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asummary of changes in the stock option plan for the years ended October 31, 2020 and 2019 is as follows (in thousands, exceptshare and per share data):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Shares         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Weighted          <br/>          Average          <br/>          Exercise Price         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Weighted          <br/>          Average          <br/>          Remaining          <br/>          Contractual Life          <br/>          In Years         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Aggregate          <br/>          Intrinsic Value         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 44%">          Outstanding as of October 31, 2018         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 10%; text-align: right">          330,071         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 10%; text-align: right">          122.79         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 10%; text-align: right">          6.56         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 10%; text-align: right">          -         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          Granted         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          265,882         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2.36         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Cancelled or expired         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (35,463         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          29.52         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>          Outstanding as of October 31, 2019         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          560,490         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          71.56         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          7.34         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          1         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          Granted         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          645,000         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          0.61         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          Cancelled or expired         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (193,722         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          34.47         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 2.5pt">          Outstanding as of October 31, 2020         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          1,011,768         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          33.43         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          8.04         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          4         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 2.5pt">          Vested and exercisable at October 31, 2020         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          307,467         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          105.69         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          4.91         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          1         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefollowing table summarizes information about the outstanding and exercisable options at October 31, 2020:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid">          Options Outstanding         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">          Options Exercisable         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2">         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom">         <td colspan="2">         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">          Weighted         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">          Weighted         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">          Weighted         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">          Weighted         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">         </td>         <td>         </td>        </tr>        <tr style="vertical-align: bottom">         <td colspan="2">         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">          Average         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">          Average         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">          Average         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">          Average         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">         </td>         <td>         </td>        </tr>        <tr style="vertical-align: bottom">         <td colspan="2" style="text-align: center">          Exercise         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">          Number         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">          Remaining         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">          Exercise         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">          Intrinsic         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">          Number         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">          Remaining         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">          Exercise         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: center">          Intrinsic         </td>         <td>         </td>        </tr>        <tr style="vertical-align: bottom">         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Price Range         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Outstanding         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Contractual         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Price         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Value         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Exercisable         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Contractual         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Price         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Value         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 8%; text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           .30-$10.00          </font>         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 6%; text-align: right">          746,579         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 8%; text-align: right">          9.41         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 8%; text-align: right">          1.10         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 7%; text-align: right">          1         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 7%; text-align: right">          68,655         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 8%; text-align: right">          8.67         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 8%; text-align: right">          2.62         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 6%; text-align: right">          -         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          $         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           10.01-$100.00          </font>         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          102,951         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          7.23         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          28.77         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          76,574         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          7.16         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          29.67         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          $         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           100.01-$200.00          </font>         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          92,847         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2.76         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          166.04         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          92,847         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          2.76         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          166.04         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          $         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           200.01-$277.50          </font>         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          69,391         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1.58         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          210.79         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          69,391         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1.58         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          210.79         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 80 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           19           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefair value of each option granted from the Company’s stock option plans during the years ended October 31, 2020 and 2019was estimated on the date of grant using the Black-Scholes option-pricing model. Using this model, fair value is calculated basedon assumptions with respect to (i) expected volatility of the Company’s common stock price, (ii) the periods of time overwhich employees and Board Directors are expected to hold their options prior to exercise (expected lives), (iii) expected dividendyield on the Company’s common stock, and (iv) risk-free interest rates, which are based on quoted U.S. Treasury rates forsecurities with maturities approximating expected lives of the options. The Company used their own historical volatility in determiningthe volatility to be used. The expected term of the stock option grants was calculated using the “simplified” methodin accordance with the SEC Staff Accounting Bulletin 107. The “simplified” method was used since the Company believesits historical data does not provide a reasonable basis upon which to estimate expected term and the Company does not have enoughoption exercise data from its grants issued to support its own estimate as a result of vesting terms and changes in the stockprice. The expected dividend yield is zero as the Company has never paid dividends to common shareholders and does not currentlyanticipate paying any in the foreseeable future.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefollowing table provides the weighted average fair value of options granted to directors and employees and the related assumptionsused in the Black-Scholes model:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">          Year Ended         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="padding-bottom: 1.5pt; text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">          October 31, 2020         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">          October 31, 2019         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          Expected term         </td>         <td>         </td>         <td colspan="2" style="text-align: right">          5.50-6.50 years         </td>         <td>         </td>         <td>         </td>         <td colspan="2" style="text-align: right">          5.50-6.51 years         </td>         <td>         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Expected volatility         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           100.27-105.21          </font>         </td>         <td style="text-align: left">          %         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           90.24-104.99          </font>         </td>         <td style="text-align: left">          %         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; text-align: left">          Expected dividends         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 16%; text-align: right">          0         </td>         <td style="width: 1%; text-align: left">          %         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 16%; text-align: right">          0         </td>         <td style="width: 1%; text-align: left">          %         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Risk free interest rate         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           0.36-0.62          </font>         </td>         <td style="text-align: left">          %         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           1.35-3.15          </font>         </td>         <td style="text-align: left">          %         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Totalcompensation cost related to the Company’s outstanding stock options, recognized in the statement of operations for theyears ended October 31, 2020 and 2019 was approximately $0.7 million and $1.2 million, respectively.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Duringthe fiscal year ended October 31, 2020, 645,000 options were granted with a total grant date fair value of approximately $0.3million. During the fiscal year ended October 31, 2019, 265,882 options were granted with a total grant date fair value of approximately$0.5 million.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof October 31, 2020, there was approximately $0.6 million of unrecognized compensation cost related to non-vested stock optionawards, which is expected to be recognized over a remaining weighted average vesting period of approximately 1.50 years.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         EmployeeStock Purchase Plan        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheAdvaxis, Inc. 2018 Employee Stock Purchase Plan (ESPP) was approved by the Company’s shareholders on March 21, 2018. The2018 ESPP allows employees to purchase common stock of the Company at a 15% discount to the market price on designated exercisedates. Employees were eligible to participate in the 2018 ESPP beginning May 1, 2018. 1,000,000 shares of the Company’sCommon stock are reserved for issuance under the 2018 ESPP.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Duringthe fiscal year ended October 31, 2020, 14,148 shares were issued under the 2018 ESPP and the Company recorded an expense of approximately$1,000. During the fiscal year ended October 31, 2019, 7,435 shares were issued under the 2018 ESPP and the Company recorded anexpense of approximately $2,000.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asof October 31, 2020, 976,517 shares of Company’s common stock remain available for issuance under the 2018 ESPP.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 81 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           20           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         8.COLLABORATION AND LICENSING AGREEMENTS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         OSTherapies LLC        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnSeptember 4, 2018, the Company entered into a development, license and supply agreement with OS Therapies (“OST”)for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. Under the termsof the license agreement, as amended, OST will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2in recurrent, completely resected osteosarcoma. Under the most recent amendment to the licensing agreement, OST agrees to payAdvaxis $25,000 per month (“Monthly Payment”) starting on April 30, 2020 until it achieves its funding milestone of$2,337,500. Upon receipt of the first Monthly Payment, Advaxis will initiate the transfer of the intellectual property and licensingrights of ADXS31-164, which were licensed pursuant to the Penn Agreement, back to the University of Pennsylvania. Contemporaneously,OST will enter negotiations with the University of Pennsylvania to establish a licensing agreement for ADXS31-164 to OST for clinicaland commercial development of the ADXS31-164 technology.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Providedthat OST meets its ongoing obligation to make its Monthly Payments to Advaxis for six consecutive months, Advaxis agrees to transfer,and OST agrees to take full ownership of, the IND application for ADXS31-164 in its entirety to OST, along with agreements andpromises contained therein, as well as all obligations associated with this IND or any HER2 product/program development. UntilOST makes its Monthly Payments to Advaxis for six consecutive months, Advaxis will continue to bear the costs of the regulatoryfiling services related to the IND application for ADXS31-164.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Withinfive business days of achieving the funding milestone of $2,337,500 for the performance of the Children’s Oncology Groupstudy (knowns as the “License Commencement Date”), OST will make a non-refundable and non-creditable payment to Advaxisof $1,550,000 less the cumulative Monthly Payments previously made (the “License Commencement Payment”). Within fivedays following the License Commencement Date, Advaxis will provide existing drug supply “as is” to OST, and untilthe drug supply is supplied to OST, Advaxis will bear the storage costs for the drug product. Pursuant to the agreement, the Companyis also to receive sales-based milestone payments and royalties on future product sales. In addition, the Company and OST willestablish a Joint Steering Committee to oversee the R&amp;D activities.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thepromises to (1) Maintain the HER2 product until transfer to OST, (2) Provide the IND application ownership for ADX321-164 to OST,(3) Participate in the Joint Steering Committee, (4) Transfer of IP &amp; licensing rights of ADXS31-164 and related Patents,and (5) Provide Clinical Drug Supply represent one combined performance obligation for revenue recognition purposes. The Companyconcluded that the transfer of the IP and licensing rights provides OST with a functional, or “right to use,” license,and thus the Company will recognize the upfront fees of $1,550,000 from the license at a point in time. The revenue from the transferof the license cannot be recognized until the transfer of the corresponding IP to OST has occurred and OST has the ability tobenefit from the right to use the license. As the right to use the license begins when OST makes the upfront payment within fivedays of the License Commencement Date and the IP transfers to OST at that time, the upfront fees from the license will be recognizedupon the transfer of the intellectual property to OST.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        SinceOST is making $25,000 monthly payments that will be creditable against the $1,550,000, as well as additional upfront paymentsnot specified in the contract, the Company will receive payments prior to the performance of the single distinct performance obligation.Due to this, the Company will defer any of the monthly payments until the IP and licensing rights are transferred to OST. However,if OST terminates the contract, which they are able to do with 60-day notice, the Company would recognize any of the paymentsreceived when the contract terminates. As of October 31, 2020, OST has made payments totaling $164,653 and this has been recordedas other liabilities in the balance sheet.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Amgen        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnAugust 1, 2016, the Company entered into a global agreement (the “Amgen Agreement”) with Amgen for the developmentand commercialization of the Company’s ADXS-NEO, a then- preclinical investigational immunotherapy, using the Company’sproprietary Listeria monocytogenes attenuated bacterial vector which activates a patient’s immune system to respond againstunique mutations, or neoepitopes, contained in and identified from an individual patient’s tumor. Under the terms of theAmgen Agreement, Amgen received an exclusive worldwide license to develop and commercialize ADXS-NEO. Amgen made an upfront paymentto Advaxis of $40 million and purchased directly from Advaxis 203,163 shares of the Company’s common stock, at approximately$123.00 per share (representing a purchase at market using a 20 day VWAP methodology) for a total of $25 million. Amgen assistedin funding the clinical development and commercialization of ADXS-NEO and Advaxis retained manufacturing responsibilities. Advaxisand Amgen collaborated through a joint steering committee for the development and commercialization of ADXS-NEO. Advaxis receivedreimbursements for research and development costs and Advaxis was eligible to receive future contingent payments based on development,regulatory and sales milestone payments of up to $475 million and high single digit to double digit royalty payments based onworldwide sales by Amgen.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 82 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           21           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Amgen, is a customer.The Company identified the following material promises under the arrangement: (1) licenses, (2) research and development activities,(3) clinical supplies, (4) regulatory responsibilities and (5) participation on a Joint Steering Committee (JSC). The Companydetermined that the licenses and research and development activities were not distinct from another, as the licenses had limitedvalue without the performance of the research and development activities. Participation on the JSC to oversee the research anddevelopment activities was determined to be quantitatively and qualitatively immaterial and therefore was excluded from performanceobligations. The clinical supply and regulatory responsibilities did not represent separate performance obligations based on theirdependence on the research and development efforts. Based on this assessment, the Company identified one performance obligationat the outset of the Amgen Agreement, which consists of: (1) licenses, (2) research and development activities, (3) clinical suppliesand (4) regulatory responsibilities.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Underthe Amgen Agreement, in order to evaluate the appropriate transaction price, the Company determined that the upfront amount of$40 million constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement,which is allocated to the single performance obligation. The Company concluded that a time-based method was most appropriate tomeasuring progress toward completion given that the research and development services are satisfied reasonably evenly over theagreement and the Company has a stand-ready obligation to perform over such time. Accordingly, progress toward completion andrelated revenue recognition is measured using the input method of time elapsed relative to the estimated timeline for Advaxisto submit the Phase 2 package to Amgen, or perform the contractual research and development services, which was the predominantpromise in the Company’s combined performance obligation to Amgen.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thereimbursement for the research and development costs was variable consideration that was included in the transaction price atthe outset, subject to the constraint. The Company estimated the consideration from the reimbursement of the research and developmentcosts using the most-likely amount. When the research and development costs are no longer constrained, they are added to the transactionprice for the single, combined performance obligation and recognized over the same recognition period as the rest of the performanceobligation’s allocated revenue. The potential milestone and sales-based royalty payments that the Company was eligible toreceive were excluded from the transaction price, as all milestone and sales royalty amounts were fully constrained based on theprobability of achievement. The Company reevaluated the transaction price at the end of each reporting period and as uncertainevents were resolved or other changes in circumstances occurred, and, as necessary, adjusted its estimate of the transaction price.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnDecember 10, 2018, the Company received a written notice of termination from Amgen with respect to the Amgen Agreement. The terminationbecame effective as of February 8, 2019, and the Company regained worldwide rights for the development and commercialization ofits ADXS-NEO program. On October 24, 2019, Advaxis announced that it has enrolled its last patient in its ADXS-NEO program inmonotherapy and will not enter Part B.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theremaining deferred revenue of approximately $18.2 million on December 10, 2018 related to the $40 million non-refundable, up-frontpayment received from Amgen was accounted for as of the modification date. As of that notification date, the Company adjustedrevenue on a cumulative catch-up basis considering the revised measure of progress for the combined performance obligation basedon the modified service period up to and through the contract termination date of February 8, 2019. The Company recognized cumulativecatch-up revenue of approximately $15.6 million on December 10, 2018. The remaining $2.6 million was recognized over the subsequent60 days until the performance obligation was satisfied on February 8, 2019.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Duringthe years ended October 31, 2020 and 2019, the Company recognized revenue from the Amgen Agreement of approximately $0 and $20.6million, respectively. During the years ended October 31, 2020 and 2019, the Company received reimbursement of research and developmentcosts of approximately $0 and $2.0 million, which was included in revenue.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 83 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           22           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Merck&amp; Co., Inc.        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnAugust 22, 2014, the Company entered into a Clinical Trial Collaboration and Supply Agreement (the “Merck Agreement”)with Merck, pursuant to which the parties collaborated on a Phase 1/2 dose-determination and safety trial. The Phase 1 portionof the trial evaluated the safety of our        <i>         Lm        </i>        -LLO based immunotherapy for prostate cancer, ADXS-PSA (the “AdvaxisCompound”) as monotherapy and in combination with KEYTRUDA® (pembrolizumab), Merck’s humanized monoclonal antibodyagainst PD-1, (the “Merck Compound”) and has determined a recommended Phase 2 combination dose. The Phase 2 portionevaluated the safety and efficacy of the Advaxis Compound in combination with the Merck Compound. Both phases of the trial werein patients with previously treated metastatic castration-resistant prostate cancer. The last patient was dosed in August 2019and the Company is in the surveillance stage of the study. A joint development committee, comprised of equal representatives fromboth parties, is responsible for coordinating all regulatory and other activities under, and pursuant to, the Merck Agreement.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Eachparty is responsible for their own internal costs and expenses to support the trial, while the Company was responsible for allthird-party costs of conducting the trial. Merck was responsible for manufacturing and supplying the Merck Compound. The Companywas responsible for manufacturing and supplying the Advaxis Compound. The Company is the sponsor of the trial and holds the INDrelated to the trial.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Alldata and results generated under the trial (“Collaboration Data”) will be jointly owned by the parties, except thatownership of data and information generated from sample analysis to be performed by each party on its respective compound willbe owned by the party conducting such testing. All rights to all inventions and discoveries, which claim or cover the combineduse of the Advaxis Compound and the Merck Compound shall belong jointly to the parties. Inventions and discoveries relating solelyto the Advaxis Compound, or a live attenuated bacterial vaccine, shall be the exclusive property of Advaxis. Inventions and discoveriesrelating solely to the Merck Compound, or a PD-1 antagonist, shall be the exclusive property of Merck.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Duringthe each of the years ended October 31, 2020 and 2019, the Company incurred approximately $0.9 million in expenses pertainingto the Merck agreement, and such expenses were a component of research and development expenses in the statement of operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         ElancoAnimal Health (formerly Aratana Therapeutics)        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnMarch 19, 2014, the Company and Aratana entered into a definitive Exclusive License Agreement (the “Aratana Agreement”).Pursuant to the Agreement, Advaxis granted Aratana an exclusive, worldwide, royalty-bearing, license, with the right to sublicense,certain Advaxis proprietary technology that enables Aratana to develop and commercialize animal health products that will be targetedfor treatment of osteosarcoma and other cancer indications in animals. Under the terms of the Aratana Agreement, Aratana paidan upfront payment to the Company, of $1 million. As this license has stand-alone value to Aratana (who has the ability to sublicense)and was delivered to Aratana, upon execution of the Aratana Agreement, the Company recorded the $1 million payment as licensingrevenue during the fiscal year ended October 31, 2014. Aratana will also pay the Company up to an additional $36.5 million basedon the achievement of certain milestones with respect to the advancement of products pursuant to the terms of the Aratana Agreement.In addition, Aratana may pay the Company an additional $15 million in cumulative sales milestones pursuant to the terms of theAratana Agreement.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Duringthe fiscal year ended October 31, 2018, the USDA’s Center for Veterinary Biologics granted Aratana conditional approvalfor its canine osteosarcoma vaccine using Advaxis’ technology. During the years ended October 31, 2020 and 2019, Advaxisrecognized royalty revenue totaling approximately $3,000 and $8,000, respectively, from Aratana’s sales of the canine osteosarcomavaccine. On July 16, 2019, Aratana announced their shareholders approved a merger agreement with Elanco Animal Health (“Elanco”)whereby Elanco will be the majority shareholder in Aratana. On October 6, 2020, the Company received a notice from Aratana, datedSeptember 17, 2020, indicating that Aratana was terminating the Exclusive License Agreement effective December 21, 2020. The Companydid not incur any early termination penalties as a result of the termination. Aratana was required to make all payments to theCompany that were otherwise payable under the Exclusive License Agreement through the effective date of termination.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <!-- Field: Page; Sequence: 84 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           23           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         GlobalBioPharma Inc.        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnDecember 9, 2013, the Company entered into an exclusive licensing agreement for the development and commercialization of axalimogenefilolisbac with Global BioPharma, Inc. (GBP), a Taiwanese based biotech company funded by a group of investors led by Taiwan BiotechCo., Ltd (TBC). During each of the years ended October 31, 2020 and 2019, the Company recorded $0.25 million in revenue for theannual license fee renewal. Since Advaxis has no significant obligation to perform after the license transfer and has providedGBP with the right to use its intellectual property, performance is satisfied when the license renews.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         9.COMMITMENTS AND CONTINGENCIES        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         LegalProceedings        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         Stendhal        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnSeptember 19, 2018, Stendhal filed a Demand for Arbitration before the International Centre for Dispute Resolution (Case No. 01-18-0003-5013)relating to the Co-development and Commercialization Agreement with Especificos Stendhal SA de CV (the “Stendhal Agreement”).In the demand, Stendhal alleged that (i) the Company breached the Stendhal Agreement when it made certain statements regardingits AIM2CERV program, (ii) that Stendhal was subsequently entitled to terminate the Agreement for cause, which it did so at thetime and (iii) that the Company owes Stendhal damages pursuant to the terms of the Stendhal Agreement. Stendhal is seeking torecover $3 million paid to the Company in 2017 as support payments for the AIM2CERV clinical trial along with approximately $0.3million in expenses incurred. Stendhal is also seeking fees associated with the arbitration and interest. The Company has answeredStendhal’s Demand for Arbitration and denied that it breached the Stendhal Agreement. The Company also alleges that Stendhalbreached its obligations to the Company by, among other things, failing to make support payments that became due in 2018 and thatStendhal therefore owes the Company $3 million. Advaxis is also seeking fees associated with the arbitration and interest.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        FromOctober 21-23, 2019, an evidentiary hearing for the arbitration was conducted. On April 1, 2020, the Arbitrator issued a finalaward denying Stendhal’s claim in full. The Arbitrator found that the Company had not repudiated the Agreement and did notowe Stendhal damages, fees, or interest associated with the arbitration. The Arbitrator also denied the Company’s claimthat Stendhal breached its obligations to the Company. The parties were ordered to bear their own attorneys’ fees and evenlysplit administrative fees and expenses for the arbitration.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         10.LEASES        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         OperatingLeases        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany leases its corporate office and manufacturing facility in Princeton, New Jersey under an operating lease that expiresin November 2025. The Company has the option to renew the lease term for two additional five-year terms. The renewal periods werenot included the lease term for purposes of determining the lease liability or right-of-use asset. The Company has provided asecurity deposit of approximately $182,000, which is recorded as Other Assets in the balance sheet.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany identified and assessed the following significant assumptions in recognizing its right-of-use assets and correspondinglease liabilities:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           As    the Company does not have sufficient insight to determine an implicit rate, the Company estimated the incremental borrowing    rate in calculating the present value of the lease payments. The Company utilized a synthetic credit rating model to determine    a benchmark for its incremental borrowing rate for its leases. The benchmark rate was adjusted to arrive at an appropriate    discount rate for the lease.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Since    the Company elected to account for each lease component and its associated non-lease components as a single combined component,    all contract consideration was allocated to the combined lease component.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 85 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           24           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Renewal    option periods have not been included in the determination of the lease terms as they are not deemed reasonably certain of    exercise.          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>        </tr>        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           ●          </font>         </td>         <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           Variable    lease payments, such as common area maintenance, real estate taxes, and property insurance are not included in the determination    of the lease’s right-of-use asset or lease liability.          </font>         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Supplementalbalance sheet information related to leases as of October 31, 2020 was as follows (in thousands):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Operating Leases:         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="width: 78%; text-align: left; padding-bottom: 1.5pt">          Operating lease right-of-use assets         </td>         <td style="width: 2%; padding-bottom: 1.5pt">         </td>         <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">          $         </td>         <td style="width: 18%; border-bottom: Black 1.5pt solid; text-align: right">          4,839         </td>         <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Operating lease liability         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          962         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Operating lease liability, net of current portion         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          5,055         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">          Total operating lease liabilities         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          $         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          6,017         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Supplementallease expense related to leases was as follows (in thousands):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center; border-bottom: Black 1.5pt solid">          Lease Cost (in thousands)         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="text-align: center; border-bottom: Black 1.5pt solid">          Statements of Operations Classification         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          For the Year          <br/>          Months Ended          <br/>          October 31, 2020         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 36%; text-align: justify">          Operating lease cost         </td>         <td style="width: 2%">         </td>         <td style="width: 36%; text-align: center">          General and administrative         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 22%; text-align: right">          1,158         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: justify">          Short-term lease cost         </td>         <td>         </td>         <td style="text-align: center">          General and administrative         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          320         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: justify; padding-bottom: 1.5pt">          Variable lease cost         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="text-align: center; padding-bottom: 1.5pt">          General and administrative         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          547         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">          Total lease expense         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          $         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          2,025         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Otherinformation related to leases where the Company is the lessee is as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: justify">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="margin-top: 0; margin-bottom: 0">           For the Fiscal Year          </p>          <p style="margin-top: 0; margin-bottom: 0">           Ended           <br/>           October 31, 2020          </p>         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: justify">          Weighted-average remaining lease term         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           5.1 years          </font>         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="width: 78%; text-align: justify">          Weighted-average discount rate         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 18%; text-align: right">          6.5         </td>         <td style="width: 1%; text-align: left">          %         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Supplementalcash flow information related to operating leases was as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: justify">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          <p style="margin-top: 0; margin-bottom: 0">           For the Fiscal Year          </p>          <p style="margin-top: 0; margin-bottom: 0">           Ended           <br/>           October 31, 2020          </p>         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 74%; text-align: justify; padding-bottom: 1.5pt">          Cash paid for operating lease liabilities         </td>         <td style="width: 2%; padding-bottom: 1.5pt">         </td>         <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">          $         </td>         <td style="width: 22%; border-bottom: Black 1.5pt solid; text-align: right">          1,233         </td>         <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Futureminimum lease payments under non-cancellable leases as of October 31, 2020 were as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: bottom">         <td style="border-bottom: Black 1.5pt solid">          Fiscal Year ending October 31,         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: right">         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 78%; text-align: left">          2021         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 18%; text-align: right">          1,318         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: justify">          2022         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,369         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: justify">          2023         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,395         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: justify">          2024         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,419         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: justify">          2025         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,444         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 1.5pt">          Thereafter         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          120         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; text-align: left">          Total minimum lease payments         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          7,065         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          Less: Imputed interest         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (1,048         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 2.5pt">          Total         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          6,017         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 86 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           25           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        UnderASC 840, future minimum payments under the Company’s operating lease were as follows (in thousands):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">       <tbody>        <tr style="vertical-align: bottom">         <td style="border-bottom: Black 1.5pt solid">          Fiscal Year ending October 31,         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2">         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 78%; text-align: justify">          2021         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 18%; text-align: right">          1,318         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: justify">          2022         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,369         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: justify">          2023         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,395         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: justify">          2024         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,419         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: justify">          2025         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,444         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-bottom: 1.5pt">          Thereafter         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          120         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 2.5pt">          Total         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          7,065         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        UnderASC 840, rent expense for the fiscal year ended October 31, 2019 was approximately $1.2 million.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         11.INCOME TAXES        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theincome tax provision (benefit) consists of the following (in thousands):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          October 31, 2020         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          October 31, 2019         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td>          Federal         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt">          Current         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt; width: 60%">          Deferred         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 16%; text-align: right">          (4,578         </td>         <td style="width: 1%; text-align: left">          )         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 16%; text-align: right">          32,673         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          State and Local         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-left: 10pt">          Current         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="padding-left: 10pt">          Deferred         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (1,445         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (1,634         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Change in valuation allowance         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          6,023         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (31,039         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 2.5pt">          Income tax provision (benefit)         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          -         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          -         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany has U.S. federal net operating loss carryovers (“NOLs”) of approximately $89.4 million and $74.0 million atOctober 31, 2020 and 2019 respectively, available to offset taxable income which expire beginning in 2023. If not used, theseNOLs may be subject to limitation under Internal Revenue Code Section 382 should there be a greater than 50% ownership changeas determined under the regulations. During the years ended October 31, 2020 and 2019, the Company performed a detailed analysisof any historical and/or current Section 382 ownership changes that may limit the utilization of the net operating loss carryovers.From the entire federal NOL of $299.2 million as of October 31, 2020, approximately $89.4 million is available for use based onInternal Revenue Code Section 382 analysis. The NOL and the deferred tax asset table below does not include approximately $209.8million of NOL’s that may expire unused. The Company also has New Jersey State Net Operating Loss carryovers of approximately$137.7 million as of October 31, 2020 available to offset future taxable income through 2040.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Inassessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion orall of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon futuregeneration for taxable income during the periods in which temporary differences representing net future deductible amounts becomedeductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planningstrategies in making this assessment. After consideration of all the information available, management believes that significantuncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuationallowance.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 87 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           26           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font: 10pt Times New Roman, Times, Serif">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany evaluated the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in an enterprise’sfinancial statements. ASC 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertainpositions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax positionmust be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken orexpected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred toas “unrecognized benefits.” A liability is recognized (or amount of net operating loss carry forward or amount oftax refundable is reduced) for unrecognized tax benefit because it represents an enterprise’s potential future obligationto the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Ifapplicable, interest costs related to the unrecognized tax benefits are required to be calculated and would be classified as otherexpense in the statement of operations. Penalties would be recognized as a component of general and administrative expenses inthe statement of operations.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Nointerest or penalties on unpaid tax were recorded during the years ended October 31, 2020 and 2019, respectively. As of October31, 2020 and 2019, no liability for unrecognized tax benefits was required to be reported. The Company does not expect any significantchanges in its unrecognized tax benefits in the next year.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany files tax returns in the U.S. federal and state jurisdictions and is subject to examination by tax authorities beginningwith the fiscal year ended October 31, 2017.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany’s deferred tax assets (liabilities) consisted of the effects of temporary differences attributable to the following(in thousands):       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">          Years Ended         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          October 31, 2020         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          October 31, 2019         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-decoration: underline; text-align: left">          Deferred Tax Assets         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="width: 60%; text-align: left">          Net operating loss carryovers         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          28,553         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 16%; text-align: right">          22,627         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Stock-based compensation         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          10,132         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          11,767         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Research and development credits         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          10,742         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          10,234         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Capitalized R&amp;D costs         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          13,822         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          13,399         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Deferred revenue         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Adoption of ASC 842 – Lease Liability         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1,691         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          Other deferred tax assets         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          224         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          405         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Total deferred tax assets         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          $         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          65,164         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          $         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          58,432         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          Valuation allowance         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (62,845         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (56,822         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Deferred tax asset, net of valuation allowance         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          2,319         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">          $         </td>         <td style="text-align: right">          1,610         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td>         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-decoration: underline; text-align: left">          Deferred Tax Liabilities         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Adoption of ASC 842 – ROU Asset         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (1,360         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Patent Cost         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (917         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          Other deferred tax liabilities         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (42         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (1,610         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Total deferred tax liabilities         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          $         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (2,319         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">          $         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (1,610         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 2.5pt">          Net deferred tax asset (liability)         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          -         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          -         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theexpected tax (expense) benefit based on the statutory rate is reconciled with actual tax expense benefit as follows:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">          Years Ended         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom">         <td>         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          October 31, 2020         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          October 31, 2019         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 60%; text-align: left">          US Federal statutory rate         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 16%; text-align: right">          21.00         </td>         <td style="width: 1%; text-align: left">          %         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 16%; text-align: right">          21.00         </td>         <td style="width: 1%; text-align: left">          %         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          State income tax, net of federal benefit         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          5.48         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          9.84         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Permanent differences         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (0.05         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1.23         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Research and development credits         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          1.73         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          17.30         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Change in valuation allowance         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (22.82         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          186.84         </td>         <td style="text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          §382 Impact on NOL         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (233.87         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left; padding-bottom: 1.5pt">          Stock Option Expirations         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (5.33         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (2.34         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Income tax (provision) benefit         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          0.00         </td>         <td style="text-align: left">          %         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          0.00         </td>         <td style="text-align: left">          %         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thestatement of operations discloses income tax expense of $50. This is a Taiwan Excise tax of 50 levied in connection with the GPPRevenue.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">      </p>      <!-- Field: Page; Sequence: 88 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           27           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         12.        </b>       </font>       <font style="font: 10pt Times New Roman, Times, Serif">        <b>         STOCKHOLDERS’ EQUITY        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         PublicOfferings        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InApril 2019, the Company issued 2,500,000 shares of the Company’s common stock in a public offering at $4.00 per share, lessunderwriting discounts and commissions. The net proceeds to the Company from the transaction was approximately $9 million.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InJuly 2019, the Company closed on an underwritten public offering of 10,650,000 shares of its common stock, pre-funded warrantsto purchase 13,656,000 shares of common stock and warrants to purchase up to 17,142,000 shares of common stock for gross proceedsof $17.0 million. Each share of common stock was sold together in a fixed combination with a warrant to purchase 0.75 shares ofcommon stock for $0.70, and each pre-funded warrant was sold together in a fixed combination with a warrant to purchase 0.75 sharesof common stock for $0.699. The pre-funded warrants are exercisable immediately, do not expire and have an exercise price of $0.001per share. The warrants are exercisable immediately, expire five years from the date of issuance, have an exercise price of $2.80per share and are subject to anti-dilution and other adjustments for certain stock splits, stock dividends, or recapitalizations.The warrants also provide that if during the period of time between the date that is the earlier of (i) 30 days after issuanceand (ii) if the common stock trades an aggregate of more than 35,000,000 shares after the pricing of the offering, and ending15 months after issuance, the weighted-average price of common stock immediately prior to the exercise date is lower than thethen-applicable exercise price per share, each Common Warrant may be exercised, at the option of the holder, on a cashless basisfor one share of Common Stock. After deducting the underwriting discounts and commissions and other offering expenses, the netproceeds from the offering were approximately $15.5 million.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InJanuary 2020, the Company closed on a public offering of 10,000,000 shares of its common stock at a public offering price of $1.05,for gross proceeds of $10.5 million. In addition, the Company also undertook a concurrent private placement of warrants to purchaseup to 5,000,000 shares of common stock. The warrants have an exercise price per share of $1.25, are exercisable during the periodbeginning on the six-month anniversary of the date of its issuance (the “Initial Exercise Date”) and will expire onthe fifth anniversary of the Initial Exercise Date. The warrants contain a change of control provision whereby if the change ofcontrol is within the Company’s control, the warrants could be settled in cash based on the Black-Scholes value of the warrantsat the option of the warrant holder. The warrants also provide that if there is no effective registration statement registering,or no current prospectus available for, the issuance or resale of the warrant shares, the warrants may be exercised via a cashlessexercise. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offeringwere approximately $9.6 million.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InMay 2020, the Company entered into a sales agreement related to an ATM equity offering program pursuant to which the Company maysell, from time to time, common stock with an aggregate offering price of up to $40 million through A.G.P./Alliance Global Partners,as sales agent. From May 2020 to October 2020, the Company sold 2,489,104 shares of its common stock under the ATM program for$1.583 million, or an average of $0.64 per share, and received net proceeds of $1.531 million, net of commissions of $52,000.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <i>         LincolnPark Purchase Agreement        </i>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        OnJuly 30, 2020, the Company entered into a Purchase Agreement (the “Purchase Agreement”) and a Registration RightsAgreement (the “Registration Rights Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”).Over the 36-month term of the Purchase Agreement, the Company has the right, but not the obligation, from time to time, to sellto Lincoln Park up to an aggregate amount of $20,000,000 of shares of common stock, in its sole discretion and subject to certainconditions, including that the closing price of its common stock is not below $0.10 per share, to direct Lincoln Park to purchaseup to 1,000,000 shares (the “Regular Purchase Share Limit”) of its Common Stock (each such purchase, a “RegularPurchase”). Lincoln Park’s maximum obligation under any single Regular Purchase will not exceed $1,000,000, unlessthe parties mutually agree to increase the maximum amount of such Regular Purchase. The purchase price for shares of Common Stockto be purchased by Lincoln Park under a Regular Purchase will be the equal to the lower of (in each case, subject to the adjustmentsdescribed in the Purchase Agreement): (i) the lowest sale price for the Company’s common stock on the applicable purchasedate, and (ii) the arithmetic average of the three lowest sale prices for the Company’s common stock during the ten tradingdays prior to the purchase date.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 89 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           28           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Asconsideration for entering into the Purchase Agreement, the Company issued 1,084,266 shares of common stock to Lincoln Park asa commitment fee. The shares were valued at approximately $0.6 million and were recorded as deferred offering expenses in thebalance sheet. The deferred charges were charged against paid-in capital upon future proceeds from the sale of common stock underthe Lincoln Park Purchase Agreement.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        FromAugust 2020 to October 2020, Lincoln Park purchased 11,242,048 shares of common stock for gross proceeds of approximately $5.1million. Approximately $50,000 of legal fees were netted against the gross proceeds.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         13.        </b>       </font>       <font style="font: 10pt Times New Roman, Times, Serif">        <b>         FAIR VALUE        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Theauthoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an assetor paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability inan orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in theprincipal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidancedescribes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the lastunobservable, that may be used to measure fair value which are the following:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        ●Level 1 — Quoted prices in active markets for identical assets or liabilities.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        ●Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similarassets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observablemarket data or substantially the full term of the assets or liabilities.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        ●Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value ofthe assets or liabilities.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefollowing table provides the assets and liabilities carried at fair value measured on a recurring basis as of October 31, 2020and October 31, 2019:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center; border-bottom: Black 1.5pt solid">          October 31, 2020         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Level 1         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Level 2         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Level 3         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Total         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 52%; text-align: left">          Common stock warrant liability, warrants exercisable at $0.372 through September 2024         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 8%; text-align: right">          -         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 8%; text-align: right">          -         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 8%; text-align: right">          17         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 8%; text-align: right">          17         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center; border-bottom: Black 1.5pt solid">          October 31, 2019         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Level 1         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Level 2         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Level 3         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          Total         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 52%; text-align: left">          Common stock warrant liability, warrants exercisable at $0.372 through September 2024         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 8%; text-align: right">          -         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 8%; text-align: right">          -         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 8%; text-align: right">          19         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 8%; text-align: right">          19         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        Thefollowing table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities:       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">       <tbody>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">          Year Ended October 31,         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom">         <td style="text-align: center">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2020         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">          2019         </td>         <td style="padding-bottom: 1.5pt">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="width: 68%; text-align: left">          Beginning balance         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          19         </td>         <td style="width: 1%; text-align: left">         </td>         <td style="width: 2%">         </td>         <td style="width: 1%; text-align: left">          $         </td>         <td style="width: 12%; text-align: right">          6,517         </td>         <td style="width: 1%; text-align: left">         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left">          Shares issued in settlement of warrants         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          -         </td>         <td style="text-align: left">         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (3,856         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="text-align: left">          Warrant exercises         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (2         </td>         <td style="text-align: left">          )         </td>         <td>         </td>         <td style="text-align: left">         </td>         <td style="text-align: right">          (53         </td>         <td style="text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: White">         <td style="text-align: left; padding-bottom: 1.5pt">          Change in fair value         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          -         </td>         <td style="padding-bottom: 1.5pt; text-align: left">         </td>         <td style="padding-bottom: 1.5pt">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: left">         </td>         <td style="border-bottom: Black 1.5pt solid; text-align: right">          (2,589         </td>         <td style="padding-bottom: 1.5pt; text-align: left">          )         </td>        </tr>        <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">         <td style="padding-bottom: 2.5pt">          Ending Balance         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          17         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>         <td style="padding-bottom: 2.5pt">         </td>         <td style="border-bottom: Black 2.5pt double; text-align: left">          $         </td>         <td style="border-bottom: Black 2.5pt double; text-align: right">          19         </td>         <td style="padding-bottom: 2.5pt; text-align: left">         </td>        </tr>       </tbody>      </table>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 90 -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           29           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <div style="break-before: page; margin-top: 6pt">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         14.        </b>       </font>       <font style="font: 10pt Times New Roman, Times, Serif">        <b>         EMPLOYEE BENEFIT PLAN        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        TheCompany sponsors a 401(k) Plan. Employees become eligible for participation upon the start of employment. Participants may electto have a portion of their salary deferred and contributed to the 401(k) Plan up to the limit allowed under the Internal RevenueCode. The Company makes a matching contribution to the plan for each participant who has elected to make tax-deferred contributionsfor the plan year. The Company made matching contributions which amounted to approximately $0.1 million and $0.2 million for theyears ended October 31, 2020 and 2019, respectively. These amounts were charged to the statement of operations. The employer contributionsvest immediately.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>         15.        </b>       </font>       <font style="font: 10pt Times New Roman, Times, Serif">        <b>         SUBSEQUENT EVENTS        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <b>        </b>       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InNovember 2020, the Company closed on a public offering of 30,666,665 shares of its common stock at a public offering price of$0.30, for gross proceeds of $9.2 million, which gives effect to the exercise of the underwriter’s option in full. In addition,the Company also undertook a concurrent private placement of warrants to purchase up to 15,333,332 shares of common stock. Thewarrants have an exercise price per share of $0.35, are exercisable immediately and will expire five years from the date of issuance.The warrants also provide that if there is no effective registration statement registering, or no current prospectus availablefor, the issuance or resale of the warrant shares, the warrants may be exercised via a cashless exercise. After deducting theunderwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $8.5million.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       Subsequent to year end, warrant holders from the Company’s November 2020 offering exercised 4,610,000 warrants in exchange for4,610,000 shares of the Company’s common stock. Pursuant to these warrant exercises, the Company received aggregateproceeds of about $1.6 million which were payable upon exercise.      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        InDecember 2020 and January 2021, the Company received an aggregate of $1,345,000 from OS Therapies upon achievement of the$1,550,000 funding milestone set forth in the license agreement. For more information on the license agreement with OS Therapies,please see Note 8 – “Collaboration and Licensing Agreements” above.       </font>      </p>      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </font>      </p>      <!-- Field: Page; Sequence: 91; Options: Last -->      <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="text-align: center; width: 100%">           F-           <!-- Field: Sequence; Type: Arabic; Name: PageNo -->           30           <!-- Field: /Sequence -->          </td>         </tr>        </tbody>       </table>      </div>      <!-- Field: /Page -->      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">      </p>     </text>    </filename>   </sequence>  </type> </document></body>